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Abstract 
The expressions of seven biologic parameters including p53, PCNA, Ki-67, 
EGFr, E-Cadherin, CD44, and nm23 were evaluated by immunohistochemical 
methods from 122 Hong Kong Chinese patients including 28 cases of prostatic 
hyperplasia, 46 cases of Prostatic Intraepithelial Neoplasia (PIN) and 48 cases of 
prostatic carcinoma (PCa). Their immunoreactivities were correlated with the 
histological grades ofPINf and carcinoma, but data on the clinical stage and patient's 
survival were not available for correlation. 
The aim of this study is to examine whether these markers may play a role 
in tumor development, and also to determine whether the sequence of hyperplasia, 
dysplasia (intr naepithelial neoplasia), and carcinoma applies to prostatic cancer, or 
whether PIN lesions represent a precursor that would lead to the development of 
carcinoma. 
Overexpression of p53 and EGFr was demonstrated in carcinomas, and was 
correlated with increasing grade ofPCa suggesting that alterations of p53 and EGFr 
genes may be a late event in prostatic cancer progression. The low incidence ofp53 
alterations also indicated that such genetic event only affects a small subset ofPCa. 
E-cadherin and CD44 expressions were down-regulated in ?IN lesions and 
PCa, reflecting the loss of epithelial integrity and the acquisition of metastatic 
potential. Both E-cadherin and CD44 appeared to be implicated in early 
tumorigenesis, and CD44 appeared to be implicated in tumor progression. These 
observations also supported the link between VJN and PCa. Expressions of PCNA, 
Ki-67, and nm23 were increased in ?IN lesions and PCa. Alteration of the putative 
anti-metastatic nm23 gene appeared to be implicated in the early stage of tumor 
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development, but not in the tumor progression. Immunoreactivity of PCNA, Ki-67 
and nm23 demonstrated a continuity in the sequence of hyperplasia, PIN and 
carcinoma, supporting the concept of PDsf as a lesion precursor to malignant 
progression. PCNA and Ki-67 may represent useful prognostic markers in PCa. 
Several markers, including E-cadherin, CD44, nm23 protein, PCNA and Ki-
67 demonstrated similar alterations between VW and carcinoma, and supported the 
concept that PES[ is a preinvasive lesion. The progressive changes from ? W to 
carcinoma also lend support for a link between these lesions. Although p53 and 
EGFr showed a marked difference between PINf and PCa, this does not exclude a 
relationship between them as supported by other biological markers. 
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ABSTRACT (Chinese translation) 
用組織免疫化學檢測香港122位華藉病人之前列腺樣本中七 
種生物指標的表達，包括？53，PCNA, Ki-67, EGFr, E-Cadherin, 
CD44及nm23。樣本中有28個前列腺體增生，46個前列腺上皮内 



















為惡性進行之前身病變的概念。此外，PCNA和 t a -67在前列腺癌 
中可能代表有效的預後指標。 
研究結果發現多個指標，包括E-cadherin，CD44，nm23，PCNA 





Chapter 1. Introduction 
I. Epidemiology of Prostate Cancer 
Prostate cancer is a disease that affects mainly older men and is the second 
most common cause of cancer deaths in men after lung cancer in most countries of 
the Westem world. In United States, it is responsible for more than 12% of all cancer 
deaths in men on average from 1991 to 1995 and is also the most frequently 
diagnosed cancer (1). It has been estimated that 184,500 new incidence cases will be 
diagnosed during 1998 and 39,200 man may die of it (1). As depicted in Figure 1, 
during the 1970s and 1980s, prostate cancer incidence and mortality increased 
steadily at small average rates of about 5% and 1% per year respectively. However, 
the rate increased rapidly during the late l980s. The incidence is not accompanied by 
a correlated increase in mortality and is possibly artifactual due to increase of patient 
awareness, increasing life expectancy, and in particular the widespread use of the 
blood test for serum prostatic specific antigen (PSA) and other modalities for 
screening including ultrasound and organ imaging (2). 
Adenocarcinoma of prostate (PCa) is common in North America and North-
western Europe but is rare in the Near East, Africa, and South America. The 
incidence varies greatly among different racial or ethnic groups of male. The 
incidence and mortality rates in American blacks are distinctively higher than that of 
American whites. The average incidence rates of prostate cancer of American blacks 
and whites during the period from 1991 to 1995 were 241.2 and 157.6 per 100,000 
population respectively. About 55.1 and 26.1 per 100,000 American blacks and 
whites respectively died each year from 1991 to 1995 on average (1). 
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US Incidence and Mortality Rates ofProstate Cancer 
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Figure 1. Incidence rate and mortality rate among the men's population in the 
United States from 1973 to 1995. (Data obtained from the National Cancer 
Institute's Surveillance, Epidemiology End Results program.) (Appendix I) 
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Figure 2. Incidence and mortality rates of prostate cancer among the men's 
population in Hong Kong from 1975 to 1996 (Appendix II). 
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In Hong Kong, although lung cancer is also the leading cause of cancer 
death, prostate cancer only contributed to 2.41% of all cancer deaths in men in 1996 
and is the ninth leading cause of cancer death in men (3) (Appendix II). As depicted 
in Figure 2, although the mortality rate due to prostate cancer had increased 2.5 fold 
and 3.9 fold of the cancer death caused by prostate cancer in 1985 and 1975 
respectively, it is only 4.7 per 100,000 men's population in 1996 in contrast to 26.0 
cancer deaths per 100,000 men's population in the United States (Appendix III). 
While the occurrence of prostate cancer gradually increased from 4.45 in 1980 to 
8.65 in 1994 per 100,000 men in the Hong Kong population, the incidence of 
prostate cancer is considerably lower in contrast with the American population 
which increased from 79.8 in 1980 to 190.1 in 1992 per 100,000 men although the 
incidence rate in American population have dropped to 137.2 per 100,000 men in 
1995 (1). The increasing incidences both in Hong Kong and the United States can 
only partly be explained by a wider use of screening semm prostatic specific antigen 
levels and rectal ultrasound examination. Whether additional factors are contributing 
to such increase in incidence is not certain. The differences in the rate of occurrence 
and mortality of prostatic cancer between different racial or ethnic groups are 
undetermined, but have been attributed to genetic factors and environmental factors. 
Studies of migrants from low-incidence to high-incidence countries show an increase 
in clinical prostate cancers suggestive of a role of environmental factors. The 
incidence of prostate cancer in native Japanese is 7.7 per 100,000 men in 1990 
whereas the incidence increases to 88 per 100,000 men on average during 1988 to 
1992 in those living in the United States (4,5). Although there are marked 
differences in incidence and mortality rates between Americans and Hong Kong 
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Chinese, men under the age of 50 from both regions have low incidence and 
mortality rates of prostate cancer. Both incidence and mortality rates rise steeply 
thereafter. 
The significance of numerous epidemiologic factors associated with the 
development of PCa varies, but in general none of these appear to play a determinant 
role. The factors regarded to be associated with increase in risk include a family 
history of prostate cancer, dietary intake of fat, obesity and chronic alcohol abuse, 
while smoking, venereal diseases and viral infection, sexual activity and vasectomy 
have not been conclusively associated with PCa (6,7,8,9,10). No putative gene loci 
have been identified to date. It has been estimated that less than 10% of prostatic 
cancer are associated with a family history or heredity. Countries with high average 
fat consumption have been correlated with higher rates of prostate cancer death 
(increased relative risk by 1.6 to 1.9) while studies on populations with diet rich in 
fiber and presumably lower in fat are associated with lower incidence of prostate 
cancer (8,11). The precise mechanism is not well defined. But increased hormonal 
bioavailabilty due to high fat diet has been implicated. Occupation in welding and 
electroplating industry where workers are exposed to cadmium has been shown to 
have increased risk of prostate cancer possibly due to antagonistic effect to zinc in a 
number ofbiological reactions. Zinc is also a crucial cofactor for several DNA repair 
enzymes. And prostate has been demonstrated to have a high concentration of zinc. 
Other occupational risks attributed to workers in rubber industries, newspapers, 
plumbing, sexually transmitted viruses, serum androgen levels, vasectomy, prostatic 
hyperplasia have been implicated as causal factors. But studies of such factors have 
either been inconclusive or controversial (6,7,8,9,11,12,13). 
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It has been suggested that, provided careful autopsy studies are carried out, 
finding of small, well differentiated, occult PCa is a common place in all male 
population although prostate cancer as a clinical disease and cause of morbidity or 
mortality varied remarkably in frequency all over the world and within countries, 
particularly among different ethnic or racial groups. It is of interest to identify factors 
which cause such PCa in a small fraction of men to evolve into rapid growing 
malignant cancer that kills (14). 
II. The Normal Prostate - Prostatic Anatomy 
The normal adult prostate weighs about 20 g and is shaped as an inverted 
cone, where the base forming part of the bladder neck and the apex forming the 
urethral outlet. It surrounds the urethra at the origin from the urinary bladder. The 
apex rests directly above the urogenital diaphragm. Its position is maintained by the 
puboprostatic ligaments attached to its anterior surface. There is a longitudinal 
midline depression called the median sulcus in the broad, flattened triangular 
posterior surface (15,16). 
The prostate gland contains four glandular compartments, the peripheral 
zone, the central zone, the transition zone and the periurethral gland region. The 
peripheral zone is the largest glandular region, constituting approximately 70% of 
the glandular tissue. It forms the posterior, lateral, and apical regions of the prostate 
and surrounds the central zone and partially the transition zone. The peripheral zone 
is readily visualized by transrectal ultrasound and is the area that is primarily 
sampled by transrectal biopsies. The central zone is cone-shaped and comprises 
about 25% of the prostate. The base of the cone forms the major part of the base of 
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the prostate (seminal vesicle/bladder junction). The vertex of the cone is located at 
the verumontanum. The ejaculatory ducts pass through the central zone. The 
transition zone consists of two lobes that surround the proximal urethral segment 
laterally and anteriorly. The transition zone is surrounded posteriorly and laterally by 
a band of fibromuscular tissue called transition zone boundary or "surgical capsule" 
that separates the transition zone from the peripheral zone. The transition zone is the 
region sampled predominantly by transurethral resection procedures. The volume of 
this zone is variable due to frequent development of benign prostatic hyperplasia 
(BPH). The transition zone constitutes about 5 to 10% of the prostatic volume before 
development of prostatic hyperplasia. Benign prostatic hypertrophy may also arise in 
the periurethral gland region which surrounds the proximal urethral segment of the 
prostate and is confined by the preprostatic sphincter, constituting less than 1% of 
the prostatic volume (15,16). 
The prostatic urethra extends from the bladder neck to the prostatic external 
sphincter and is divided into two segments of approximately equal lengths. The 
proximal urethral segment extends from the bladder neck to the verumontanum. The 
distal urethral segment extends from the verumontanum to the external sphincter. 
The two segments are joined at the level of the verumontanum at an angle of 35 
degrees. The proximal urethral segment receives the ducts of the transition zone and 
the minute ducts from the periurethral gland region. The base of the verumontanum 
is located on the posterior wall of the distal urethral segment. The distal urethral 
segment receives the ejaculatory ducts and the ducts of the central zone at the level 
of the verumontanum and the ducts of the peripheral zone along the entire length of 
the distal urethral segment. The prostate is surrounded posteriorly and laterally by 
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the outer fibromuscular rim or "capsule" that separates the prostate from the 
surrounding tissue. At the prostatic base and along the anterior surface of the 
prostate, a well defined anatomic separation between the prostate and adjacent 
tissues and bladder neck is lacking. The prostate receives blood from a braneh of the 
internal iliac artery via the inferior vesical artery. The venous drainage of the gland 
empties into the prevertebral plexus and the hypogastric venous system. Lymphatic 
drainage occurs through the external and internal iliac as well as obturator lymph 
nodes. It is innervated with both sympathetic and parasympathetic fibers. 
Growth and development of the prostate are hormone dependent and need 
the tropic action of both oestrogens and androgens. The prostate is immature at birth 
and only grows to its normal size at puberty when androgen secretion commences. 
Microscopically, the prostate gland is composed of branched tubuloalveolar 
glands forming lobules. The ducts converge to terminal tubules which open into the 
urethra. The tubules or alveoli are surrounded by abundant fibromuscular and 
fibroelastic supportive stromal tissue constituting one-third or more of the whole 
mass of the prostate. The epithelium shows a great variation between different 
glands and alveoli and even within a single alveolus. It is usually composed of the 
secretory or luminal cells, which consist of simple cuboidal or columnar cells with a 
clear cytoplasm. The cytoplasm may also contain secretion granules and lipid 
droplets. The epithelium and adjacent connective tissue may form folds that project 
into the lumen of the glands. The ducts are lined by a simple columnar secretory 
epithelium that changes to the transitional epithelium near the termination of the 
ducts. These secretory or luminal cells produce and express prostatic specific antigen 
and prostatic acid phosphatase (17). The ducts and acini all demonstrate the presence 
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of a basal cell layer, which are cuboidal or flattened and attenuated, and which 
contrast with secretory cells by lacking prostatic specific antigen or prostatic acid 
phosphatase, but expressing high molecular weight cytokeratins (18). The supporting 
connective tissue stroma also include bundles of smooth muscles. 
III. Pathology of Prostatic Cancers 
Nearly 90% of prostatic cancers exhibit some morphologic features of 
prostate glandular epithelium and are referred to as acinar adenocarcinoma of 
prostate or simply prostatic carcinoma (PCa). Ductal carcinoma or large duct 
adenocarcinoma constitutes less than 5% of prostate. The remaining types are rare 
and represent morphologic variant of prostatic acinar carcinoma. Carcinomas of 
prostate may be multifocal and frequently involve the peripheral zone of the prostate 
and less commonly the central zone and transitional zone of the prostate. 
Grossly, at the early stages where carcinoma is confined within the organ, 
the tumor may appear as a poorly delineated, white-yellow, firm area, located at the 
periphery of the gland. At later stages, when the tumor is bulky and infiltrating 
adjacent structures, the tumor may show extensive necrosis and hemorrhages. 
Microscopically, PCa may exhibit a wide morphologic spectrum, ranging from well-
formed small glands to anaplastic sheets, files, and single tumor cells. They are 
recognized by their atypical architectures and cytologic features. Infiltrative tumor 
alters the lobular architecture, and presents as inconspicuous small glands crowding 
the lobules. They are characterized by enlarged nuclei, with a high nuclear 
cytoplasmic ratio, coarse nuclear chromatins and membrane, and prominent nucleoli. 
Mucin production may become recognizable and prominent. The lumen of tumor 
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glands may demonstrate presence of crystalloids secretions. 
The clinical behavior of PCa is remarkably variable. Patients with 
undifferentiated, DNA-aneuploid PCa at the time of diagnosis are biologically fated 
to poor outcome even when the high-grade carcinoma is confined within the prostate 
capsule and treated by radical retropubic prostatectomy. The low-grade (well or 
moderately differentiated) PCa of low volume (<4ml) and DNA-diploid are 
recognized by clinicians to be clinically indolent which progress slowly with little 
morbidity even untreated (14). 
Histologic grading is one of the strongest predictors of the biologic behavior 
of PCa. Many grading systems have been proposed but are lacking of either 
reproducibility or reliability. The Gleason grading system, which is based on the 
architectural arrangement of the malignant epithelial cells within the prostatic stroma, 
is widely accepted and utilized, and has been strongly correlated with survival, 
tumor-free survival, metastasis-free survival, and time interval to disease recurrence 
(19). The system was developed by the Veterans Administration Cooperative 
Urological Research Group (VACURG). Nine histological patterns grouped into 5 
histological grades were identified and correlated with malignancy as determined by 
mortality data (Table 1). While different histological grades are usually present in 
PCa, the behavior of PCa has been correlated with mortality rates and is proportional 
of the average histological grade. The Gleason score is conceived and used to 
account for the heterogeneity of each tumor, where often a mixture of several grades 
are present. The Gleason score is obtained from the sum of the dominant grade and 
the grade of the second most important pattern. More recently, the Gleason score is 
modified for prostatic biopsy, where often the score is underestimated, and the new 
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recommendation for assigning the Gleason score in prostate biopsies is added up 
from the dominant grade and the worse grade (20,21,22). 
Table 1. Simplified Gleason grading system 
Grade Description 
1 Simple round glands, closely packed in rounded masses with well-defined 
edges. 
2 Simple rounded glands, loosely packed in vague, rounded masses with 
loosely defined edges. 
3A Medium sized single glands of irregular shape and irregular spacing with 
ill-defined infiltrating edges. 
3B Very similar to 3A, but small to very small glands, which must not form 
significant chains or cords. 
3C Papillary and cribriform epithelium in smooth, rounded cylinders and 
masses; no necrosis. 
4A Small, medium, or large glands fused into cords, chains, or ragged, 
infiltrating masses. 
4B Very similar to 4A, but with many large clear cells, sometimes resembling 
"hypernephroma". 
5A Papillary and cribriform epithelium in smooth, rounded masses, more solid 
than 3C and with central necrosis. 
5B Anaplastic adenocarcinoma in ragged sheets. 
Despite the high prevalence of prostate cancer in the Westem countries 
including U.S. and the second leading cause of cancer mortality, relatively little is 
known regarding the molecular mechanisms involved in prostate tumorigenesis. The 
etiology of prostatic cancers remains poorly understood. It is believed that malignant 
transformation or tumor progression involves a multistep acquisition of genetic 
alterations involving activation of oncogenes and repression of tumor suppression 
genes. The progression of tumorigenesis represents a continuum of phenotypic and 
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genetic changes from a premalignant state to invasive carcinoma (2,5,14). 
Premalignant lesions have been clearly defined for organs such as the colon, 
bladder, and cervix. The recognition and the establishment of specific features of 
such premalignant or precursor lesions have allowed better understanding of the 
natural history of their related cancer, and helped to identify prognostic factors that 
allow prediction on the outcome of individual patient with cancer. This concept may 
also apply to prostatic cancer, and lead to the search and recognition of precursor 
lesions which can be detected and which may permit application of prevention to the 
development of PCa. Recently, Prostatic Intraepithelial Neoplasia (FTN) have been 
widely recognized as potentially representing such precursors or premalignant 
lesions of prostatic adenocarcinoma, similar to the lesions of Cervical Intraepithelial 
Neoplasia (CES[) which are closely associated with carcinoma of the uterine cervix. 
Hence, there have been increasing recognition of FJN lesions, as well as increasing 
investigations in this area, as knowledge on PES[ lesions may also help better 
understanding of risks factors in prostate cancer (23,24,25,26,27,32,33,28). 
15 
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I. Introduction 
The concept of Prostatic Intraepithelial Neoplasia (PIN) originated from the 
observation of an atypical epithelial proliferation characterized by cellular atypia of 
the epithelium lining preformed prostatic ducts and acini (23,24,25,26,27,28). It is 
widely recognized as a possible biological precursor of prostatic adenocarcinoma 
based on its close association with PCa, and thus possibly representing the 
premalignant end of the morphologic continuum of cellular proliferations within 
prostatic ducts and acini to carcinomatous proliferation. It has been recognized as 
having a high predictive value as a marker for adenocarcinoma, its identification in 
biopsy specimens warrants further search for concurrent invasive carcinoma 
(23,24,25,26,27,28,29,30,31). Despite of a close relationship in anatomical 
distribution and in prevalence between PES[ lesions and prostatic adenocarcinoma, 
the supporting evidence establishing a definite link between PES[ and carcinoma is 
still lacking. But it appears to be logical that investigations focus on the relationship 
between PES[ lesions and PCa. 
II. Definition, Characteristics and Grading 
A. Definition 
PEsf is defined as an atypical epithelial proliferation characterized by 
cellular atypia of the epithelium lining preformed prostatic ducts and acini 
(23,24,25,26,27). Earliest description of premalignant change of prostate dated back 
to 1926 by Oerteil (32). Subsequently, many reports referred to this notion as 
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premalignant changes, and it was not until 1965 that the concept of prostatic 
intraepithelial neoplasia, then referred to as "intraductal dysplasia", was first 
described by McNeal, referring to these premalignant changes in prostatic epithelium 
seen in patients with PCa (33). He demonstrated microscopic foci of invasive cancer 
arising directly from dysplastic ducts and acini. The transition was described as 
typically abrupt, with a strand of invasive carcinoma penetrating the duct or acinar 
wall at a single point. The characterization of PIN lesions was reported only much 
later in 1986 by McNeal and Bostwick (24). 
The term "prostatic intraepithelial neoplasia" or “PEST, was proposed in 
1987 by Bostwick and Brawer, and was accepted by consensus at the 1989 
Workshop on Prostatic Dysplasia (Bethesda, Maryland, March, 1989) to replace 
previous terms as "large acinar atypical hyperplasia", “atypical primary hyperplasia", 
"hyperplasia with malignant change", "marked atypia", "duct-acinar dysplasia", and 
"intraductal dysplasia" (24,28,29,30,31,34). 
B. Histologic Characteristics 
PIN lesions develop from pre-existing prostatic ducts and acini, and is 
characterized on one hand by a normal glandular architecture which is better 
appreciated at low power microscopy, and on the other hand, by atypical cytologic 
features which are better recognized at high magnification, and are reminiscent of 
those seen in carcinoma. 
1. At low magnification - the architecture of FJN lesions : 
PES[ is readily identified at low magnification because glandular structures 
involved by PES[ appear darker staining than the surrounding normal ducts and acini 
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due to the hyperchromatism associated with crowded enlarged nuclei. The 
architectural patterns of cellular proliferations in PLN vary from flat epithelium to 
tufting and a florid cribriform pattern. Four main architectural patterns of high-grade 
PES[ have been described: tufting, micropapillary, cribriform, and flat 
(29,30,31,34,35) (Figures 3 to 6). The patterns often merge with each other. Clinical 
significance of these patterns is not known. 
• The micropapillary pattem is characterized by numerous slender, finger-like 
structures with bulbous tips projecting into the lumens, occasionally 
accompanied by delicate fibrovascular cores (Figure 3). 
• The tufting pattem is characterized by stratified mounds and heaps of cells 
protruding into the lumens, usually no more than 5 cell layers in thickness. 
These tufts are evenly spaced around most involved glands, imparting an 
undulating appearance to the epithelium due to the convex luminal profiles 
(Figure 4). 
• The cribriform pattem represents Gleason grade C cribriform type of PCa and is 
characterized by complex intraluminal proliferation of cells punctuated by 
multiple lumens varying from rigid, neatly punched-out rounded spaces to 
variably sized, ovoid to slit-like spaces (Figures 4,5). 
參 The flat pattem can consist of one or two layers of cells lining glands without 
evidence of stratification, but can also be a flat proliferation of pseudostratified 
epithelium (Figure 6). 
Other features such as arches (gently curving, "collapsible" epithelial 
structures), trabecular bars (curvaceous or rigid serpentine epithelial structures that 
traversed the glandular lumens and inserted into opposite or adjacent walls), 
18 
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"Roman" bridges (rigid, "non-collapsible" curved epithelial structures with 
supporting pillars) and apparent disruption of the basal cell layer with glandular 
outpouchings into the stroma may be found in high-grade PrN. 
2. At higher magnification - the cytologic features ofPIN lesions : 
The epithelium with PIN lesions is broadened due to proliferation and 
crowding of cells exhibiting the following salient cytologic abnormalities (Figure 7): 
參 nudear crowding causing overlapping or nuclear stratification 
• nuclear enlargement of varying degrees 
• nuclear pleomorphism 
• coarsening of chromatin causing hyperchromasia 
• nucleolar prominence or enlargement. 
These cytologic alterations are often associated and combined in varying 
degree of severity, and hence a grading system has been designed to differentiate the 
severity of these lesions (see below). FJN is usually multifocal and involves glands 
at many sites of the peripheral lobes. But occasionally PEN can be limited to a single 
gland either partially or completely. A variety of other cytologic features may be 
present in high-grade PIN including apical cytoplasmic luminal blebs suggestive of 
apocrine secretion (“apocrine snouts"), cytoplasmic pigment varied from scant fine 
brown or golden-brown particles to abundant coarse granules, optically clear 
cytoplasm, and microcalcifications within the epithelium. Proteinaceous eosinophilic 
secretions, corpora amylacea and crystalloids may be present in the prostatic lumen 
involved by high-grade PENL Unusual histologic types of FIN lesions that are 
uncommonly seen include signet-ring cell type, small cell neuroendocrine cell type, 
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Figure 3. Micropapillary pattem of PIN showing slender fmger-like projections, 
often with bulbous tips, with or without flbrovascular cores. (Hematoxylin-eosin 
stain, magnification x500) 
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Figure 5. Cribriform pattem of PIN showing a sieve-like pattem with complex 
intraluminal proliferation of cells. (Hematoxylin-eosin stain, magnification xl280) 
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Figure 6. Flat pattem ofPIN lesion with one crowding of dysplastic cells, exhibiting 
i prominent nucleoli. (Hematoxylin-eosin stain, magnification xlOOO) !• I L i 21 
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Figure 7. VTN lesion showing cytologic features of enlarged nuclei, nuclear 
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C. Grading 
The grading of PESf is established at high magnification microscopy. 
Initially three different grades of PIN have been identified, and characterized as 
follows: 
• PCs[ 1 - presence of variable nuclear enlargement, irregular cell spacing causing 
some nuclear stratification and generally inconspicuous nucleoli (Figure 8) 
• PIN 2 - additional presence of nuclear hyperchromasia and many cells exhibiting 
nucleoli (Figure 9) 
• PIN 3 - more extensive hyperchromasia and nearly all cell demonstrate prominent 
nucleoli (Figure 10) 
At the 1989 Workshop on Prostatic Dysplasia, it was agreed to designate 
PrN 1 as low-grade PINf, and PIN 2 and PESf 3 were grouped together as high-grade 
? m (29). 
• Low-grade PINf - characterized by presence of variable nuclear enlargement and 
irregular cell spacing resulting in nuclear stratification and crowding within the 
epithelium. Elongated hyperchromatic nuclei and small nucleoli are also present, 
but are usually not prominent. The cytoplasm may stain more densely than 
normal. 
• High-grade ?IN - in addition to the above features seen in low-grade FJN, there 
are more pronounced nuclear stratification and nuclear crowding. The majority of 
nuclei are enlarged with less variability in nuclear size. The nuclei are 
hyperchromatic with presence of prominent nucleoli. In PINF 2 lesions, prominent 
nucleoli are observed only in some cells, whereas in PDs[ 3 lesions, almost all 
cells exhibit prominent nucleoli. 
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Figure 8. PIN 1 lesion characterized by enlarged, crowded nuclei showing 
anisokaryosis, inconspicuous nucleoli, and uneven spacing. (Hematoxylin-eosin 
stain, magnification xl280) 
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Figure 9. PIN 2 lesion. In addition to the features of ?W 1, there are 
hyperchromatism and a few scattered cells with prominent nucleoli. (Hematoxylin-
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Figure 10. PIN 3 lesion. In addition to features ofPESf 2, more widespread cells with 
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III. Incidence and Prevalence of PIN 
The incidence of PES[ on needle biopsy varies from 7.6 to 31% in various 
studies depending on the population studied (37). In studies of whole prostate 
specimens, PIN lesions were present in most of consecutive cases of localized 
prostatic cancer and vary from 59 to 100%. PES[ is more commonly found in the 
apical portion of the prostate gland and resides in the peripheral zone in most cases. 
PrN was also found in the central zone in 21% and in the transition zone in 18 to 
31% (37). The incidence of PIN has been shown to increase with patient age in 
various studies. In an autopsy study with systematically step-sectioned whole 
prostates to study the incidence of PESf and invasive carcinoma in young men less 
than 50 years of age, Sakr et al observed presence of microscopic foci of ducts with 
low-grade PESf in the third decade of life with a frequency of 9% which increased to 
‘ 20 and 44% in the fourth and fifth decades of life respectively. High-grade PIN 
occurred only in men older than 40 years and in conjunction with prostate cancer 
(38,39). Moreover, in the study of McNeal and Bostwick, it was noted that 45% of 
men aged 50 to 59 years and 52% of those aged 60 to 69 years had PEST in prostates 
without carcinoma (24). The frequency decreased to 37% in men aged 70 to 79 years 
and 38% in those aged 80 years or more. The similar trend was also noted by Kovi et 
al (40). This suggested that the peak incidence of FIN appears to antedate that of 
invasive carcinoma. Other studies similarly observed that the frequency of high-
grade PESf was found to increase with age (39,41,44). In another series of studies of 
Troncoso et al , 70% of high-grade PIN with a mean age of 63.5 years was found 
associated with prostate cancer (23). 
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IV. Evidence Linking PIN with Prostatic Carcinoma 
A. Frequency, Extent and Grade of PIN in Prostates With and Without 
Carcinoma 
Several studies have established that the prevalence, extent and grade of 
PIN lesions in prostate glands harboring carcinoma are significantly higher than in 
prostates without invasive carcinoma, supporting the notion that PIN lesions may 
represent a precursor of carcinoma (23,24,30,41,42,43).(Table 2) McNeal and 
Bostwick compared the incidence of PES[ in 100 prostates with cancer and 100 
prostates without invasive carcinoma in an autopsy series and found that PDsT was 
present in 82% of prostates with invasive carcinoma but in only 43% of prostates 
without cancer (24). Oyasu et al also reported a more than 2 fold higher incidence of 
PIN in prostates with invasive carcinoma (94% of 51 cases) as compared to those in 
prostates without invasive carcinoma (38% of37 cases) (44). 
In a study of PES[ in steps-sectioning of prostates obtained at 
cystoprostatectomy for transitional cell carcinoma by Troncoso et al, the extent of 
PESf in prostates with carcinoma, as measured by number and size of separate foci of , 
PrN, was significantly greater than in cases without carcinoma (23). While only 15% 
ofthe prostates without carcinoma contained more than 10 foci ofPES[, 71% ofthe 
prostates with carcinoma had more than 10 foci and 28% had more than 20 foci of 
PESL Moreover, large foci of ?IN were also more frequent in prostates with 
carcinoma than those without carcinoma. 
In the same study, Troncoso et al showed an association of higher grade of 
PrM with invasive carcinoma. Foci of ?IN 3 were present in 72% of the prostates 
with carcinoma, but in only 18% of the prostates without carcinoma. Foci of PIN 1 
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were present in 7% and 14% of the prostates with and without carcinoma 
respectively. Moreover, 90% of cases with PES[ 3 were found to be associated with 
carcinoma (23). 
Table 2. Frequency of PES[ (all grades) and PIN 3 in prostates with and without 
carcinoma observed in various studies. 
Authors PES[ (all grades) FJN 3 Specimen 
Type 
(o/o) (o/o) 
Without With PCa Without With PCa 
PCa PCa 
McNeal & Bostwick(24) 43 82 4 33 A 
Oyasu et al(44) 38 94 8 82 A & R P 
Kovi et al (30) 46 59 15 33 A & R P 
Troncoso et al (23) 72 100 18 72 CP 
Epstein et al (42) - 100 - 100 RP 
(Stage A) 
Quinn etal (43) - 100 - 100 RP 
(Stage B) 
Abbreviations: PCa - prostatic carcinoma; A - autopsy; RP - radical prostatectomy; 
CP - cystoprostatectomy for bladder carcinoma. 
B. Zonal Distribution and Spatial Association of PIN with Carcinoma 
Similar to PCa, PE^ is multifocal and more commonly found in the 
peripheral zone of the prostate. Its incidence is much lower in the central and 
transition zones of the prostate (33). Troncoso et al noted that 81% and 86% ofthe 
foci of ?JN occurred in the peripheral zone of prostates with and without invasive 
carcinoma respectively (23). (Table 3) Occurrence of foci of PIN in transition and 
28 
Chapter 2. Prostatic Intraepithelial Neoplasia 
central zone of prostate was rare. In the same study, it was noted that ?JN is also 
spatially closely associated with carcinoma. PIN[ was found immediately adjacent to 
or within the same low power field as carcinoma in 62% of the cases. A similar 
study by Bostwick and Brawer noted that in 1093 ducts and acini with PEST, 41% 
(453 acini) were found within 1 high-power microscopic field of invasive carcinoma 
in a radical prostatectomy series (28). Moreover, 87% of the 453 acini were involved 
by PESf 3 indicating a relation of grade of ? W with proximity to carcinoma. This 
close association of PES[ and carcinoma was first described by McNeal in 1965 who 
noted in some cases a transition from ducts lined by highly atypical epithelium to 
invasive carcinoma (33). This supports the idea that invasive carcinoma may arise 
from PINf by budding off of small glandular structures at the sites of basement 
membrane and basal cell disruption. 
Table 3. Zonal distribution ofPIN in prostates with and without invasive carcinomas 
(Troncoso et aO(23) 
Zone of prostate Foci of PESf in prostate with Foci of PESf in prostates without 
carcinoma (%) 
carcinoma (%) 
Peripheral 147/182 (81) 916/1068 (86) 
Transition 8/182 (4) 7/1068 (1) 
Central 6/182 (3) 142/1068 (13) 
Uncertain 21/182 (12) 3/1068 (<1) 
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C. Basal Cell Layer Disruption 
The basal cells of the prostatic glands express high molecular weight 
cytokeratins which are not expressed in the luminal cells (18,28). The basal cells of 
the prostatic glands can be selectively labeled with monoclonal antibodies directed 
against these cytokeratins such as clone 34pE12. The basal cell layer is present in 
benign epithelial proliferations as a continuous circumferential layer but absent in 
carcinoma. However, the basal cell layer is disrupted in PESL (Figures 11 and 12). 
Bostwick and Brawer have shown that the frequency and extent of disruption of the 
basal cell layer is related to the grades of PINf and is greatest in FJN 3 adjacent to 
foci of carcinoma (18,28). Disruption was present in 56% of cases with high-grade 
PIN and was more common in acini adjacent to invasive carcinoma than in distant 
acini. More than 30% of the cell layer was disrupted in 52% of the high-grade PD^. 
On the contrary, less than 1% of ?W 1 was associated with disruption of the basal 
cell layer. These disruptions of the basal cell layer have been interpreted by some to 
represent the earliest stage of invasion or progression of PIN into invasive carcinoma. 
In their study, foci of basal cell disruption were associated with small glandular 
outpouchings resembling early invasion of carcinoma or progression of ?IN into 
invasive carcinoma (18,28). McNeal et al have also shown that areas of ?TN 
apparently giving rise to invasive carcinoma (so-called "transitive glands") 
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Figure 11. (A) PFN lesion. Epithelium linings involved by PIN are more 
hyperchromatic and heaped up at low magnification compared to surrounding 
normal glands at the top of the photomicrograph. (Hematoxylin-eosin stain, 
magnification x200). (B) Immunostaining for high molecular weight cytokeratin[ 
clone 34pEi2 showing discontinuous basal cell layer ofPINf foci in contrast with normal glands at both sides of the figure. (Immunoperoxidase method, magnification , x200) ^ 
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Figure 12. Higher magnification of immunostaining for high molecular weight 
cytokeratin in FJN lesions, demonstrating discontinuous basal cell layer. 
(Immunoperoxidase method, magnification xlOOO) 
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D. Morphometric Features, Proliferative Activity and DNA Content 
Morphometric studies by digital image analysis of Feulgen-stained tissue 
sections and cytospin preparations showed progressive abnormalities of nuclei and 
nucleoli in the progression of low-grade ?JN to high-grade FJN to invasive 
carcinoma. There is progressive increase in nuclear size, decrease in nuclear 
roundness, and increase in size and number of nucleoli and eccentrically located 
nucleoli (45,46,47). Studies evaluating the number of argyrophilic nucleolar 
organizer regions (AgNOR's) indicated that FJN has similar proliferative activity as 
PCa. The AgNOR count for FJN is significantly higher than benign prostatic 
proliferations but is similar to that of invasive carcinoma (48,49). Increasing grade of 
PIN have been correlated with increasing DNA proliferative activity and frequency 
of aneuploidy (50). The proportion of aneuploid nuclei increases from 20% in PES[ 1 
to approximately 50% in high-grade PIN. Moreover, aneuploid PIN tends to occur 
adjacent to aneuploid cancer, although diploid PIN has been found adjacent to 
aneuploid and diploid cancer. Aneuploid FJN next to diploid carcinoma was not 
observed (51). 
E. Immunophenotypic Profile 
Various immunohistochemical and histochemical studies showed that PJN is 
associated with abnormalities of phenotype and genotypic expressions, which are 
intermediate between normal prostatic epithelium and invasive carcinoma or similar 
with invasive carcinoma (Table 4). These results indicate impairment of cell 
differentiation and regulatory control with advancing stages of prostatic 
carcinogenesis. Nagle et al showed progressive changes of cytoskeletal proteins 
3 3 
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similar in PIN and PCa (52). They showed that both PIN and invasive carcinoma 
exhibit significantly increased reactivity with a monoclonal antibody KA4 directed 
against cytokeratins 14, 15, 16, and 19. About 90% of cases ofPEs[ and invasive 
carcinoma are immunoreactive with this antibody in contrast with only 4% of cases 
of prostatic hyperplasia. Vimentin expression was also shown to decrease 
progressively from expression in prostatic hyperplasia to reduced expression in PIN 
to absent in invasive carcinoma. Certain secretory proteins including PSA, PAP and 
Leu-7 which are secreted by the prostatic epithelium are reduced in PES[ suggesting 
loss of biochemical differentiation early during preinvasive phase of prostate cancer 
(31).However, two enzymes pepsinogen II (PG-II) and tissue plasminogen activator 
(t-PA) which are normally identified in luminal cells of the benign glands of the 
central zone were detected in FJN in the peripheral zone. These findings showed 
presence of deregulation and impaired differentiation in PIN. Neuroendocrine 
differentiation was also shown to be impaired and progressively decrease in normal 
epithelium, high-grade PIN, and carcinoma by Bostwick et al (53). 
Lectins bind with specific terminal sugars, some internal sugars and 
particular sugar linkages and to some oligomers in complex sugars present in 
membrane-bound and cytoplasmic glycoproteins (54). Variations in lectin binding 
are related to degrees of cell maturation and differentiation which may be altered in 
malignant transformation. In a study of lectin binding in prostatic tissue, McNeal et 
al reported decreased binding of Ulex europaeus (UEA-1) and seven other lectins in 
foci of dysplasia as compared to normal prostatic epithelium (55). In contrast, 
binding of Ulex europaeus lectin (UEA-1) was reported by Nagle et al to be 
increased in both ?JN and invasive carcinoma with little or no reactivity in 
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hyperplastic epithelium (52). A recent study of Drachenberg and Papadimitriou also 
found increased lectin binding with four of nine lectins investigated, including UEA-
1，in all grades of PIN and carcinoma suggesting similar aberrant expression of 
glycoprotein components in both PrN and invasive carcinoma (56). Aberrant 
expression of the ABH blood group antigens as well as the Lewis (Le) antigens 
commonly occur in many malignancies. The A, B, Le^ Le^ and X antigens were 
found to be reduced in PES[ and invasive carcinoma but present in 5 to 50% of 
normal cells by a study of Perlman and Epstein (57). Proliferating cell nuclear 
antigen, a cell-cycle proliferation marker, has been demonstrated to be increased in 
PESf and invasive carcinoma (58). 
Other markers have been reported to show progressive increase in PIN[ and 
carcinoma, including c-erbB-2 oncoproteins (59), bcl-2 oncoprotein (60), epidermal 
growth factor and epidermal growth factor receptor (61), type IV collagenase (62), 
Lewis Y antigen (57), transforming growth factor-alpha, and apoptotic bodies (63). 
F. Chromosomal and Molecular Genetic Alterations 
Chromosome mapping studies by fluorescence in situ hybridization and 
polymerase chain reaction techniques showed allelic losses involving chromosomes 
8, 10 and 16 in prostatic cancer (64,65). The short arm of chromosome 8 (8p), and 
the long arms of chromosomes 10 (lOq) and 16 (16q) appear to be particularly 
affected. The 8p and 16q losses frequently occur also in early carcinomas, whereas 
the 10q loss appears to be a later event. Frequent 8p allelic loss has been reported in 
low-grade localized and in high-grade invasive tumors, as well as in PESf which 
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Table 4. List of various studies on immunophenotypic changes in PES[ lesions and 
invasive carcinoma (37) 
Authors Biologic Markers PIN PCa 
Montironi et al (58) PCNA Increase Decrease 
Nagle et al (52) Cytokeratins 14, Increase Increase 
15, 16and 19 
Perlman and Epstein (57) Ulex Increase Increase 
Martenson et al (67) Lewis X Increase Increase 
Bostwick and Brawer (28) Basal cell specific Decrease Decrease 
cytokeratin 
McNeal (55), Lectins Decrease Decrease 
Drachenberg and 
Papadimitriou (56) 
McNeal et al (31), PSA Decrease Decrease 
Maygarden (68) 
Nagle et al (52) Vimentin Decrease Decrease 
Hughes et al (69), p53 Increase Increase 
Myers et al (70), 
Humphrey and 
Swanson (71) 
Cooney et al (72) Rb ？ Increase 
McDonnell et al (73), bcl-2 Increase Increase 
Stattin et al (74) 
• Myers et al (59), c-erB-2 Increase Increase 
Bostwick (75), 
Ware (76) 
Kuczyk et al (77) Cathepsin D Increase Increase 
Iwamura et al (78,79) PTHLP Increase Increase 
Bostwick et al (53) Neuroendocrine Decrease Decrease 
Abbreviations: PCa _ prostate carcinoma. 
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V. Conclusion 
Despite the observation of anatomical, morphological, immuno-
histochemical, and genetic features suggesting and attributing a malignant potential 
of PIN lesions, and despite the strong association of ? W lesions with PCa, the role 
of PIN in prostatic tumorigenesis, and the prove that PES[ is the biological precursor 
of PCa remain to be demonstrated. The clinical observations of the progression of 
dysplastic lesions to development of invasive are lacking, and the current imaging 
modalities have not been capable to do so. It is difficult to assess the malignant 
potential of a histologic abnormal lesion in a solid organ, such as the prostate, due to 
impossibility to follow clinically the evolution of such a lesion found at biopsy. The 
original biopsy site cannot be located subsequently with an acceptable degree of 
precision, and if carcinoma develops later, the tumor is usually too large by the time 
of detection to allow determination of its exact point of origin. 
Clinical observations also indicate that PESf lesions and PCa can be 
dissociated, in that FJN lesions can occur without carcinoma, and prostate with 
carcinoma may demonstrate complete absence of PIN lesions. In the study by Sakr et 
al of incidence of PIN in 249 younger male, they noted that the onset of high-grade 
FJN occurred later than the onset of carcinoma (39). While this observation does not 
exclude PIN as a precursor lesion to PCa, it also suggests that PINf lesions may not 
represent a necessary step in the development of cancer. Moreover, 70% of the 
prostates with early carcinomas lacked any high-grade PESF within the entirely 
embedded prostate gland (39). In those cases where both early cancer and high-grade 
PESf were present, only one-third of them clearly demonstrated the proximity of PIN 
lesions with carcinoma. It has also been argued that FJN lesion may be related to a 
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field effect, or to the intraepithelial spread of an adjacent carcinoma. It is possible 
that in cases where both PESf lesions and PCa are present, the two conditions may 
share some common steps in the process of oncogenesis. On the other hand, it may 
also be speculated that, while PES[ lesions and carcinoma coexist, they have different 
pathways in proliferation and growth. Clearly, many questions on the relationship 
between FJN and carcinoma remain unanswered, and further studies of the 
development, and the biological behavior of ?JN are therefore required to evaluate 
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Although severely dysplastic cells of PJN lesions are indistinguishable from 
the malignant cells seen in PCa, such cytological similarities appear insufficient to 
attribute a role to FJN lesions. A comparison of the phenotypic and genotypic 
characteristics of VJN and PCa is useful in understanding the relationship of this 
lesion to invasive adenocarcinoma. Studies of potential biomarkers such as growth 
factors and their receptors, oncogene products, and other biomarkers in PDsF lesions 
are difficult due to focal occurrence of these lesions. Other techniques involving 
microdissection of focal PIN lesions from tissue or tissue sections are tedious and 
have the disadvantage of contamination by surrounding stroma and histologically 
normal epithelium. Immunohistochemical techniques may be more suitable and are 
relatively simple to perform and can allow differentiation of biomarker expressions 
among the various components of the dysplastic gland or ducts (80). Expression of 
various biologic markers among PIN, benign epithelium and PCa were examined in 
this study by immunohistochemical techniques. 
I. p53 Protein 
Cancers are considered to result from aberrations in cellular proliferation 
and differentiation brought about by an accumulation of genetic alterations in or on 
the cells with activation of oncogenes or inactivation of tumor suppressor genes. 
Tumor suppressor genes are now known to play an important role in the 
development of a wide variety of human cancers. Various tumor suppressor genes 
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mutated in colorectal carcinoma (MCC) gene, the adenomatous polyposis coli (APC) 
gene, the neurofibromatosis type I fNFl) gene, and the p53 gene have been 
identified (81,82,83). 
Tumor suppressor genes are mainly involved in the regulation of cell 
growth and differentiation. The p53 gene is a well known tumor suppressor gene and 
its tumor suppressor function of p53 gene has been intensively studied. Alterations in 
the structure of p53 gene represent one of the most common genetic changes 
associated with human cancer, and experimental and clinical evidence have 
implicated p53 in the development of a wide range of malignancies. Over 2,000 
mutations in the DNA encoding the p53 gene have been analyzed in human 
neoplasms. Mutation of p53 gene, as expected for a tumor suppressor gene, may 
induce either an increased proliferative activity or appearance of a new function 
which is usually highly oncogenic (81). 
Mutations of p53 gene have been identified in colon and breast 
adenocarcinomas, small cell and non-small cell carcinomas of the lung, and brain 
tumors. The p53 immunohistochemistry is frequently employed to investigate the 
role of p53 gene in the tumorigenesis according to the currently accepted concepts 
that p53 gene mutations lead to accumulation of highly stabilized p53 mutant 
proteins which can be detected using monoclonal antibody immunohistochemical 
technique (5). 
A. p53 Protein Structure 
p53 protein was first identified in the late 1970s as a nuclear phosphoprotein 
which co-immunoprecipitated with the simian vims 40 large tumor antigen (SV40 T-
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Ag) (82). The p53 protein is encoded by a gene on the short arm of human 
chromosome 17 (17pl3 position) encoding for 11 exons. It contains 393 amino acids 
with a molecular weight of 53 kilodaltons (kDa) (81). 
Three distinctive regions can be identified in the wild-type p53 protein. The 
N-terminal is acidic and manifests activity of a transcriptional transactivation 
domain when fused to other DNA binding domains. It encompasses the binding sites 
of the adenovirus ElB protein, the host MDM-2 protein, and the binding site for the 
TATA box binding basic transcription factor TBR The C-terminal is more basic 
containing motifs involved in the regulation of DNA binding activity and 
oligomerization. The central region is conformationally flexible and contains the 
binding site for SV40 large T-antigen and sequence specific dsDNA (81). 
There are multiple phosphorylation sites located at both the amino- and 
carboxy-termini of the protein molecule. It can be phosphorylated at different amino 
residues by various protein kinases which may be accounted for different 
immunologic phenotypes of p53 found in human tumor cells. The sequence of amino 
acids from residues 234 to 258 is highly susceptible to cancer-related mutations (81). 
B. Biological/Physiological Function of p53 Protein 
Wild-type p53 is normally expressed at low level in all normal mammalian 
cells and has a short half-life of 20-30 minutes (83). It has an essential role in cell 
growth or differentiation and is implicated in nearly all forms of cell growth 
stimulation and inhibition (84). Previous studies indicated that p53 may be required 
early in the induction of cell proliferation, p53 is a transcriptional regulatory protein, 
capable of both stimulating and repressing gene expression. It can bind directly with 
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DNA in a sequence-specific manner and also influences gene expression indirectly 
by interaction with other transcription factors (81,82). 
A number of biological functions have been attributed to p53 protein. An 
important function of p53 protein is to regulate cell proliferation following DNA 
damage, by mediating G1 arrest or apoptosis. p53 expression is induced in cells 
exposed to DNA-damaging agents. As a transcriptional activator, the increased p53 
expression activates the expression of a number of genes in response to the DNA 
damage. Among the gene expressions activated by p53 protein are the 
p21WAFl/CIPl, GADD45 and cyclin G genes. The p21 gene encodes for a 21 kDa. 
protein which is an inhibitor of the cyclin-dependent kinases. Protein product of p21 
gene may regulates the transition of cell-cycle from G1 to S phase by blocking the 
kinase activity of cyclinA:yclin dependent kinases (Cdk) complexes which, in tum, 
prevent the phosphorylation of the retinoblastoma gene product (Rb). p21 also 
participate in DNA repair by binding with proliferating cell nuclear antigen (PCNA) 
which is a normal component of Cdk complexes and a regulatory subunit of DNA 
polymerase (84). The GADD45 protein binds with PCNA and stimulates DNA 
excision repair. It also inhibits entry of cells into S-phase of cell-cycle. Cyclin G may 
influence cell-cycle progression by modulating the activity of cyclin-dependent 
kinases. 
p53 also plays a direct role in excision repair. It interacts with proteins 
implicated in excision repair, including replication factor A (RPA), and three 
components of the EFIIH basal transcription factor, XPB/ERCC3, XPD, and CSB 
(84). In cell types that undergo terminal differentiation, overexpression of p53 
induces programmed cell death. Under the influence of certain cytokines, p53 has 
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also been associated with the induction of differentiation (81). 
p53 can bind nonspecifically to regions of single-stranded DNA in regions 
of DNA repair or replication forks and favors in annealing of base-paired regions. 
The p53 protein is inactivated by binding with mdm-2 protein which is 
transactivated by p53 expression forming a negative feedback control of p53 
activities (81). 
C. p53 Protein and Neoplastic Transformation 
Alterations in the structure of p53 gene are one of the most common genetic 
changes in human malignancies (85). Both overexpression and loss of p53 function 
can contribute to oncogenic transformation. Most of the p53 mutations are missense 
point mutations clustered in highly conserved domains of the gene spanned by four 
to nine exons. Several sites with frequent mutations have been described as 'hot 
spot’ mutations and vary among cancers with different tissue types. For example, the 
squamous cell carcinomas of head and neck have a hot spot region at codons 238-
248. Mutation at codon 175 is common in colon carcinoma but is unusual in 
carcinoma of the lung (81,85). 
Mutant p53 proteins have poor. DNA binding activity and lack function to 
transactivate p53 responsive genes. Most ofthe missense mutations of p53 are found 
in the central conformational domain of p53 which binds DNA directly. Mutations in 
the central domain abolish or weaken the DNA-binding and transactivation 
properties of p53. Mutant p53 proteins may also exert a "dominant negative" effect 
over wild-type alleles by forming oligomeric complexes with wild-type p53 protein, 
inhibiting the normal activity of p53 protein, p53 function may also be disrupted by 
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DNA tumor viruses that encode p53 binding proteins which either interfere with p53 
transcriptional activity (SV40 T-Ag, adenovirus ElB 55 kDa tumor antigen) or target 
p53 for proteolytic degradation (human papillomavirus E6). Overexpression or 
amplification of mdm-2 gene is found in a number of solid tissue tumors that binds 
to p53 and regulates its fiinction (81). 
The loss of regulatory effect of p53 in response to DNA damage increases 
genomic instability and promotes gene amplification. This releases the defective cell 
from Gl-S cell cycle control as well as p53 dependent apoptosis following DNA 
damage. The cell may proliferate to produce clones that are more susceptible to 
further genetic damage which may result in neoplastic transformation. 
Mutant p53 frequently have a much longer half-life than wild-type p53 
protein. It can be accumulated in the cell to high levels which can be detected by 
immunohistochemical methods. Immunoreactivity of anti-p53 antibodies is thus 
considered to be indirect evidence of p53 gene mutation (86). The increased stability 
of mutant p53 protein has been attributed to altered conformation which aid in 
stabilizing the p53 protein. Antibodies that recognize different conformational states 
of wild-type and mutant p53 protein products have been produced (81). Monoclonal 
antibody clone DO-7 which recognizes wild-type and mutant p53 proteins was used 
to detect accumulation of p53 protein in both benign and malignant prostatic lesions 
in this study. 
II. Proliferating Cell Nuclear Antigen (PCNA) 
It has been suggested that the metastatic potential of a tumor relies upon the 
random acquisition of genetic information (87,88). Higher rates of cell turnover 
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increase the likelihood of acquisition of such information (89). Proliferation rate may 
therefore be a determinant of a tumor's metastatic capability (90). Proliferation 
activity has been widely used as an important and independent prognostic factor in 
certain human cancers (91,92). Various methods have been used to determine the 
cellular proliferation rate including mitotic count, flow cytometry, and tritiated 
thymidine or bromodeoxyuridine incorporation. However, such methods have their 
limitations. Consistency of mitotic count is affected by variations in counting 
methods, technical factors, and dependence on objective identification of mitotic 
figures. Use of mitotic count may have problem when applied to prostate cancers 
which have an extremely low mitotic rates (93). Flow cytometry requires expensive 
equipment and the results may be affected by presence of cellular debris and non-
neoplastic cells yielding imprecise counting (94). Tritiated thymidine or bromo-
deoxyuridine incorporation techniques involves handling of radioactive isotopes, and 
can only be used with fresh specimens. Immunohistochemical assessment of cell 
proliferation offers the advantages of well preservation of cellular and tissue 
architecture during assessment and can be applied to retrospective studies with 
routine formalin-fixed, paraffin-embedded specimens. The technique is relatively 
simple and rapid. No radioactive isotopes are involved (95). Evaluations of PCNA 
and Ki-67 antigen immunostaining have been widely used to measure proliferative 
activities of various tumors. 
Proliferating Cell Nuclear Antigen (PCNA) is an auxiliary protein of DNA 
polymerase d and is essential for DNA synthesis (96). It is found to increase during 
Gi phase of the cell-cycle and is present in highest concentrations during S. Its level 
decreases during G � p h a s e and is lowest during mitosis (97). It was originally 
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detected with autoimmune semm from patients with systemic lupus erythematosus, 
which was found to contain an antibody against a nuclear antigen present in 
proliferating cells. Since then, a number of commercially available monoclonal 
antibodies to PCNA have been produced, including 19A2, 19F4 and PC10 (96). 
PCNA expression detected with these antibodies has been used as an index of cell 
proliferation in various studies. It has been suggested as an independent prognostic 
indicator in lymph node positive breast cancer (95). 
A. Biochemical Characteristics and Function 
PCNA is a 36 kDa non-histone acidic nuclear protein which is an auxiliary 
protein for DNA polymerase 5 and is required for DNA synthesis or replication (96). 
Immunofluorescence studies showed that there are two populations of PCNA 
existing during S phase of cell-cycle. One of them is nucleoplasmic as in quiescent 
cells and is easily extracted by detergent. The other is associated to specific nuclear 
structures and resistant to detergent extraction. Immunoreactivity of the detergent 
resistant PCNA is co-localized with bromodeoxyuridine (incorporated into DNA 
during S phase) in replication complexes, and their order of appearance throughout 
the S phase are identical. This shows that PCNA is tightly associated to the sites of 
DNA replication and probably has a role in DNA synthesis. Moreover, use of 
antisense oligonucleotides which lower the levels of PCNA are associated with 
inhibition of DNA synthesis. In the presence of PCNA and a multi-subunit complex 
called replication factor C, the enzyme polymerase 5 initiates leading-strand DNA 
synthesis by catalyzing elongation of Okazaki fragments to long DNA chains 
(91,94,96). 
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PCNA is also involved in DNA nucleotide excision-repair. PCNA can be 
found associated with chromatin at all phases of the cell cycle after ultraviolet 
irradiation in vitro. It is also expressed in non-cycling normal human keratinocytes in 
vivo after mild UV exposure (96). 
B. Regulation of PCNA Expression 
PCNA expression is regulated at both the transcriptional and post-
transcriptional levels. PCNA mRNA has been well documented to be induced by 
growth factors. However, the regulation in quiescent cells and those which are 
continuously cycling is different. In the continuously cycling fraction of cells, there 
is very little variation in protein or mRNA levels during the cycle. The contribution 
of transcriptional control is not clearly understood. But homeodomain-containing 
proteins bind to the PCNA promoter which probably modulate gene expression as it 
was found the homeodomain proteins regulate gradients of gene expression in other 
genes (91,94,96). 
Post-transcriptional mechanisms of regulation appear to be more important 
by in vivo studies. It has been observed that PCNA mRNA is stabilized in the 
presence of growth factors. It was therefore suggested that many cells continuously 
produce PCNA mRNA (at least at low levels) but rapidly degraded without 
translation. Consequently, in response to growth factors, cells may induce PCNA 
production by stabilizing PCNA mRNA. The mechanism is intriguing and involves 
alteration in mRNA stability as a consequence of splicing of intron 4 (96). 
Oncogenes may also participate in the regulation of PCNA mRNA levels by causing 
deregulation ofPCNA expression (96). 
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III. Ki-67 Antigen 
The Ki-67 murine monoclonal antibody was originally raised by Gerdes et 
cil against a crude nuclear fraction of the Hodgkin's disease derived cell line L428 
(98). The Ki-67 clone recognizes a labile epitope on a nuclear antigen which was 
expressed in cycling cells but absent from quiescent cells. It was named after its 
place of production in Kiel, West Germany and because the clone producing the 
antibody was grown in the sixty-seventh well of the tissue culture plate. 
The Ki-67 antibody recognizes a nuclear antigen of 395 kDa encoded by a 
gene located on chromosome 10 at position 10q25 (99). Cell cycle analysis showed 
that the Ki-67 antigen is expressed in dividing cells in all stages of the cell cycle 
except G�with expression appearing in mid to late G ,^ rising through S phase and G2 
to reach a maximum in mitosis (91,100). 
Study of topographical distribution of Ki-67 antigen by Braun et al showed 
that distribution of Ki-67 antigen in the nucleus is cell-cycle dependent and the 
staining patterns varied with the cell cycle (101). In the late Gj phase, the Ki-67 
antigen was present within the perinucleolar region. In S phase the antigen was also 
homogeneously stained in the karyoplasm. In G] phase, the staining within the 
karyoplasm existed as a mixed, finely granular and speckled pattern with 
perinucleolar staining still present. There was an intense perichromosomal Ki-67 
staining pattem during pro- and metaphase, in addition to karyoplasmic staining in 
prophase and cytoplasmic staining in metaphase. The intensity of staining rapidly 
diminishes during anaphase and telophase. The half-life of detectable Ki-67 antigen 
is therefore very short and is about 1 hour or less. This is probably due to the 
presence of numerous PEST ^)roline-glutamic acid-serine-threonine) motifs in the 
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protein which facilitate its rapid catabolism (102). 
The exact function of Ki-67 antigen is not known. It has been suggested as a 
timer for regulation on cell proliferation but was controversial. The Ki-67 has also 
been suggested as a major structural protein with DNA binding properties and a 
primary role in maintaining higher order structure for DNA during mitosis (102). 
Nevertheless, the Ki-67 antigen as a marker of cell proliferation has been used as a 
prognostic indicator in various malignancies, including PCa (102,105). 
The original mouse monoclonal antibody to Ki-67 could be applied only to 
frozen sections (98). Recently, the microwave antigen retrieval technique allowed 
antibodies produced against recombinant portions of the Ki-67 antigen to be 
successfully applied on formalin fixed tissues. A monoclonal antibody (MIB-1) was 
later produced which can be used with formalin fixed, paraffin embedded material 
after microwave antigen retrieval. More recently, a polyclonal antiserum was 
produced by immunizing rabbits with a synthetic peptide deduced from a 62 base 
pair DNA region encoding for the Ki-67 antigen, and was reported to have identical 
immunostaining pattem with the MIB-1 antibody(103). The proliferative activity of 
PCNA has been correlated and implicated in many tumors (100,104,105). 
IV. Epidermal Growth Factor Receptor 
I Epidermal Growth Factor Receptor (EGFr) is a growth factor receptor 
I 
I which can be activated by a family of growth factors including transforming growth 
factor a (TGF-a), amphiregulin, epidermal growth factor (EGF), and heparin-
binding EGF (106). The receptor is a transmembrane glycoprotein with intrinsic 
tyrosine kinase activity which mediates proliferative effects on cells upon activation 
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by binding with its ligands such as the EGF or TGF-a. Many types of epithelial 
malignancies have been found to display increased EGFrs on their cell-surface 
membranes including lung cancer, glioblastoma, breast cancer, head and neck cancer, 
and carcinoma ofthe bladder (107,108,109). 
A. The Protein Structure of EGFr 
The EGFr is a 170 kDa transmembrane glycoprotein with intrinsic tyrosine 
kinase activity (106,115). The receptor protein is composed of 1186 amino acid 
residues. The receptor protein can be divided into three domains. The extracellular 
domain comprises the aminoterminus of 621 amino acids containing the recognition 
site of EGF. There are 12 potential sites for amino-linked glycosylation. The 
membrane-spanning segment comprised of a hydrophobic domain of 23 amino acids. 
The intracellular carboxyterminal domain of 742 amino acids corresponds to the erb-
B oncoprotein and contains the tyrosine kinase with binding sites for ATP and 
substrate and can be closely aligned with retroviral protein-tyrosine kinases and to 
the catalytic subunit of cAMP-dependent protein kinase. The carboxyterminal tail 
has three tyrosine residues which are substrates for the intrinsic kinase. Binding of 
ligand causes dimerization (or oligomerization) with activation of tyrosine kinase 
activity that mediates transphosphorylation of both of the receptors (115). The 
cytoplasmic domain of EGFr has a close structural similarity to other cellular 
protein-tyrosine phosphotransferases identified as the proto-oncogenes of several 
： retroviral transforming proteins. This family of proteins is important in the 
regulation of cell proliferation and, when abnormally expressed, dictates the altered 
growth control of the transformed state (106). 
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B. Physiological Functions of EGFr 
The EGFr can be activated by a family of growth factors including EGF and 
TGF-a. Binding of its ligands with EGFr activates the intrinsic tyrosine kinase 
activity which initiates second messenger pathways associated with increased cell 
growth. The binding of the growth factor does not permanently activate the signal 
transduction pathway. The EGF receptor-ligand complex is subsequently internalized 
in pinocytotic vesicles and degraded in lysomsomes (110,111,112). 
Increased receptor expression is often associated with increased production 
of TGF-a by the same tumor cells, a condition known as "autocrine stimulation" 
(115). The concept of autocrine growth regulation was hypothesized by Spom and 
Todaro that autoproduction of growth factors essential for proliferation could provide 
a mechanism by which a cell could escape from the requirement for those particular 
growth factors in its environment, resulting in unregulated cell growth (113,114). 
The escape from growth regulation is one of the primary characteristics of malignant 
cell transformation (115). 
V. E-Cadherin 
Cadherins are a family of transmembranous glycoproteins responsible for 
homotypic (to same type) and homophilic (to same molecule) calcium-dependent 
cell-cell adhesion, important for establishing and maintaining intercellular 
connections (116,117). Cadherins play a major role in mediating intercellular 
physical adhesion. When cadherins are functioning, the inactivation of other 
J adhesion systems has little effect on cell-cell adhesion. Conversely, blockage of 
cadherins activity with anti-cadherins antibodies induces the dispersion of cell layers �i I 
丨 5 1 
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(116,118,119). 
Inter-cellular junctional complexes are responsible for the maintenance of 
epithelial structure. Weakening of which may possibly provide opportunity for 
cancer cells to detach from their epithelium of origin. Homotypic cell-cell adhesion 
molecules are found at the lateral border of most cells in normal epithelia (117). 
Cadherins play an important role in embryonic development and 
morphogenesis and in the maintenance of the normal structure and function of adult 
tissues (117). They may also play an important role in formation and maintenance of 
cancer cell nests and may be involved in the process of metastasis (119,120). 
A. Structure of Cadherins 
Cadherins are encoded by a gene located in the region of chromosome 16q 
at position 16q22.1 where multiple genes resided in this region are known commonly 
deleted in prostate cancer (117,121,122). They are classified into subclasses that 
share a basic structure and more than 10 subclasses of cadherins have been identified 
(117). The molecular characteristics of four subclasses, E-cadherin (epithelial 
cadherin or uvomorulin), P-cadherin (placental cadherin), N-cadherin (neural 
“cadherin), and L-CAM(liver cell adhesion molecule) have been well established 
(116). 
Cadherins typically contain an extracellular segment with distinctive 
sequence motif which is tandemly repeated forming autonomously folded protein 
modules, a single membrane-spanning region, and a cytoplasmic region. 
Experiments with molecular chimeras, neutralizing antibodies and peptide inhibitors 
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essential for binding specificities of cadherins (116,121). 
The intracellular carboxy-terminus interacts with a group of cytoplasmic 
proteins, the catenins, which function to mediate the cell-cell adhesion of cadherins 
by coupling the cadherin molecule to the microfilament cytoskeleton of the cell 
(122). 
B. E-cadherin Involvement in Neoplastic Invasion and Metastasis 
While Shiozaki et al showed that E-cadherin is expressed in the normal 
epithelium ofvarious tissues, heterogeneous expression was found in primary tumors 
of esophagus, stomach, and breast. E-cadherin was expressed in cell cytoplasm in 
some tumor cells with reduced expression. These results indicated that E-cadherin-
related intercellular adhesion is impaired in certain human cancer cells 
(119,123,124,125,127). 
There is evidence from in vitro and in vivo experiments that down-
regulation of E-cadherin favors the process of invasion and metastasis in some cell 
lines (123,124,127). Fixen et al showed that cancer cell lines that demonstrate an 
epithelioid phenotype and express E-cadherin by immunofluorescence, Westem blot, 
and Northern blot studies are noninvasive, whereas invasive cell lines express less E-
j cadherin and are dedifferentiated. Moreover, transfection and expression of E-
I cadherin complementary DNA (cDNA) prevents invasiveness and induces 
differentiation. But treatment with anti-E-cadherin antibodies restores invasiveness 
！ (125,126). 
！ Another study using Madin-Darby canine kidney (MDCK) cells, have 
f 
I 
shown a correlation between cadherin expression and cell behavior after 
1! 
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transformation with Harvey and Moloney sarcoma viruses. Nontransformed E-
cadherin-positive MDCK cells were not invasive but transformed E-cadherin-
negative MDCK cells were invasive in vitro (119). 
Correlation have been reported between the loss of E-cadherin expression 
and dedifferentiation, invasiveness, and poor prognosis in gastric cancer, breast 
cancer, colon cancer, hepatocellular carcinoma, and head and neck cancer 
(123,124,126). 
VI. CD44 
Metastasis in tumor progression is associated with detachment of 
carcinomatous cells from their primary tumor, penetration through the basement 
membrane in the connective tissue and invade adjacent structures including lymph 
and blood vessels, thus attaining metastatic outgrowth. Loss of adhesive function 
resulting from down-regulation of adhesive molecule plays a crucial role in the 
initial steps of the metastatic cascade of events. Expression of invasion-related 
proteins is of particular clinical relevance because failure of cancer treatment results 
from metastases development. CD44 is a typical example of a cell adhesion protein 
which undergoes dramatic structural and functional changes during malignant 
transformation (128,129). 
CD44 is a cell surface hyaluronate receptor and a cell adhesion molecule. It 
has been found to be widely expressed in a variety of cells of hematopoietic, 
epithelial, and mesothelial origins (129,130). The CD44 molecule has been 
associated with diverse physiological functions such as cell-cell adhesion, cell-
j matrix interaction, lymphocyte homing and circulation, T-lymphocyte activation, 
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signal transduction, hyaluran binding and internalization, and drug uptake and 
sensitivity. 
CD44 received its name during the Third International Workshop on 
Leukocyte Differentiation Antigens. It was first described in the early 1980s, based 
on the reactivity of an antibody called FlO.44.2. CD44 was previously referred to as 
lymphocyte homing receptor (gp90 sup Hermes), phagocytic glycoprotein (Pgp-l), 
extracellular matrix receptor III (ECMRIII), and hyaluronate receptors (H-CAM) and 
HUTCH-1 (128). 
A. Molecular Structure of CD44 
CD44 is a family of integral membrane glycoprotein molecules with 
molecular weights ranging from 80 to 250 kDa encoded by a single gene located on 
the short arm of human chromosome 11 ( l lp l3 position). Genomic DNA studies 
have documented that CD44 is encoded by at least 20 exons. The exons 1 to 5 (sl-s5) 
and 16 to 20 (s6-sl0) are almost invariably expressed by a large number of non-
I i 
I epithelial cells, including those which are hematopoietic; their product is referred to 
i j 
I as the "standard" or "hematopoietic" form of CD44 (abbreviated to CD44s or 
i 
j CD44H) (6). Exons 6 to 15, more often called vl-vlO, are alternatively spliced 
,i 
.1 
1 resulting in large number of possible isoforms. (Almost 100 isoforms have been 
号 
1 ¾ 
j documented to date. But more than 1000 combinations of isoforms are possible 
i 
theoretically) (128). 
The CD44 molecule consists of an extracellular domain, a transmembrane 
^ domain and a cytoplasmic tail. The extracellular domain consists of the N-terminal 
..丨 
'i 
1 domain and a membrane proximal domain. The N-terminal domain is encoded by 
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exons sl to s5 and is folded into globular loops with two binding sites for hyaluronic 
acid, also called hyaluronan. Two chondroitin sulphate chains can also be attached to 
the product ofexon s5. The membrane proximal domain is encoded by exons s6 and 
s7. It contains the site for insertion of the alternative splicing products between 
exons s5 and s6. Up to 381 amino acids encoded by various combinations of 
alternatively spliced exons vl to vlO are inserted at amino acid 223. The 
alternatively spliced exons do not show any significant homology with any other 
protein sequences and their functions are largely unknown (128). 
The short hydrophobic transmembrane domain is encoded by exon s8. The 
cytoplasmic tail is encoded by exons s9 and slO. The cytoplasmic domain contains 
two putative ankyrin binding sites which associate the CD44 molecule to 
cytoskeletal proteins (128). 
B. Physiological Functions of CD44 
CD44 is a hyaluronan binding protein which confer binding of cells to 
extracellular matrix even without the presence of calcium ions (128,129,130,131). 
Hyaluronate is the main ligand of CD44. It is an abundant saccharide component of 
the extracellular matrix that is believed to be important in a variety of pathological 
processes, including inflammation and tumorigenesis (131). Standard form (CD44s) 
or haematopoietic form (85 to 95 kDa) which has no expression of any of the 10 
variant isoforms is the most abundant form of CD44 in tissues (130). 
The binding affinity of CD44 molecule is modified by presence of various 
sugar moieties. 0-glycosylation and to a lesser extent N-glycosylation of the 
i 
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cells to bind to hyaluronan (128,132). However, glycosylation of some of the variant 
domains of CD44 has the opposite effect. This indicates that variable glycosylation 
of the CD44 molecule can serve as a mechanism regulating lectin function of CD44 
parallel to alternative splicing (128). 
The hyaluronan binding capacity is reduced by attachment of chondroitin 
sulphate or heparan sulphate to isoforms with regions encoded by exons v3. Variant 
CD44 isoforms with sequences encoded by v7 to vlO are shed quite easily into the 
extracellular space and abolish hyaluronan binding capacity. (128). The binding 
affinities of variant CD44 isoforms to hyaluronan also vary depending on type of 
alternatively spliced variant exon in the molecule. 
Apart from the hyaluronan binding capacity, CD44 can also bind with some 
other extracellular ligands such as chondroitin sulfate, heparin sulfate, fibronectin, 
serglycin and osteopontin but with lower affinity (130). 
Differential response of binding of CD44 with hyaluronate and osteopontin 
has been reported in the study of Weber et al (133). They observed that binding of 
CD44 with osteopontin mediates chemotaxis or attachment, depending on 
presentation of osteopontin in soluble or immobilized form but binding of CD44 
with hyaluronate mediates aggregation or attachment but not chemotaxis indicating 
different response of CD44 binding with separate matrix proteins. 
Consensus sequences indicate that CD44 has homology with ras oncogene 
and that CD44 may be a quanine nucleptide-binding protein with GTPase (quanine 
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C. CD44 Involvement in Neoplastic Invasion and Metastasis 
Studies on CD44 in various carcinomas and tumors showed that the 
expression of CD44 and its variant isoforms are associated with tumor progression, 
grade and aneuploidy (130). Elevated CD44 expression has been associated with 
systemic disease and poor outcome in non-Hodgkin's lymphoma (135). Increased 
expression of CD44 protein has been reported in breast carcinoma and gastric 
adenocarcinoma (136,137). Expression of CD44 variant isoforms has been correlated 
with tumor dedifferentiation and progression in stomach, lung, breast, colon and 
cervical cancer (138,139,140,141,142). However, down-regulation of CD44 
expression has been reported in urinary bladder transitional cell carcinoma, 
neuroblastoma and endometrial carcinoma which appears to be correlated with 
increase tumor grade and aneuploidy (143,144,145). 
VII. nm23 
The nm23 gene is a putative anti-metastatic gene initially identified by 
differential hybridization of a cDNA library with total RNA extracted from weakly 
and strongly metastatic murine melanoma cell lines (146,147,148). Nm23 expression 
was reduced in highly metastatic murine melanoma cell line (K-1735). Previous 
I 
studies showed that expression of nm23-Hl mRNA is inversely correlated with 
metastatic potential in several human malignant tumors, including primary breast 
carcinoma, gastric carcinoma and malignant melanoma (148,149). Moreover, 
mutation with deletion of the coding sequence of the nm23 gene has been reported in 
primary colorectal, breast, renal and lung carcinoma (149). Mutations and/or genetic 
i 
alterations of nm23 have been reported to be associated with a more malignant 
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phenotype in neuroblastoma and colon (150). Konishi et al reported reduced nm23 
immunoreactivity in metastatic PCa (151). Alteration of nm23 gene or gene product 
may cause loss of suppressor activity correlated with loss of differentiation in cell 
growth and possibly acquisition of metastatic phenotypes (149,152). 
Two nm23 genes, nm23-Hl and nm23-H2 (or NME1 and NME2 
respectively), have been identified which are 88 percent homologous to each other. 
Both genes are located on chromosome 17 at position 17q22, within 18 kb apart 
encoding for the 18.5 and 17 kDa proteins, nm23-Hl and nm23-H2 proteins 
respectively (152). 
A. Physiological Functions of nm23 Gene Products 
The specific function of nm23 gene products is not well understood. The 
gene products, nm23-Hl and nm23-H2 proteins, are identical to human nucleotide 
diphosphate kinases subunits A and B respectively purified from human erythrocytes 
(153). Nucleotide diphosphate fNDP) kinases are ubiquitous enzymes that catalyzes 
the transphosphorylation of nucleoside triphosphates to diphosphates involving 
transfer of the terminal phosphate of adenosine triphosphate (ATP) to a histidine 
residue of the enzyme and then to a nucleotide diphosphate through a ping-pong 
mechanism. They have a broad specificity for nucleotide substrates and accept both 
nucleotides and deoxynucleotides as substrates. Thus they are involved in the supply 
of most of the RNA and DNA precursors except ATP to cells (153,147). As a major 
source of guanosine triphosphates (GTP), NDP kinase occupies a central position in 
I 
I the control of cell functions and development. NDP kinase may play some roles in 
i 
signal transduction by supplying GTP to GTP-binding proteins. Eukaryotic NDP 
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kinases have been proposed to interact with heterotrimeric G proteins which are 
associated with signal transduction (154) Different functions have been proposed for 
nm23 gene including maintenance of nucleotide triphosphate's pool, direct or 
indirect interaction with GTP-dependent proteins and regulation of gene transcription 
(147). 
The regulatory function of gene transcription of nm23 gene have been 
implicated by the studies of Postel et al who identified that nm23-H2 gene is 
identical with the gene encoding the c-myc purine-binding factor (PuF), which is a 
transcription factor necessary for the expression of the c-myc proto-oncogene. The 
protein product of c-myc proto-oncogene functions in cellular proliferation, 
differentiation and tumor formation, presumably by modulating the expression of 
genes involved in these processes (155). 
Nm23 gene has also been associated with cell growth and proliferation 
based on observations that anti-nm23 antibodies recognize mitotic spindle 
microtubules and nm23 is highly homologous to pl9 protein, a neuroblastoma cell 
proliferation-related protein (156,157). This is supported by the studies of Caligo et 
al on nm23 gene expression in relation to growth state of the cells and observed the 
expression of nm23 mRNA in PHA-stimulated peripheral blood lymphocytes but 
undetectable in the resting counterparts (147). The level of nm23-Hl mRNA in 
synchronously cycling MCF-10 A cells was found to be high in the S-phase and late 
S-phase of the cell cycle but was absent or nearly absent in G�phase. The nm23-H2 
gene was expressed in growth-arrested MCF-lOA cells. Both genes were subject to 
up-regulation following serum re-addition to cell medium. The nm23 mRNA 
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in microtubule mitotic spindle polymerization. It has also been suggested that 
quantitative changes of nm23 protein on the cell surface control the cell 
attachment/detachment to the extracellular matrix through its shared arginine-
glycine-aspartic acid (RGD) sequence, a consensus motif for binding to the integrin 
family(158). 
B. Association of nm23 Expression in Tumors 
The metastasis suppressor function of nm23 in tumor progression is 
controversial. Although low levels of nm23-Hl expression have been linked to 
increased metastatic potential of some cell lines and tumors. Yet the A chain product 
of nm23-Hl is overexpressed in highly proliferative cells and in a variety of invasive 
human tumors. Thus its role in metastasis control is disputable (154). 
In colorectal cancer, conflicting results have been reported regarding nm23 
expression and tumor aggressiveness. Somatic allelic deletion of the nm23 gene has 
been reported in advanced cases of colon cancer, although not found by others. 
Reduced expression of nm23-Hl mRNA has been reported in patients with 
colorectal cancer associated with distant and hepatic metastases while others failed 
to find an association between its expression and metastatic spread. These 
.i 
] 
I discrepancies have been attributed to cross-reactivities of the antibodies or gene 
I . , 







Chapter 4. Objectives of Study 
1. To examine and compare the immunohistochemical expression of several 
biomarkers including p53, PCNA, Ki-67, EGFR, E-Cadherin, CD44, and nm23, 
in prostatic hyperplasia, ?JN lesions, and prostatic acinar carcinoma. 
2. Based on these expressions, to assess the possible correlation of these biological 
markers among prostatic hyperplasia, ?JN lesions, and carcinoma of the 
prostate, and to determine any relationship between these prostatic lesions. 
3. To determine from these cell proliferative biomarkers, whether there is a 
progression or continuum exist among prostatic hyperplasia, PIN lesions, and 










Chapter 5. Materials and Methods 
I. Materials 
A. Prostatic Specimens 
Prostatic specimens from the Prince of Wales Hospital (PWH) and the Hong 
Kong Baptist Hospital (HKBH) during the period between 1989 to 1994 were 
reviewed and a total of 122 cases were selected for this study. The patients were all 
Hong Kong Chinese with diagnosis of prostatic hyperplasia in 28 cases, of prostatic 
intraepithelial neoplasia (PIN) lesion alone in 46 cases, and of prostatic 
adenocarcinoma in 48 cases. Formalin-fixed paraffin embedded tissue blocks of 52 
patients were obtained from the Department of Anatomical and Cellular Pathology, 
Prince of Wales Hospital and prostatic tissue blocks of 70 patients were obtained 
from the Pathology Laboratory of the Hong Kong Baptist Hospital. The 
haematoxylin and eosin (H&E) stained slides for each case was examined and a 
representative paraffin block was selected for each case. 
Details of the types and sources of specimens, and of the pathology 
according to the type of specimens from these 122 patients are presented in Tables 5 
and 6. Of the 48 patients with prostatic carcinoma, only 3 were from radical 
prostatectomy performed for the treatment of prostatic carcinoma clinically confined 
to the organ. The remaining 45 cases were diagnosed from transurethrral prostatic 
resection (TUR-P) specimens performed for obstructive symptoms or prostatism. 
During the period of study, radical prostatectomy performed for the treatment of 
prostatic carcinoma was just beginning to be introduced in the 2 institutions. Of 
these 3 prostatectomies, only one case was associated with PINF 3 lesions. 
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Table 5. Distribution of types and sources of prostatic specimens. 
PWH HKBH Total 
TURP 49 20 69 
Prostatectomy, Partial 1 16 17 
Prostatectomy, Cystectomy 2 3 5 
Prostatectomy, Total 0 31 31 
Total No. 52 70 122 
Table 6. Summary of classification of pathology according to the type of prostatic 
specimens studied. 
Pathology TUR-P Total or Partial Total Average 
Prostatectomy Patients' 
Age 
PWH HKBH PWH HKBH (SD) 
Hyperplasia 5 2 0 21 28 67.3 (7.9) 
Pn^ 1 3 3 0 13 19 68.8 (11.0) 
PE^2 4 1 0 2 7 73.0(11.4) 
PnS[3 3 3 2 12 20 70.4(8.2) 
Prostatic carcinoma: 
Low-grade 10 3 0 0 13 72.3 (8.2) 
Intermediate-grade 10 5 0 1 16 72.2 (7.6) 
High-grade 14 3 1 1 19 74.9(7.1) 
Total 49 20 3 50 122 70.7 (8.8) 
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Ofthe 28 cases of prostatic hyperplasia, 21 cases were from partial or total 
prostatectomy, all performed as the Millin's operation at the Hong Kong Baptist 
Hospital, while the remaining 7 cases were from TUR-R 
Of the 46 cases of PrN lesions, 29 were from partial or total prostatectomy 
including 24 from the Millin's operation at the Hong Kong Baptist Hospital, and 5 
with cystectomy from both institutions. Of these 29 cases, 22 were identified as from 
the peripheral zone, including 12 cases ofPE^ 3, and 2 cases ofPDs[ 2, and 8 cases of 
PE^ 1. The remaining cases were removed piecemeal and the zonal distribution 
could not be ascertained. The 17 remaining cases of PDsf lesions were from TUR-P 
and were presumed to be from the transitional zone. 
B. Histological Classification 
Selected cases of nodular hyperplasia may show overgrowth of glands, 
smooth muscle stroma or both, and no other lesions such as prostatitis or PIN. Only 
nodular hyperplasia of glands were examined, and for each case, areas with 
proliferative glands and exhibiting uniform benign cytology of the secretory cells 
(Figure 13) were outlined and marked with a marker pen on the slides for study. The 
same area in each case was examined for all biological markers. 
Prostatic specimens with foci of PES[ were identified and classified into PIN 
1 (Figure 8), FJN 2 (Figure 9) and ?JN 3 (Figure 10) according to McNeal's initial 
grading system as described in Chapter 3 on PIN. Similarly, selected glands or group 
of glands with PESf lesions were marked on the H&E slides, and on serial 
consecutive sections to examine the same glands or group of glands for different 
immunohistochemical markers. All the sections in each case with ?JN were 
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reviewed to ensure that no coexisting PCa was present in the same patient. In a few 
cases of high-grade PIN lesions, the presence of basal layer was confirmed using 
specific antibodies for high molecular weight cytokeratin (clone 34pE12, Dako, 
Denmark)(159). 
Prostatic adenocarcinomas were graded according to the scheme proposed 
by Gleason as described in Chapter 2 (III), Pathology ofProstatic Cancers. For PCa, 
a Gleason score was obtained in each case by combining the predominant Gleason 
grade with the second most extensive Gleason grade. Based on their score, the 
prostatic carcinomas were grouped into low-grade, intermediate-grade and high-
grade carcinoma, respectively for a score ranging between 2 to 5, 6 to 7, and 8 to 10 
as described by Gleason (19). Low-grade carcinomas, including grade 1 and 2, were 
circumscribed and relatively confined with regular borders, small glands with or 
without some size variation, and some intervening stroma (Figure 14). Intermediate-
grade carcinomas included lesions similar to grade 2, with more complex glands to 
cribriform glands, and irregular invasive borders (Figure 15). High-grade tumors 
may present with interconnecting glands of grade 3 or large sheets (Figure 16), and 
poorly differentiated tumor with cords or single cells (Figure 17) The histological 
classification ofbenign and malignant lesions, as well as the number of cases studied 
per group are shown in Table 6. 
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Figure 13. Prostatic hyperplasia. (A) The acini are enlarged tortuous with 
papilliform growth of epithelium into the lumens in many of them. (Hematoxylin-
eosin stain; magnification x500); (B) The cells lining the glandular acini are tall, 
well-differentiated columnar cells with pale vacuolated eosinophilic cytoplasm and 
uniform round basal nuclei. (Hematoxylin-eosin stain; magnification xlOOO) 
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Figure 14. Low-grade prostate adenocarcinoma (Gleason grades 1,2). (A) 
Circumscribed tumor composed of simple rounded glands which are close to loosely 
packed. (Hematoxylin-eosin stain, magnification x500); (B) Glands consist of single cell layer with relat vely u iform tumor cells but more conspicuous nucleoli. Basals r  absent. (Hemat xyl n-eosin stain, magnification xlOOO) 
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Figure 15. (A) Intermediate-grade PCa (Gleason grade 3,3) with cribriform 
epithelium in smooth, rounded cylinders and solid masses. (Hematoxylin-eosin stain, 
magnification x400) (B) Higher magnification show pleomorphic tumor cells with 
pale to eosinophilic cytoplasm, high nuclear cytoplasmic ratio, anisonucleosis with 
conspicuous to prominent nucleoli (Hematoxylin-eosin stain, magnification xlOOO) 
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Figure 16. High-grade PCa (Gleason grade 4,5). Tumor cells are fused into cords 
and ragged infiltrating mass, with no glandular formation. (Hematoxylin-eosin stain; 
magnification xlOOO) 
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Figure 17. High-grade PCa (Gleason grade 5,5) showing anaplastic carcinoma with marked pleomorphic tumor ce ls arrange  in cords and nests. (Hematoxylin-eosinst in; magnification x1000) 
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II. Methods 
A. Preparation of Slides 
For each case, the block selected was sectioned into twenty consecutive 
paraffin unstained sections of 3 ^m thick using a Reichert Jung 2030 Biocut rotary 
microtome. The sections were mounted on 3-aminopropyltriethoxysilane-coated 
slides and dried in an oven at a temperature of 60^C for 1 hour. The slides were then 
kept in a cool dry place until further staining. For each case, a new H&E stained 
section was obtained and examined for 2 purposes: one was to confirm that the 
consecutive sections showed the desired pathological features; the second was to 
select and highlight with a permanent marker pen the area that would be examined in 
subsequent immuno stainings. 
B. Antibodies Used 
The antibodies, the manufacturers, and the antibody dilutions used in this 
study are presented in Table 7. Monoclonal mouse anti-human p53 antibody, clone 
DO-7 was purchased from the Dako Corporation, Demnark. The antibody recognizes 
an epitope between amino acids 19 to 26 in the N-terminus of the human p53 protein. 
The antibody was previously characterized and is specific for both mutant and wild-
type human p53 protein. 
Monoclonal mouse anti-PCNA, clone PC10, obtained from Novocastra 
Laboratories, New Castle, UK, was raised with rat PCNA made with the protein A 
expression vector pRlT2T as immunogen. It recognizes PCNA from all vertebrate 
species. 
The polyclonal rabbit anti-human Ki-67 was purchased from Dako 
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Corporation, Denmark, UK. The antibody was raised with synthetic peptide deduced 
from a 62 base pair region of the human Ki-67 gene as immunogen. 
Monoclonal mouse anti-epidermal growth factor receptor antibody was 
purchased from Novocastra Laboratories, Newcastle, UK. Recombinant fusion 
protein to the external domain ofEGFr was used as immunogen. 
Monoclonal mouse anti-human E-cadherin was obtained from the Progen 
Biotechnik GMBH, Heidelberg. The antibody was raised with human uvomomlin as 
immunogen. 
The monoclonal mouse anti-human CD44 protein, purchased from 
Novocastra Laboratories, Newcastle, UK, was raised with human T cells as 
immunogen. 
The mouse monoclonal anti-human nm23/NDPK-A protein purchased from 
Novocastra Laboratories, Newcastle, UK. is specific for human nucleoside 
diphosphate kinase A fNDP kinase A) with low crossreactivity with nucleoside 
diphosphate kinase B fNDP kinase B). Nucleoside diphosphate kinase A purified 
from human erythrocytes was used as immunogen. 
All primary antibodies were diluted with Tris-buffered saline (TBS), pH7.6^ 
in this study except for the anti-E-cadherin antibody which was diluted with 0.01M 
Tris-HCl-CaCl2 buffer, pH7.2l 
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Table 7. List of primary antibodies with dilutions and incubation time used. 
Antibody Clone Source Catalogue no. Dilution and 
incubation time 
Monoclonal anti- DO-7(IgG2b) DakoCorp., M7001-l l:50for30min 
human p53 Denmark 
5 ^g/ml IgG or 
.2 mgAnL protein 
Monoclonal anti-rat PC 10 (IgG2a) Novocastra NCL-PCNA 1:50 for 30 min. 
PCNA Laboratories, 
Newcastle, UK 
Rabbit anti-human Polyclonal Dako Corp., A047 1:75 for 30 min. 
Ki-67 Denmark 
Monoclonal anti- EGFr.ll3, Novocastra NCL-EGFr 1:15, overnight 
EGFr antibody (IgG2a) Laboratories, at 4°C 
Newcastle, UK 
(External domain) 
Monoclonal anti- 6F9 (IgGl) Progen PC10704 1:50，overnight 
human E-cadherin Biotechnik at 4°C 
GMBH, 
Heidelberg 
Monoclonal anti- F1044-2 (IgG2a) Novocastra NCL-CD44 1:80 for 30 min 
human CD44: Laboratories, 
HCAM Newcastle, UK 
Monoclonal anti- 37.6 (IgG2a) Novocastra NCL-nm23 1:200 for 30min 
nm23/NDPK-A Laboratories, 
protein Newcastle, UK 
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C. Determination of Conditions and Dilutions of Antibodies 
The specific conditions for inununostaining with each primary antibody 
were determined in preliminary studies. Firstly, the effects of heat-induced epitope 
enhancement and protease enzyme digestion were determined using positive control 
tissue sections treated each with either microwave heat treatment, trypsinization, or 
both microwave irradiation and trypsinization or no treatment prior to 
immunostaining with the labeled streptavidin biotin method as described by Elias et 
a/(160). 
Different tissues were used as positive controls for different biomarkers. 
Two cases each of breast adenocarcinoma and of colonic carcinoma were used as 
positive controls for p53 protein, EGFr, and Ki-67 antigen detection. A case each of 
normal colon and normal stomach was used as positive control for E-cadherin 
detection. Normal prostatic glands were used as positive control for PCNA and 
CD44 immunostainings. 
The microwave antigen retrieval technique as described by Shi et al was 
applied using a household microwave oven (SMEG, PBI International) with a 
maximum power output of 1000W (161). The slides were immersed in 65 ml of 10 
mM citric acid buffer, pH 6.0^ in a heat resistant plastic Hellendall stainingjar with a 
capacity of 16 slides and heated to boiling temperature by microwaving at maximum 
power (1000W) for 1 minute. They were then microwaved for 2 cycles of 5 minutes 
each at 40% power level (400W) such that the citric acid buffer boils every 10 to 15 
seconds. The buffer volume was maintained by topping up with additional buffer in 
between each microwave treatment. The slides were then allowed to cool for 20 
minutes in the buffer and then immersed in TBS, pH 7.6. 
74 
Chapter 5. Materials and Methods 
For the study of the effect of enzyme digestion, the slides were immersed in 
0.1% Trypsin solution' in 0.005M TRIS-HCl-CaCl2 buffer, pH 7.8' for 30 minutes, 
maintained at 37°C in a water bath. 
For study of the effect of both heat-induced antigen retrieval and enzyme 
digestion, the slides were treated with the microwave antigen retrieval method as 
described above, followed by enzyme digestion by immersing in 0.025% Trypsin 
solution^ for 1 minute at room temperature. 
Each primary antibody was tested at the dilution recommended by the 
manufacturer and incubated at room temperature (20 to 24°C) for 30 minutes. The 
immune reaction with each primary antibody was detected with the labeled 
streptavidin-biotin peroxidase method (LSAB). The method involved detection of 
specifically bound primary antibodies with species specific biotinylated secondary 
antibodies which were subsequently detected with streptavidin which was 
conjugated with the enzyme horse-radish peroxidase. The signal was then visualized 
with the substrate diaminobenzidene (DAB). 
Immunostaining results showed that microwave treatment resulted in 
enhanced staining of p53 protein, PCNA，Ki-67 antigen, EGFr, CD44, and nm23 
protein while trypsinization is more effective for E-cadherin detection. The effect of 
trypsinization was further tested by immunostaining for E-cadherin with various 
duration and concentrations of trypsin solution. 
The optimal dilution of primary antibody was then determined by staining 
with the selected antigen retrieval treatment but at different antibody dilutions 
varying from 1 in 50 to 1 in 1600 in 2 fold increments. For antibodies such as anti-E-
cadherin and anti-EGFr which showed very weak immune reaction, the primary 
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antibodies were incubated ovemight in a refrigerator at about 4°C. The staining 
results varied from a spectrum of weak to strong staining with varying degree of 
background staining. The highest dilutions with strong staining and absence of non-
specific background staining were selected for the study. But for PCNA 
immunostaining, a dilution was selected such that only the strongly stained positive 
nuclei remained positive whilst most of the secretory cells of normal prostatic 
epithelium were weakly to negatively stained. 
D. Immunostaining 
Paraffin sections were dewaxed with 2 changes of xylene for 3 minutes each 
and then rehydrated with graded alcohols. For detection of Ki-67, PCNA, CD44, 
nm23 and p53 proteins, tissue sections were pretreated with microwave antigen 
retrieval technique as described previously. For detection of E-cadherin, the slides 
were immersed in 0.1% Trypsin solution^ for 2 hrs, maintained at 37�C in a water 
bath. Subsequent immunostaining for p53 protein, PCNA, Ki-67, nm23, and CD44 
expressions was performed with an automatic immunostainer, Optimax 
immunostainer (Biogenex, San Ramon, CA). Immunostaining for EGFr and E-
cadherin, which required ovemight incubation of primary antibodies, was done 
manually. 
The slides were treated with 3% hydrogen peroxide (Catalog no. H-6520, 
Sigma) for 10 minutes at room temperature (about 20 to 24�C) to bleach endogenous 
peroxidase. This was followed by treatment with 3% bovine serum albumin? for 10 
minutes to block non-specific protein binding. The slides were then incubated with 
one of the primary antibodies. Species-specific biotinylated antibodies were then 
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applied as linking antibodies. For detection of p53 protein, PCNA, E-cadherin 
molecules and CD44 protein, biotinylated sheep anti-mouse whole antibody^ was 
applied at a dilution of 1 in 50 and incubated for 30 minutes at room temperature. 
For detection of nm23 protein, the above linking antibody was applied at a dilution 
of 1 in 200 and incubated for 45 minutes at room temperature. For detection ofKi-67 
protein, biotinylated donkey anti-rabbit whole antibody^ was applied at a dilution of 
1 in 200 and incubated for 30 minutes. 
All slides were then treated with streptavidin-peroxidase conjugate (Catalog 
no. P397, Dako Corporation, Denmark) at a dilution of 1 in 400 in TBS, pH7.6 and 
incubated for 30 minutes followed by color development with diaminobenzidene 
solution (DAB)(Catalog no. HK153-5K, Biogenex, San Ramon, CA, USA) for 10 
minutes. The slides were then counterstained with either Harris's haematoxylin^® 
(p53, PCNA, CD44, nm23) or methyl green^^ solutions (Ki-67 and E-cadherin). 
Dilution of anti-E-Cadherin antibody was done with 0.01 M Tris-HCl-CaCl2 
buffer, pH7.2. Other primary antibodies, linking antibodies and streptavidin-
peroxidase conjugates were diluted with 0.05 M TBS, pH7.6. The incubation steps 
were performed at room temperature of 18 to 24°C except for incubation with anti-E-
cadherin and CD44 antibodies which were performed in the refrigerator at a 
temperature of about 4°C. After each incubation step, the slides were washed 3 times 
with the washing buffer^^. 
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III. Interpretation of Immunostaining Results 
A. p53 Protein 
Immunostaining for p53 protein overexpression was considered positive, 
when brown nuclear staining was identified, regardless of its intensity. The 
proportion of p53-positive cells in the secretory or luminal prostatic epithelium for 
prostatic hyperplasia and PIN lesions or among tumor cells for carcinoma were 
graded semi-quantitatively as followed: 0 when all cells are negative, 1 when up to 
5% of lesional cells are positive, 2 when positive cells are greater than 5% and up to 
33% of positive cells, 3 when positive cells represent 33% to up to 66% of lesional 
cells, and 4 when more than 66% of cells to all cells are positive for p53 protein 
expression. Cases with expression of more than 5% or graded as 2 or above were 
considered to be positive for p53 mutation. 
B. PCNA 
Specific PCNA expression was accepted when positive brown diffuse or 
granular immunostaining confined to the nuclei was detected in lesional cells (162). 
A PCNA labeling index was obtained for prostatic hyperplasia, PESf lesions and 
carcinoma of the prostate, and it is expressed as the percentage of positive nuclei in 
these lesions when a minimum of 500 cells were examined, choosing the most 
positively stained area of the section, and using a 40X microscope objective. 
C. Ki-67 Antigen 
Immunoreactivity for specific Ki-67 expression was considered positive, 
when brown nuclear signal was unequivocally seen, regardless of the intensity. The 
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Ki-67 immunoreactivity was assessed semi-quantitatively by two light microscopic 
methods: one by cell counting by visual histological assessment and the other using a 
computer-assisted image analysis. Results from both methods were subsequently 
statistically compared and analyzed using Mann-Whitney U and Spearman's Rank 
significance methods. 
1. Cell Counting by Visual Histological Immunostaining 
For cell counting method, a Ki-67 labeling index was determined by 
observing the percentage of positive nuclei among at least 500 cells in an area of the 
section with highest labeling frequency with a 40X microscope objective. 
2. Image Analysis of Ki-67 immunostaining 
Quantitative analysis of Ki-67 protein expression was performed with the 
CAS200 Image Analyzer (Beckon-Dickinson, San Jose, California, USA). The 
percentage of area of Ki-67 immunoreactive nuclei to the total area of nuclei in 
tissue sections was measured with the Quantitative Proliferation Index (QPI) CAS 
Software Program (Cell Analysis Systems), provided by the manufacturer. The 
software utilizes the sum of the optical density of each nucleus to calculate the 
amount of nuclear immunostain present, according to the Beer-Lambert Law. The 
measurement of immunostaining relies on the principle of spectral separation, which 
allows discrimination between areas stained with two chromogens (DAB or methyl 
green) with complementary spectral characteristics. The CAS200 Image Analyzer is 
equipped with two matched image sensors which are set to capture images at 
wavelengths of 500 and 620 nm simultaneously. Microscopic fields of 300x200 um^ 
were measured with a 40X objective and can be displayed on the computer monitor. 
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The antibody threshold to account for background staining was established in a field 
without brown reaction product in each case. During measurement, an image of the 
total nuclear area in a microscopic field was mapped using a red (620/10-nm band 
pass) filter after adjusting the nuclear threshold such that only methyl green or DAB 
stained nuclei were measured. Then in the same microscopic field, a map ofpositive 
nuclear staining was obtained using a green (500/10-nm band pass) filter. The areas 
of the positive nuclear staining and the total nuclear area of each microscopic field 
were accumulated by the QPI CAS200 program. The proliferation index was 
expressed as the ratio of the total area mapped by the brownish nuclear staining and 
the total nuclear area. 
Before each measurement, Kohler illumination was first set up. A "Set 
Light" function provided by the QPI CAS program was then run to match 
illumination of the two image sensors and compensate for uneven illumination ofthe 
microscopic field by adjusting the light intensity and condenser position. For the 
assessment of Ki-67 proliferation index in PCa and benign proliferative lesions, an 
microscopic field with highest positivity was first selected and measured. Four 
adjacent fields above, below, to the left and right of it were then measured. If the 
total area of the measured fields was less than 10,000 um^ which is the total area of 
about 100 to 200 cells, additional nearby microscopic fields together with their 
adjacent fields were measured in similar manner. For the measurement of Ki-67 
proliferation index in prostates with FJN, due to limited number of microscopic 
fields with presence of PEST, as many fields as available were measured or until a 
total area of 10,000 um^ was measured. During measurement, only secretory or 
luminal cells in prostatic hyperplasia or FJN lesions were measured by using a 
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special image segmentation feature of the QPI CAS software of the image analyzer 
such that interested areas of the image displayed on a monitor were outlined with a 
computer mouse before measurement. 
D. E-cadherin, CD44 and EGFr 
Clearly defined brown immunostaining of the cell membranes of lesional 
cells were considered as positive expression for either E-cadherin, CD44 or EGFr. 
For CD44 immunostaining, the proportion of cells with specific antigen expression 
on the cell membranes of luminal cells or tumor cells were graded semi-
quantitatively as followed: 0 for absence of staining, 1 for up to 33% positive cells, 2 
for greater than 33% and up to 66% positive cells, and 3 for greater than 66% and to 
100% of positive cells, respectively. 
For EGFr immunostaining, the intensity of staining of specific antigen 
expression on the cell membranes of luminal cells or tumor cells were graded semi-
quantitatively as followed: 0 for absence of staining, 1 for weak staining, 2 for 
positive staining, and 3 for strong to very strong positive staining. Presence of 
cytoplasmic staining was noted and also recorded. For semi-quantitation of E-
cadherin, the expression for such marker was scored as 0 when immunostaining was 
absent, as 1 when immuno staining was heterogeneous, comprising mixed positive 
and negative cells, and as 2 when all lesional cells were uniformly positive, as 
described by Umbas et al (117). 
E. nm23 
Brown immunostaining signal in the cell membrane, cytoplasm or nuclei 
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was considered specific for nm23 protein expression or immunoreactivity. The 
extent and intensity of nm23 reactive cells in the luminal layer of prostatic 
epithelium and foci of carcinoma were assessed semi-quantitatively. The intensity of 
nm23 staining was graded as followed: 0 for negative staining, 1 for weak staining, 2 
for moderate staining, and 3 for strong intense staining. 
IV. Statistical Analysis 
Statistical analysis was performed with the SPSS statistical package, release 
7 (SPSS Inc.). The Mann-Whitney U significance test was used to test for significant 
differences in rank-ordered measurements between groups. Kruskal-Wallis 
significance test was used to test for significant differences among multiple groups. 
Comparison of proportions was done using Fisher's exact probability and Chi-square 
tests. Spearman's Rank test was used for correlation between different groups of 
cases. A probability level of 0.05 or smaller was considered statistically significant 
throughout the study. 
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One hundred and twenty two archival prostatic specimens from the 
Anatomical and Cellular Pathology Department of the Prince of Wales of Hospital 
and the Pathology Laboratory of the Hong Kong Baptist Hospital in Hong Kong 
were examined for expression of various biological parameters by 
immunohistochemical technique. The biological parameters include p53 protein 
expression, Ki-67 antigen, Proliferative Cell Nuclear Antigen (PCNA), CD44, E-
cadherin, Epidermal Growth Factor Receptor (EGFr), and the nm23-Hl polypeptide. 
The 122 prostatic specimens comprised of 28 prostatic hyperplasia (23%), 46 ?JN 
lesions (38%), and 48 PCa (39%). The 46 PES[ lesions were subdivided in 19, 7, and 
20 cases ofPES[ 1, ?W 2 and FW 3 (41%, 15% and 43% ) respectively. The 48 PCa 
were subdivided in 13, 15 and 17 cases, respectively of low-grade, intermediate-
grade and high-grade PCa. Patients' age ranged from 45 to 91 with a mean of 71. 
There was no significant difference in patient's age among the different sub-groups 
of lesions (Kruskal-Wallis, p-0.062). 
I. Immunohistochemical Results for p53 Protein 
The results of p53 expression for all prostatic lesions examined are 
summarized in Table 8. All 28 cases with prostatic hyperplasia and 46 cases of PIN 
lesions were negative for p53 immunostaining except for occasional equivocal weak 
staining accounting for less than 5% of cells. In prostatic hyperplasia, the luminal or 
secretory cells do not express p53, in contrast to many basal cells (Figure 18). 
However, not all basal cell layers demonstrated the presence of p53 positive cells, 
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and often both PIN lesions and their basal cell layer showed abscncc of p53 
immunostain (Figure 19). Positive nuclear staining of p53 protein with a proportion 
of more than 5% of cells, graded as 2 or above, was seen in 15 of the 48 (31.2%) 
PCa. In most cases, cells with nuclear expression of p53 protein were scattered 
within the neoplastic acini or sheets, such that not all tumor cells apparently showed 
accumulation of p53 protein (Figure 20). Diffuse expression of p53 protein was seen 
in 1 case of high-grade prostatic adenocarcinoma with Gleason score 9 (Figure 21). 
Cytoplasmic expression of p53 was noted in some mitotic cells. 
There was variation in p53 protein accumulation among the various 
histological types of prostatic carcinomas. While only 1 of the 13 (7.7%) low-grade 
PCa was immunoreactive, 31.3% and 47.4% of intermediate-grade and high-grade 
PCa were reactive to p53, respectively. 
Table 8. p53 Protein accumulation in prostatic lesions. 
Pathology No of Score of p53 accumulation * p53 
Cases 0 1 2 3 4 Pos (%)** 
BPH 28 28 0 0 0 0 0 (0.0) 
? m 1 19 19 0 0 0 0 0 (0.0) 
PIN 2 7 7 0 0 0 0 0 (0.0) 
PrSf3 20 18 .2 0 0 0 0 (0.0) 
Prostatic carcinoma 
Low-grade 13 5 7 1 0 0 1 (7.7) 
Intermediate-grade 16 5 6 3 2 0 5 (31.3) 
High-grade 19 4 6 4 4 1 9 (47.4.) 
* p53 Score: 0: 0% positive cells; 1: 1 to 5% positive cells (interpreted as equivocal 
and negative); 2: 5 to 33% positive cells; 3: 34 to 66% positive cells; 4: 67 to 100% 
positive cells. 
**p53 positive: cases with score 2 or above. 
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Figure 18. p53 Staining in prostatic hyperplasia with weak staining in some basal 
cells whereas luminal epithelial cells were negative (Immunoperoxidase method, 
magnification x800). 
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Figure 19. None of the PIN lesions demonstrate immunoreactivity for p53. 
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Figure 20. (A) Occasional p53-positive cells scattered among neoplastic glands with 
weak to strong staining in the neoplastic proliferations in PCa (Gleason grade 2,3). 
(Immunoperoxidase method, magnification x400); (B) More frequent p53 positive 
cells in neoplastic glands in PCa (Gleason grade 3,5) (Immunoperoxidase method, 
magnification x800) 
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Figure 21. Diffuse staining of p53 in a case of high-grade PCa (Gleason score 9). 
(Immunoperoxidase method, magnification xlOOO) 
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Statistical analyses of association of p53 protein accumulation with various 
histological types of prostatic lesions are shown in Tables 9 to 11. p53 Protein 
expression was independent of patient's age. Accumulation of p53 protein in the 
benign lesions was negative and was, clearly and significantly lower than in the 
carcinomas. There was a weak association of p53 accumulation with histological grade 
of PCa (Spearman's rho=0.312, p<=0.031). Although there was no significant 
difference in p53 overexpression detected between low-grade and intermediate-grade, 
or intermediate-grade and high-grade PCa, p53 accumulation was significantly 
different between low-grade and high-grade PCa as determined by a Gleason score 
below or more than 6. Moreover, there was also a significant association of p53 
accumulation with Gleason combined score (Gleason score less than 7 versus greater 
than 6, p=0.017, Mann-Whitney U). But the association of higher p53 accumulation 
just reached statistical significance when primary Gleason grade was considered 
(Gleason primary score less than 3 versus greater than 2, p=0.050, Mann-Whitney U). 
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Table 9. Results of univariate analysis of association of p53 overexpression in 
various subgroups ofpatients and subtypes of prostates specimens 
p53 Positive Mean score Statistical Tests Results 
No. (o/o) (SD) 
Age 
< 70 (n=50) 4 (8.0) 0.30 (0.61) Mann-Whitney U, p=0.100 
> 70 (n=72) 11 (15.3) 0.61 (1.0) Chi-square, p=0.5686 
Histological Types 
Hyperplasia (n=28) 0 (0) 0 (0) Kruskal-Wallis, p<0.001 
PESn (n=19) 0(0) 0(0) 
PESf2 (n=7) 0(0) . 0(0) 
? m 3 (n=20) 0 (0) 0 (0) 
PCa (n=48) 15 (31.2) 1.19(1.07) 
Prostatic carcinoma 
Histological grades Kruskal-Wallis, p<0.100 
Low-grade (n=13) 1 (7.7) 0.69 (0.63) Spearman's rho 0.312, p=0.031 
Mermediate-grade (n=16) 5 (31.3) 1.12 (1.02) 
High-grade (n=19) 9(47.4) 1.58(1.22) 
Gleason score 
<6(n=18) 2(11.1)" 0.03(0.16) 
> 6 (n=30) 13 (43.3) 0.72 (0.83) Mann-Whitney U, p=0.017 
Primary Gleason grade 
< 2 (n=10) 1 (10) 1.08 (1.00) Mann Whitney U, p=0.050 
>2(n=37) 14 (37.8) 1.32(1.17) 
Abbreviations: SD- standard deviation. 
Table 10. Correlation of p53 accumulation in various subtypes of prostatic lesions. 
Histological types Hyperplasia PE^1 ?JN2 PIN3 Prostatic 
Carcinoma 
Hyperplasia - n.s. n.s. n.s. p<0.001 
VJN 1 - n.s. n.s. p<0.001 
PES[2 - n.s. p<0.001 
PESF3 - p<0.001 
PCa -
Abbreviation: n.s., not statistically significant at p<0.05, 2-tailed. 
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Table 11. Correlation of p53 accumulation in prostatic carcinomas. 
Histological types Low-grade Intermediate-grade High-grade 
Low-grade - n.s. p=0.045 
Intermediate-grade - n.s. 
High-grade -
Abbreviation: n.s., not statistically significant at p<0.05, 2-tailed. 
II. Results of Immunostaining of PCNA 
Intense brown nuclear staining of PCNA was seen in 99 of the 122 cases 
(81%) of prostatic lesions with a mean labeling index of 8% (SD 13%) positive 
nuclei. They were scattered among the prostatic acini or sheets of neoplastic 
proliferations. In general, PCNA expression was scanty in secretory cells of nodular 
hyperplasia, and more commonly observed in adjacent basal cells (Figure 22). ?JN 
lesions also demonstrated variable expression from absence of staining to many 
immunoreactive cells (Figure 23 A,B). Carcinoma generally distinctly exhibited 
frequent expression of PCNA, which increased with tumor grades (Figures 24 and 
25). In most cases, PCNA positive cells of varying intensity in nuclear staining were 
also present in the stromal tissues as well as basal epithelial cells of the prostate 
specimens. 
The mean and standard deviations of PCNA labeling indices with strong 
intense nuclear staining in all prostatic lesions examined are summarized in Table 12. 
Positive cells with intense nuclear staining were present in 16 of the 28 cases (57%) 
of prostatic hyperplasia. The mean PCNA labeling index was 1.41% (SD 3.31%). Of 
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the 46 ?JN lesions, 37 cases (80%) showed positive epithelial cells with intense 
nuclear staining with a mean PCNA labeling index of2.59% (SD 3.15%). There was 
progressive increase in PCNA expression from PIN 1 to PIN 3 lesions. The mean 
PCNA labeling indices ofPESf 1, ?W 2 and ?m 3 lesions were 1.31%, 1.98% and 
4.03% respectively. The PCNA expression was significantly different between PIN 1 
and ?JN 2 ¢)=0.013), and ?W 1 and ?W 3 (p<0.001). But PCNA expression 
between ?W 2 and ?JN 3 were not significantly different (p=0.162). 
All of the 48 PCa demonstrated positive PCNA expression with a mean 
PCNA labeling index of 17.03% (SD 16.65%). The PCNA labeling indices increased 
from 6.15% (SD 3.43%) in low-grade carcinoma to 13.2% (SD 7.14%) in 
intermediate-grade carcinoma to 28.39% (SD 21.03%) in high-grade carcinoma. 
.Table 12. PCNA labeling indices in various prostatic lesions 
Histological Categories No of PCNA Labeling index, % positive nuclei 
Cases Mean SD 95% CI 
Hyperplasia 28 1.41 3.31 -0.02 - 0.12 
? m 1 19 1.31 3.29 0 
P ^ 2 7 1.98 1.19 -0.53 -2.08 
Pn^3 20 4.03 3.07 -0.22 - 0.85 
Prostatic carcinoma 
Low-grade 13 6.15 3.43 1.49 -2.49 
Intermediate-grade 16 13.20 7.14 1.77 - 3.88 
High-grade 19 28.39 21.03 5.68 - 10.65 
All groups 122 8.0 12.97 
Abbreviations: SD- standard deviation; CI- confidence interval. 
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Figure 22. PCNA immunostaining in prostatic hyperplasia showing positive 
immunostaining in occasional basal cells but generally negative to weak staining in 
luminal cells (Immunoperoxidase method, magnification x600) 
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Figure 23. PCNA immunostaining in ?IN 3 lesion showing occasional 
immunoreactive cells (A) to many positive cells (B). (Immunoperoxidase method, 
magnification x800) 
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Figure 24. PCNA immunostaining in intermediate-grade PCa (Gleason grade 2,3) 
showing scattered immunoreactive cells with various intensities. (Immunoperoxidase 
method, magnification x600) 
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Figure 25. PCNA immunostaining in high-grade PCa (Gleason grade 4,5) showing distinctly widespread strong immunoreactivity. (Immunoperoxidase method,mag ification x600) 
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The results of statistical tests of association of PCNA with various 
clinicopathological variables were summarized in Tables 13 to 15. The mean PCNA 
labeling indices were not correlated with patient's age. PCNA expression was 
strongly correlated with prostatic hyperplasia, PlN and PCa (Spearman's rho 0.786, 
p<0.001). Although no statistical difference in PCNA labeling indices was detected 
between hyperplasia and PIN 1 (p=0.847), PCNA expression was significantly 
different between prostatic hyperplasia and PIN 2 (p=0.015), or prostatic hyperplasia 
and FJN 3 lesions (p<0.001). Moreover, PCNA expression in prostatic hyperplasia or 
PIN lesions were significantly lower than PCa (p<0.001). 
Among the prostatic cancers, PCNA expressions were strongly 
correlated with worsening of histological grade. The Spearman's rho of correlation 
was 0.678, p<0.001. PCNA expression was also associated with higher combined 
Gleason score (Gleason score less than 7 versus greater than 6, Mann-Whitney, 
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Table 13. Correlation of PCNA labeling index with subgroups of patient and 
histological categories and P-values generated in statistical significance tests. 
Mean PCNA Statistical Tests & P value 
Labeling index (SD) 
Age 
< 70 (n=50) 6.65 (10.51) Mann-Whitney U, p=0.241 
>70(n=71) 9.07(14.58) 
Histological Types 
Hyperplasia (n=28) 1.41 (3.31) Kruskal-Wallis, p<0.001 
? m 1 (n=19) 1.31 (3.29) Spearman's rho 0.786, p<0.001 
VJN2 (n=7) 1.98(1.19) 
VJN3 (n=20) 4.03 (3.07) 
PCa(n=48) 23.16(16.82) 
Prostatic Carcinoma 
Histological grades Kruskal-Wallis, p<0.001 
Low-grade (n=13) 6.15 (3.43) Spearman's rho 0.678, p<0.001 
Intermediate-grade (n= 16) 13.20 (7.14) 
High-grade (n=19) 28.39 (21.03) 
Gleason score 
< 6 (n=18) 8.08 (4.73) Mann-Whitney, p<0.001 
> 6 (n=30) 23.15 (19.00) 
Abbreviations: SD- standard deviation. 
Table 14. P-values of statistical significance test of association of PCNA labeling 
index among various histological groups of prostatic lesions (Mann-Whitney U test). 
Histological types Hyperplasia PESFl PE^2 FJN3 PCa 
Hyperplasia - n.s. p=0.015 p<0.001 p<0.001 
prsf 1 - p=o.oi3 p<o.ooi p<o.ooi 
PESf2 - p=0.162 p<0.001 
Pn^J3 - p<0.001 
PCa -
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Table 15. P-values of statistical significance test of association of PCNA labeling 
index in prostatic carcinomas (Mann-Whitney U test). 
Histological types Low-grade Intermediate-grade High-grade 
Low-grade - p<0.001 p<0.001 
Intermediate-grade - p=0.010 
High-grade -
III. Immunostaining and Quantitation of Ki-67 Expression 
Ki-67 Expression was confined to the nuclei of immunoreactive cells with a 
focal to diffuse staining pattern. Positive cells were scattered in prostatic acini or 
among the neoplastic cells, but were also present in occasional basal cells of 
prostatic acini, stromal tissue and other tissue components. Chromosomes of mitotic 
cells were strongly positive for Ki-67. Immunoreactive cells for Ki-67 were 
generally absent in hyperplasia and PIN lesions, but were observed in high-grade 
VJN lesions (Figure 26) and with increasing distribution in high-grade carcinoma 
(Figures 27 and 28). 
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Figure 26. Ki-67 immunostaining in PES[ 3 showing strong immunostaining in 
scattered lesional cells. (Immunoperoxidase method, magnification x800) 
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Figure 27. Ki-67 immunostaining in intermediate-grade PCa (Gleason grade 3,3) 
showing a few immunoreactive cells in the neoplastic cribriform glands. 
(Immunoperoxidase method, magnification x300) 
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Figure 28. Ki-67 immunostaining in high-grade PCa (Gleason grade 5,4) showing 
numerous immunoreactive neoplastic cells. (Immunoperoxidase method, 
magnification x800) ’ 
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The labeling indices of Ki-67 expression evaluated by manual counting and 
quantitative image analysis (QIA) were summarized in Table 16. The mean Ki-67 
labeling indices were low in prostates with benign hyperplasia, PIN 1 and ?IN 2 all 
with an index ofless than 2%. Labeling indices ofKi-67 expression in ?JN 3 lesions 
varied from 0 to 6.6% (QIA) and 0 to 9% (manual count). The mean labeling indices 
of Ki-67 expression in prostatic carcinomas as evaluated by manual method 
increased from 3.7% (SD 2.4%) in low-grade PCa to 6.7% (SD 5.5%) in 
intermediate-grade PCa to 17.4% (SD l"6.0%) in high-grade PCa. A similar trend of 
Ki-67 expression was observed in Ki-67 labeling indices as measured by QIA. The 
labeling indices were 3.6% (SD 2.5%), 6.8% (SD 5.7%) and 12.9% (SD 13.6%) in 
low-grade, intermediate-grade, and high-grade prostatic carcinomas respectively. 
Table 16. Summary ofKi-67 expression in prostate specimens. 
Manual Quantitative Image 
Analysis 
Histological Categories No of (% positive cells) 
(% positive nuclear area) 
Cases 
Mean SD Mean SD 
Hyperplasia 28 0.03 0.10 0.37 0.59 
PIN 1 19 0.14 0.39 0.25 0.40 
PIN2 7 0.27 0.41 0.99 0.86 
PIN3 20 1.16 2.07 1.50 1.68 
Prostatic carcinoma 
Low-grade 13 3.66 2.40 3.55 2.51 
Intermediate-grade 16 6.67 5.49 6.76 5.72 
High-grade 19 17.36 16.02 12.91 13.62 
Abbreviations: SD, standard deviation. 
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Statistical analyses of association of Ki-67 expression and various 
histological types of prostatic lesions are presented in Tables 17 to 21. Ki-67 
expressions as measured by quantitative image analysis and manual counting were 
independent of patient's age. Ki-67 expression as measured with both methods was 
significantly associated with histological subtypes of prostate lesions with non-
parametric Kruskal-Wallis test. Further evaluation showed that Ki-67 expression was 
strongly correlated with histological subtypes of prostate as measured by both 
methods. (Manual count, Spearman's rho=0.766, p<0.001; Quantitative image 
analysis, Spearman's rho=0.610, p<0.001). Ki-67 expression was also correlated 
with histological grade ofPCa (Manual count, Spearman's rho=0.432, p<0.002; QIA, 
Spearman's rho=0.329, p<0.023). The mean Ki-67 labeling index of prostatic 
carcinomas with primary Gleason grades 3, 4 and 5 was significantly higher than in 
prostatic carcinomas with Gleason grades 1 and 2. 
Moreover, Ki-67 labeling indices as measured by quantitative image 
analysis was strongly correlated with the results measured by manual counting. 
Regression analysis showed a linear relationship between the labeling indices 
obtained from quantitative image analysis versus manual counting with a 
proportional bias of 0.736 (95% confidence interval was 0.678 to 0.795; Pearson's 
correlation was 0.916, p<0.001). The proportional bias of less than 1 indicated that 
measurement of Ki-67 expression by quantitative image analysis always yielded a 
lower value than manual counting. (Figure 29) 
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Table 17. Expression of Ki-67 in various subgroups of patients and subtypes of 
prostates specimens 
Manual Counting Quantitative Image Analysis 
Ki-67 PI Statistical Tests Ki-67 PI Statistical Tests 
% PN (S.D) %PNA (S.D.) 
Age 
< 70 (n=50) 3.25 (7.22) Mann-Whitney, 3.47 (7.25) Mann-Whitney, 
> 70 (n=72) 4.86 (9.99) P=0.269 3 9^ (7 40) P=0.165 
Histological Types 
Hyperplasia (n=28) 0.03 (0.10) Kruskal-Wallis, 0.37 (0.59) Kruskal-Wallis, 
PIN1 (n=19) 0.14(0.39) 口<0皿 0.25 (0.40) ? < 0观 
nTXTo / n\ a ^n mA^\ Spearman's rho nooznQ<� Spearman's rho 
PD^2 (n=7) 0.27(0.41) o^66,p<0.001 0.99(0.86) o.610,p<0.001 
? m 3 (n=20) 1.16(2.07) 1.50(1.68) 
PCa (n=48) 10.09 (12.08) 8.50 (9.97) 
Prostatic Carcinoma 
Histological grade Kruskal-Wallis, Kruskal-Wallis, 
Low-grade 3.66(2.40) � 0 . 0 1 2 3.55 (2.51) P ^ 0 7 7 
Intermediate-grade 6.67(5.49) Spearman'srho 6.76(5.72) Spearman'srho 
High-grade 17.36(16.02) 0.432,p=0.002 12.91(13.62) 0.329,p=0.023 
Gleason score 
< 6 4.48 (4.11) Mann-Whitney, 3.94 (3.17) Mann-Whitney, 
> 6 13.45 (13.99) P=0.011 io.l7(11.74) P=0.024 
Primary Gleason grade 
<2(n-10) 3.20 (2.58) Mann-Whitney, 2.97 (2.57) Mann-Whitney, 
>2(n=38) 11.9(12.96) P=0.017 10.0(i0.7) P=0.037 
Abbreviations: PI- Proliferation index; PN- Positive nuclei; PNA- Positive nuclear 
area. 
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Table 18. P-values of association of Ki-67 labeling index (Manual counting) in 
various subtypes of prostatic lesions by Mann-Whitney U test. 
Histological types Hyperplasia PDsfl ?JN2 PD4 3 PCa 
Hyperplasia - n.s. n.s. p<0.001 p<0.001 
PES[ 1 - n.s. p=0.011 p<0.001 
pns[ 2 - n.s. p<0.001 
PHs[3 - p<0.001 
PCa -
Abbreviation: n.s., not statistically significant at p<0.05, 2-tailed. 
Table 19. P-values of association of Ki-67 labeling index (QIA) in various subtypes 
of prostatic lesions by Mann-Whitney U test • 
Histologicaltypes Hyperplasia PEsFl PESF2 PDsF3 PCa 
Hyperplasia - n.s. n.s. p=0.021 p<0.001 
Vm 1 - p=0.030 p=0.005 p<0.001 
PESf 2 - n.s. p=0.005 
PIN3 - p<0.001 
PCa -
Abbreviation: n.s., not statistically significant at p<0.05, 2-tailed. 
Table 20. P-values of association of Ki-67 labeling index (Manual count) in various 
histological types of prostatic carcinomas by Mann-Whitney U test. 
Histological types Low-grade Litermediate-grade High-grade 
Low-grade - n.s. p=0.006 
Intermediate-grade - n.s. 
High-grade -
Abbreviation: n.s., not statistically significant at p<0.05, 2-tailed. 
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Table 21. P-values of association of Ki-67 labeling index (QIA) in various 
histological types of prostatic carcinomas by Mann-Whitney U test. 
Histological types Low-grade Intermediate-grade High-grade 
Low-grade - n.s. p=0.030 
Intermediate-grade - n.s. 
High-grade _ 
Abbreviation: n.s., not statistically significant at p<0.05, 2-tailed. 
Figure 29. Scatter plot of Ki-67 labeling indices by Quantitative Image Analysis 
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IV. Immunohistochemical Expression of EGFr 
Positive membranous immunoreactivity for EGFr was expressed strongly in 
the basal cell layer of almost all hyperplastic prostatic glands as well as of glands 
with presence of PIN lesions. In contrast, EGFr reactivity in secretory cells in 
hyperplasia and PIN was much lower iri staining intensity or absent. The staining of 
EGFr in secretory cells was membranous and confined to the basal-lateral 
membranes between adjacent cells, though the staining was overlapping with that of 
basal cells. In prostatic carcinomas, EGFr staining was identified in membranous, 
cytoplasmic distributions, or both, with occasional nuclear staining in some cases. 
EGFr was not detectable in stromal cells or other tissue elements. The results of 
EGFr immunostaining in all prostatic lesions examined were summarized in Table 22. 
Positive staining for EGFr in the secretory cells or neoplastic cells was 
present in 38 of the 122 prostate specimens (31.1%). In prostatic hyperplasia, 
although all cases expressed strong EGFr immunoreactivity in basal cells of prostatic 
epithelium, only 5 out of 28 cases (17.9%) showed weak positive staining in the 
basal-lateral membrane of secretory cells. 
Similar strong immunoreactivity of basal cells was also present in the PIN 
lesions. Of the 45 FIN lesions, 7 cases (15.6%) showed weak immunoreactivity in 
the luminal cells (Figure 30). EGFr expressions in ?IN 1, PIN 2, and FTN 3 were 
respectively 21.1 %, 28.6% and 5.0%, but no statistical difference was observed 
between their immunohistochemical expression of EGFr. 
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Table 22. EGFr Expression in prostatic glands 
EGFr Expression * EGFr positive ** 
Pathology No of 0 1 2 3 Aberrant + (%) 
cases staining 
Hyperplasia 28 23 5 0 0 0 5 (17.9) 
PESf 1 19 15 4 0 0 0 4 (21.1) 
PrSf2 7 5 2 0 0 0 2 (28.6) 
PE^3 20 19 1 0 0 0 1 (5.0) 
Prostatic Carcinoma 
Low-grade 13 8 5 0 0 3 5 (38.5) 
Intermediate-grade 16 8 7 1 0 9 8 (50.0) 
High-grade 19 6 6 3 4 13 13 (68.4) 
Total 122 84 30 4 4 25 38 (31.1) 
* EGFr expression: 0- negative; 1- weak staining; 2- positive staining; 3- strong 
positive staining; Aberrant- with cytoplasmic staining. 
** EGFr positive: cases with EGFr scores 1 or above. 
Of the 48 PCa, EGFr immunostaining was present in 26 cases (54.2%). 
Although the immunostaining pattem was mainly membranous, focal cytoplasmic 
staining was also present in most cases (Figure 31). There was variation in staining 
intensity among different histological grades of PCa but the staining intensity was 
always lower than or similar to immunostaining of basal cells of adjacent benign 
epithelia. The frequency of EGFr expression increased from 38.5% (5 out of 13) 
low-grade carcinoma to 50% (8 out of 16) intermediate-grade carcinoma and to 
68.4% (13 out of 19) high-grade carcinoma (Figures 32 and 33). A stronger intensity 
of EGFr staining was also noted in high-grade PCa. All 4 cases with very strong 
immunoreactivity were high-grade PCa. 
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Statistical analyses comparing various prostatic lesions, and various grade 
of carcinoma, are summarized in Table 23. EGFr expression in prostatic lesions was 
not correlated with patient's age. While there was no statistical difference in the 
EGFr expression between prostatic hyperplasia and PIN lesions, EGFr expression in 
PCa was significantly higher than both prostatic hyperplasia and PIN lesions except 
PIN 2 lesions. Among the PCa, EGFr expression was correlated with histological 
grade of prostatic carcinoma.(Spearman's rho is 0.358, p<0.001) and Gleason score 
(Mann-Whitney U, Gleason score >=6 versus >6, p=0.008). 
Table 23. Results of univariate analysis of association ofEGFr expression in various 
subgroups of patients and subtypes of prostates specimens 
Mean score (SD) Statistical Tests 
A ^ ‘ “ ~ 
< 70 (n=50) 0.36 (0.75) Mann-Whitney U, p=0.223 
>70(n=72) 0.49 (0.81) 
Histological Types 
BPH (n=28) 0.18 (0.39) Kruskal-Wallis, p<0.001 
PEsf 1 (n=19) 0.21 (0.42) Spearman's rho 0.346, p<0.001 
PESf 2 (n=7) 0.29 (0.49) 
PES[ 3 (n=20) 0.05 (0.22) 
PCa(n=48) 0.85 (1.03) 
Prostatic carcinoma 
Histological grade 
Low-grade (n=13) 0.38 (0.51) Kruskal-Wallis, p=0.031 
Int. grade (n=16) 0.56 (0.63) Spearman's rho 0.358, p=0.012 
High-grade (n= 19) 1.42 (1.31) 
Gleason Score 
<6 (n=18) 0.33 (0.49) Mann-Whitney U, p=0.008 
>6 (n=30) 1.17(1.15) 
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Figure 30. E-cadherin immunostaining in FJN 3 showing partial loss ofmembranous 
staining in dysplastic cells. (Immunoperoxidase method, magnification x800) 
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Figure 31. E-cadherin immunostaining in high-grade PCa (Gleason grade 5,4) 
CLmmunoperoxidase method, magnification x500) ， 
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Figure 32. EGFr immunostaining in high-grade PCa (Gleason grade 4,4) showing 
heterogeneous expression of EGFr in neoplastic cells with both membranous and 
cytoplasmic staining. (Immunoperoxidase method, magnification x800) 
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Figure 33. EGFr immunostaining in PCa (Gleason grade 5,4) showing strong 
membranous and focal cytoplasmic expression of EGFr in neoplastic cells. 
Pmmunoperoxidase method, magnification x400) 
109 
Chapter 6. Results 
V. E-Cadherin 
The results of the E-cadherin immunostainings in all prostatic lesions 
examined are summarized in Table 24. Positive membranous immunoreactivity for 
E-cadherin was expressed in the secretory and basal epithelia of apparently normal 
glands as well as in all the proliferative glands in nodular hyperplasia. Membranous 
staining in luminal cells appeared to be most conspicuous in the basolateral aspects 
(Figure 34). However, of the 122 prostate specimens, 16 cases showed negative 
staining in the prostate epithelium of benign glands and were considered as a result 
of tissue fixation and removed from calculation of statistical analysis. Reduced 
expression of E-cadherin with a heterogeneous staining pattem or complete absence 
was present in 50 cases (47%) of the 106 remaining prostate specimens. No nuclear 
staining was seen but occasional cytoplasmic staining was observed in a few cases of 
carcinoma, representing an aberrant expression of E-cadherin. Stromal elements and 
vascular tissue did not show any immunoreactivity. All 25 cases of prostatic 
hyperplasia showed continuous membranous staining of E-cadherin in the secretory 
or luminal epithelium as well as basal cells of the prostatic epithelium. The prostatic 
epithelial cells were stained with a basolateral pattem and the luminal cell 
membranes were always unstained (Figure 34). Of the 36 cases ofPIN lesions, 17 
cases (47%) showed diffiise expression of E-cadherin (Figure 35). But the remaining 
19 cases (53%) showed reduced or complete loss of expression for E-cadherin 
including 5 cases (42%) of ?JN 1, 2 cases (33%) of ?m 2, and 12 cases (67%) of 
PD^ 3 (Figure 36). There was no statistical difference in E-cadherin expression 
between ? m 1 and ? m 2, or ? m 2 and ?JN 3. But FJN 1 and ?JN 3 were 
significantly different in E-cadherin expression. 
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Of the 45 cases of PCa, 31 cases (69%) showed reduced or loss of E-
cadherin expression including 7 cases (58%) of low-grade, 7 cases (47%) of 
intermediate-grade, and 17 cases (94%) of high-grade PCa (Figure 37). Correlation 
of loss of E-cadherin expression with tumor grade was not significant (Spearman 
rho=-0.270, p=0.073). Although high-grade carcinoma was associated with the 
lowest frequency of E-cadherin positivity and was significantly different from 
intermediate-grade PCa ¢)=0.004), its expression was not significantly different from 
low-grade carcinoma in E-cadherin expression. An association of loss of E-cadherin 
expression with high Gleason score was not observed. 
Table 24. Distribution of E-cadherin protein expression in prostate lesions. 
E-cadherin Expression * E-cadherin Loss 
Pathology No of 0 1 2 Loss (%) 
cases 
Hyperplasia 25 0 0 25 0 (0.0) 
? m 1 12 0 5 7 5 (41.7) 
VJN2 6 0 2 4 2 (33.3) 
?m 3 18 5 7 6 12 (66.7) 
Prostatic Carcinoma 
Low-grade 12 6 1 5 7 (58.3) 
Intermediate-grade 15 3 4 8 7 (46.7) 
High-grade 18 11 6 1 17 (94.4) 
Total 106 25 25 56 50 (47.2) 
* Extent of E-cadherin: 0 for negative or loss of immunoreactivity; 1 for 
heterogeneous staining or partial loss of expression; 2 for diffuse staining or normal 
expression. 
111 
Chapter 6. Results 
•4' . i - r ‘ , " ‘ ， r , , ， ’ 〜 . J . ^3 …。广：乂 , • . 
、二 一 (. , ^ . > ^ 〜 ； - ' < S a ^ _ � / ) 
....,^  .  - . -7 一 jR • ;>:"V .^  1二 - T e^ ,� 
• ^ v . 个 、 : ， • ^ : • 一 - " ^ - { ^ 、《. ―‘ - _ ^^>', * . 身 , -
, % , ^ - ^ , f .. . * S ^ . 1 , , - ^ * — : 、 _ 、 、 . : J f ^ „ ' s ^ • ‘ ， 
？ ‘”、： ^ ¾ ^ ^ - S^^-^^V1 9^ 
- : ” - > 毫 , 碰 , ‘ . W y f 醫 t | # . 夢 趣 ‘ 
Pf / ¢ ^ P ^ m M 
m ^ - 爆 . , > - i w " ' m i 
“ ^ ¾ ' 憐 ： ^ ^ ^ ^ ^ ^ m 
_ ： ； ^ ^ 1 
_ ^^ • . _ 
. . . _ ^ m 
Figure 34. E-cadherin immunostaining in prostatic hyperplasia showing continuous 
membranous staining ofbasal cells, and the basolateral aspects ofthe luminal cells of 
the prostate. (Immunoperoxidase method, magnification x400) 
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Figure 35. E-cadherin immunostaining in VW 1 showing preserved membranous 
staining in basal cells and luminal cells. (Immunoperoxidase method, magnification 
x800) 
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Figure 36. E-cadherin immunostaining in PIN 3 showing partial loss ofmembranous 
staining in dysplastic cells. (Immunoperoxidase method, magnification x800) 
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Figure 37. E-cadherin immunostaining in high-grade PCa (Gleason grade 5,4) 
(Immunoperoxidase method, magnification x500) ’ 
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Statistical analyses comparing various prostatic lesions, and various grades 
of carcinoma, are summarized in Tables 26 to 28. E-cadherin expression in the 
prostate lesions was associated with patient's age (age >70 verses < 70, p=0.004). 
There was a significant correlation of reduced E-cadherin expression from prostatic 
hyperplasia to ?JN lesions to PCa (Spearman rho=-0.553, p<0.001). Although E-
cadherin expression in prostatic hyperplasia was not significantly different from ?W 
2 lesions, there was significant loss of E-cadherin expression in PIN 3 and PCa as 
compared to prostatic hyperplasia. Moreover, PIN 3 and PDsf 2 were not significantly 
different from PCa in E-cadherin while ?JN 1 showed significantly higher E-
cadherin expression than PCa ¢)=0.001). 
Table 25. Results of univariate analysis of association of E-Cadherin expression in 
various subgroups of patients and subtypes of prostates specimens 
Mean score (SD) Statistical Tests 
^ 
< 70 (n=50) 1.58(0.69) Mann-Whitney U, p=0.002 
> 70 (n=72) 1.08(0.86) 
Histological Types 
Hyperplasia (n=25) 2.00(0) Kruskal-Wallis, p<0.001 
PES[ 1 (n=12) 1.58(0.51) Spearman's rho=-0.553, p<0.001 
^JN2 (n=6) 1.67(0.52) 
PE^3 (n=18) 1.06(0.80) 
PCa (n=45) 0.87(0.87) 
Prostatic carcinoma 
Histological grade 
Low-grade (n=12) 0.92(1.00) Kruskal-Wallis, p=0.009 
Int. grade (n=15) 1.33(0.82) Spearman's rho= - 0.270, p=0.073 
High-grade (n=18) 0.44(0.62) 
Gleason Score 
< 6 (n=17) 1.06(0.97) Mann-Whitney U, p=0.171 
> 6 (n=28) 0.75(0.80) 
114 
Chapter 6. Results 
Table 26. P-values of association of E-cadherin expression in various subtypes of 
prostatic lesions.(Mann-Whitney U test) 
Histological types Hyperplasia PESfl FJN2 PES[3 PCa 
Hyperplasia - p=0.041 n.s. p<0.001 p<0.001 
? m 1 - n.s. n.s. p=0.010 
VW 2 - n.s. p=0.047 
PESf 3 - n.s. 
PCa -
Abbreviation: n.s., not statistically significant at p<0.05, 2-tailed. 
Table 27. P-values of association of E-cadherin expression in various histological 
types of prostatic carcinomas. (Mann-Whitney U test) 
Histological types Low-grade Intermediate-grade High-grade 
Low-grade - n.s. n.s. 
Intermediate-grade - p=0.004 
High-grade -
Abbreviation: n.s., not statistically significant at p<0.05, 2-tailed. 
VI. CD44 
Positive membranous immunostaining of CD44 protein was present in 57 of 
the 122 cases (47%) of all the prostatic lesions examined. In the secretory layer of 
prostatic epithelium, positive staining was confined to the basolateral surface of the 
secretory cells. The luminal apical surface was always negative for CD44 protein 
staining. While there was variation in distribution of CD44 staining in the secretory 
cells, the basal cells in prostatic glands were always strongly stained (Figure 38). 
The results of immunostaining for CD44 protein expression are summarized 
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in Table 28. Of the 28 prostatic hyperplasia, positive CD44 staining was present in 
19 cases (67.9%). Among them, 29% showed continuous membranous staining, 39% 
showed discontinuous membranous staining in the basolateral membranes of 
adjacent luminal cells (Figure 38). No staining was observed in the rest of specimens 
except for strong CD44 expression at the adjacent membranes between the basal 
cells and luminal cells. 
Table 28. Distribution of CD44 protein expression in prostate lesions. 
Extent of CD44 Expression* CD44 
Pathology No of 0 1 2 3 Pos (%) 
cases 
Hyperplasia 28 9 8 3 8 19 (67.9) 
PD^ 1 19 5 4 4 6 14 (73.7) 
PD^2 7 2 2 2 1 5 (71.4) 
PD^3 20 12 5 1 2 8 (40.0) 
Prostatic Carcinoma 
Low-grade 13 6 2 2 3 7 (53.8) 
Intermediate-grade 16 13 2 0 1 3 (18.8) 
High-grade 19 18 0 1 0 1 (5.6) 
Total 122 65 23 13 21 57 (46.7) 
* Extent ofCD44: 0- negative; 1- 0 to 33% positive cells; 2- > 33% to 66% positive cells; 3-
> 66% to 100% positive cells. 
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Of the 46 PrN lesions, 27 cases (59%) showed positive membranous 
staining for CD44 immunoreactivity in the luminal cells of the dysplastic glands 
(Figure 38). These 27 PEs[ lesions were distributed in 73.7%, 71.4% and 40% of 
respectively ?W 1, ?W 2 and PIN 3 lesions. Among them, continuous membranous 
staining was present in 32%, 14% and 10% of PEM 1, ?W 2 and ?m 3 lesions 
respectively. Although the frequency and distribution of CD44 expression was not 
significant different between ?W 1 and PES[ 2, or ?JN 2 and ? W 3, CD44 expression 
in VJN 3 was significantly lower than in VJN 1 (p=0.026). 
Positive staining was present in 11 of the 48 (23%) PCa with 8% showing 
diffuse staining in the sheets of neoplastic cells (Figure 39). CD44 expression was 
inversely correlated with histological grade of the PCa (Spearman's rho=-0.433, 
p=0.002). The frequency of CD44 immunoreactivity reduced from 7 out of 13 cases 
(54%) of low-grade PCa, to 3 out of 16 cases (19%) of intermediate-grade PCa, to 1 
out of 19 cases (5.6%) ofhigh-grade PCa (Figure 40). 
Statistical analyses comparing CD44 expression in various prostatic 
lesions, and various grade of carcinoma, are summarized in Tables 30 to 32. There 
was an inverse correlation of the CD44 protein expression with histological 
categories from benign hyperplasia, PIN, and PCa (Spearman's rho=-0.475, 
p<0.001). While there was no statistical difference in CD44 expression among 
prostatic hyperplasia, PIN.1 and FJN 2 lesions, CD44 expression in these lesions 
were significantly higher than in PCa (prostatic hyperplasia versus PCa, p<0.001; 
PIN 1 verses PCa, p<0.001; PEN 2 versus PCa, p=0.043). However, CD44 
immunoreactivity in PIN 3 was not significantly different from PCa (p=0.195). 
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Table 29. Results of univariate analysis of association of CD44 expression in 
various subgroups of patients and subtypes of prostates specimens 
Mean score (SD) Statistical Tests 
A ^ ~~ 
< 70 (n=50) 0.54 (0.61) Mann-Whitney U, p=0.423 
> 70 (n=72) 0.68 (0.77) 
Histological Types 
Hyperplasia (n=28) 1.04 (0.74) Kruskal-Wallis, p=0.001 
PESf 1 (n=19) 0.95 (0.62) Spearman's rho -0.475, p<0.001 
PD^2 (n=7) 0.86(0.69) 
Pm 3 (n=20) 0.45 (0.60) 
PCa (n=48) 0.29 (0.58) 
Prostatic carcinoma 
Histological grade 
Low-grade (n=13) 0.69 (0.75) Kruskal-Wallis, p=0.007 
Int. grade (n=16) 0.19 (j0.40) Spearman's rho -0.433, p=0.002 
High-grade (n=19) 0.11 (0.46) 
Gleason Score 
< 6 (n=18) 0.61 (0.70) Mann-Whitney U, p=0.001 
>6(n=30) 0.10(0.40) 
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Table 30. P-values of association of CD44 expression in various subtypes of 
prostatic lesions. (Mann-Whitney U test) 
Histological types Hyperplasia VJNl PE^2 PE^ 3 PCa 
Hyperplasia - n.s. n.s. p=0.005 p<0.001 
Pn^ 1 - n.s. p-0.026 p<0.001 
PnS[ 2 - n.s. p=0.043 
^TN 3 - n.s. 
PCa -
Abbreviation: n.s., not statistically significant at p<0.05, 2-tailed. 
Table 31. P-values of association of CD44 expression in various histological types 
of prostatic carcinomas. (Mann-Whitney U test) 
Histological types Low-grade Intermediate-grade High-grade 
Low-grade - n.s. p=0.027 
Intermediate-grade - n.s. 
High-grade _ 
Abbreviation: n.s., not statistically significant at p<0.05, 2-tailed. 
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Figure 38. CD44 immunostaining in PIN 1 lesion showing strong expression of 
CD44 in the basolateral wall of luminal cells. Adjacent normal secretory cells also 
show similar expression. (Immunoperoxidase method, magnification x800) 
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Figure 39. CD44 unmunostaining in PCa (Gleason grade 2,3), showing strong 
expression of CD44 with preserved basolateral distribution in neoplastic cells but 
heterogeneous expression in the lateral borders ofadjacent cells. (Immunoperoxidase 
method, magnification x800) 
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Figure 40. CD44 immunostaining in PCa (Gleason grade 4,4)，showing 
heterogeneous or reduced expression of CD44. (Immunoperoxidase method, 
magnification x800) 
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VII. Expression of nm23 in Prostatic Lesions 
The results of nm23 immunostaining of all prostatic cases examined are 
summarized in Table 32. The nm23 immunoreactivity was mainly expressed as 
cytoplasmic staining, but cell membrane.might also demonstrate strong immunostain. 
The stromal muscle and connective tissues were consistently negative for nm23 
expression. Positive rnn23 immunostaining was observed in the prostatic glandular 
acini and neoplastic sheets of most of the prostate cases examined, though with a 
wide variation in staining intensity, but basal cells of benign prostatic glands might 
also be strongly positive. The expression of nm23 was shown to be independent of 
the patient's age. 
Table 32. nm23 Expression in various histological types of prostatic lesions. 
Pathology No of • nm23 score * nm23 positive** 
Cases 1 2 3 Pos (%) 
Hyperplasia 28 17 10 1 11 (39.3) 
PIN 1 19 5 5 9 14 (73.7) 
PES[2 7 1 3 3 6 (85.7) 
Pnsn 20 1 5 14 19 (95.0) 
Prostatic carcinoma 
Low-grade 13 0 2 11 13 (100) 
Intermediate-grade 16 0 4 12 16 (100) 
High-grade 19 0 8 11 19 (100) 
Total 122 24 37 61 98 (80) 
* nm23 Score: 1- weak, equivocal staining; 2- positive staining; 3- strong staining. 
** nm23 Positive: cases with positive or strong positive staining (scores 2 and 3). 
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Of the 122 cases examined, 98 (80%) showed positive expression for nm23. 
In prostatic hyperplasia, expression of nm23 was clearly positive in the cytoplasm of 
11 out of 28 cases (39%), but none exhibited a strong immunoreactivity (Figure 41). 
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The remaining 17 ^^ses (61%) demonstrated a weak and equivocal staining, and 
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Of the 46 PpS[ lesions, positive cytoplasmic staining were observed in 39 
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cases (85%), which were more or less distributed evenly among different grades of 
VW lesions (74%) ofPDs[ 1, 86% ofPDs[ 2 (Figure 41), and 95% o f F W 3. However, 
among these PIN lesions expressing nm23, 26 (57%) demonstrated strong 
cytoplasmic immunostaining, distributed in 47%, 43%, and 70% of respectively PIN 
1, PES[ 2, and ?JN 3 lesions (Figure 42). The frequency of such a nm23 expression 
was not significantly different between PIN 1 and FJN2, or between PEsf 2 and PD^3. 
All 48 PCa expressed nm23 but 71% of these demonstrated a strong 
cytoplasmic expression of nm23 (Figures 43 and 44). Furthermore, the staining 
pattem reflected the heterogeneous expression of nm23, with the mixture of cells 
with strong and weak immunoreactivity, with scattered tumor cells with strong 
signals intermingled with other tumor cells or sheets. However, no significant 
difference in nm23 expression was detected among different histological grades of 
PCa based on the Gleason score, and among different grades based on the Gleason 
grades (Table 33). 
Statistical analyses comparing various prostatic lesions, and various grade 
of carcinoma, are summarized in Tables 34 to 36. There was a significant difference 
in the frequency of expression of nm23 between prostatic hyperplasia and both PIN 
lesions and PCa. The frequency of expression was significantly higher in ?JN lesions 
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and PCa (Mann-Whitney U test, p<0.001). However, no significant difference was 
found in the expression of nm23 between PES[ lesions and carcinoma (Mann-
Whitney U, p=0.064). But, there was a significant correlation observed between 
stronger nm23 immunostaining and prostatic lesion from benign hyperplasia to PIN 
and to PCa. (Spearman's rho 0.585, p<0.001) 
Table 33. Results of univariate analysis of association of nm23 expression in various 
subgroups of patients and subtypes of prostates specimens 
Mean score (SD) Statistical Tests 
Age 
< 70 (n=50) 2.16 (0.84) Mann-Whitney U, p=0.120 
> 70 (n=72) 2.40 (0.73) 
Histological Types 
Hyperplasia (n=28) 1.43 (0.57) Kruskal-Wallis, p<0.001 
PIN 1 (n=19) 2.21 (0.85) Spearman's rho 0.585, p<0.001 
PIN 2 (n=7) 2.29 (0.76) 
PIN 3 (n=20) 2.65 (0.59) 
PCa (n=48) 2.71 (0.46) 
Prostatic carcinoma 
Histological grade 
Low-grade (n=13) 2.85 (0.38) Kruskal-Wallis, p=0.245 
Int.-grade (n=16) 2.75 (0.45) Spearman's rho -0.243, p=0.096 
High-grade (n-19) 2.58(0.51) 
Gleason Score 
< 6 (11=18) 2.83 (0.38) Mann-Whitney U, p=0.144 
> 6 (n=30) 2.63 (0.49) 
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Table 34. P-values of association of nm23 expression in various subtypes of 
prostatic lesions (Mann-Whitney U test). 
Histological types Hyperplasia PIN1 PESf2 PESf3 PCa 
Hyperplasia - p=0.002 p=0.013 p<0.001 p<0.001 
? m 1 - n.s. n.s. p=0.019 
?JN 2 - n.s. n.s. 
? m 3 - n.s. 
PCa -
Abbreviation: n.s., not statistically significant at p<0.05, 2-tailed. 
Table 35. P-values of association of nm23 expression among various histological 
grades of prostatic carcinomas (Mann-Whitney U test). 
Histological types Low-grade Intermediate-grade High-grade 
Low-grade - n.s. n.s. 
Intermediate-grade - n.s. 
High-grade -
Abbreviation: n.s., not statistically significant at p<0.05, 2-tailed. 
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Figure 41. nm23 Staining in PIN 1 lesion showing weak staining in the dysplastic 
cells. Basal cells are positive stained. (Immunoperoxidase method, magnification 
x800) 
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Figure 42. nm23 Staining in PIN 3 lesion showing strong cytoplasmic staining in the 
dysplastic cells. (Immunoperoxidase method, magnification x400) 
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Figure 43. nm23 Staining in PCa (Gleason grade 2,2) showing strong to very strong 
cytoplasmic staining of neoplastic proliferations in contrast to weak staining in the 
adjacent benign glands. (Immunoperoxidase method, magnification x400). 
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VIII. Correlation and Association of Expressions of All 
Biomarkers in Prostatic Lesions 
The Spearman correlation coefficients between the biologic markers 
examined in all the prostatic lesions studied are presented in Table 36, and the 
association of changes of biomarkers expression in different histological categories 
of prostate lesions are summarized in Tables 38 and 39. 
Table 36. Spearman correlation coefficients between the biologic markers in all 
prostatic lesions. 
p53 PCNA Ki67 Q Ki67 C EGFR E-Cadherin CD44 nm23 
P53 - 0.608** 0.565** 0.660** 0.431** -0.287** -0.269** 0.303** 
PCNA - 0.583** 0.720** 0.347** -0.289** -0.344** 0.467** 
Ki67 Q - 0.856** 0.376** -0.335** -0.267** 0.365** 
Ki67C - 0.421** -0.380** -0.323** 0.431** 
EGFR - -0.314** n.s. 0.239** 
E-Cadherin - n.s. -0.191* 
CD44 - n.s. 
nm23 -
Abbreviation: * - Correlation is significant at 0.05 level (2-tailed) 
** - Correlation is significant at the 0.01 level (2-tailed) 
There was significant positive correlation among p53, PCNA, Ki-67, EGFr, 
and nm23 expression, whereas inverse correlation was shown between E-cadherin 
expression and p53, PCNA, Ki-67, EGFr, or nm23 expressions. CD44 expression 
was inversely correlated with p53, PCNA, and Ki-67. CD44 expression showed no 













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Chapter 6 Results 
Apart from being significantly correlated with each other, both p53 and 
EGFr were similar or not significantly different among prostatic hyperplasia and PIN 
lesions, but were significantly increased in PCa. Although their expressions were 
significantly increased in high-grade PCa in comparison with low-grade PCa, there 
was no significant difference in the expressions between low-grade and intermediate-
grade PCa, or between intermediate-grade and high-grade PCa. 
Both PCNA and Ki-67 proliferation indices showed similar pattem of 
results in the prostate specimens examined. Both indices were significantly increased 
from nodular hyperplasia to high-grade PrK to PCa. But unlike PCNA expressions, 
no significant difference in Ki-67 expression was observed between low-grade and 
intermediate-grade PCa, or between intermediate-grade and high-grade PCa. 
Both expressions of cell adhesion molecules, E-cadherin and CD44, were 
reduced in high-grade PINf and PCa compared to nodular hyperplasia. However, 
there was no significant difference in E-cadherin expression between low-grade and 
high-grade FJN whereas CD44 expression was significantly reduced in high-grade 
PES[ compared to low-grade PESL Although both E-cadherin and CD44 expressions 
were not significantly different between high-grade PESf and low-grade PCa, there 
was significant difference in reduced CD44 expression and loss of E-cadherin 
between high-grade PESf and high-grade PCa. 
There was an inverse correlation of nm23 and E-cadherin expressions. Both 
expressions in low-grade PIN and PCa were significantly different from nodular 
hyperplasia but there was no significant difference in their expressions in low-grade 
PES[ and high-grade PIN, or high-grade PIN and PCa. 
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Prostatic intraepithelial neoplasia (PIN) have been the focus of medical 
scrutiny and investigations over a decade since McNeal and Bostwick described 
them under intraductal dysplasia and proposed them as the biologic precursor of 
invasive prostate carcinoma (24,28). PIN is characterized by cytologic atypia and 
proliferation of the luminal cell layer of both prostatic acini and ductules. While it is 
well accepted that prostatic hyperplasia is unrelated to carcinoma, the place where 
PIN lesions stand in relation to prostatic hyperplasia and to PCa is still undetermined. 
Although PESf lesions have been viewed by many as a precursor of prostate 
carcinoma, due to the similarity in their prevalence, anatomical distribution, 
cytological features and immunophenotypic expressions, certain proportion of the 
case observations also indicate that the two lesions may be independent and that a 
pathogenetic link between VW lesion and carcinoma remains to be established 
(23,24,28,30,39,52,53,55,56,57). 
Growth factors are important not only for the cell proliferation in normal as 
well as neoplastic tissues, they also have a role in cell functions, migration, 
differentiation and cellular adaptation to injury. Many growth factors are now known 
to have interrelationship with other molecular events or products, such as 
oncoproteins, tumor suppressor gene products ¢)53, TGF-beta), growth factor 
receptor and signal transduction, cell cyclins (intracellular complexes with cyclin-
kinase) and finally the extracellular matrix. Although many growth factors have been 
implicated in tumorigenesis through mutations, their excess production or increased 
synthesis alone appear insufficient for neoplastic transformations, but they contribute 
the stimuli for growth. Proto-oncogenes may be transformed into oncogenes through 
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changes in structures of the genes with ensuing production of abnormal gene 
products and functions, or through changes in their regulation. These molecular 
events may be shared by or similar between lesions such as prostatic hyperplasia, 
PIN proliferations and carcinoma of the prostate. 
Molecular events associated with the development and the progression of 
prostatic cancer remain poorly defined. Invasion and metastasis are characteristics of 
malignant tumors. But the metastatic potential of a given tumor is difficult to predict. 
The conventional assessment of the grading of a tumor is used to predict its 
biological behavior and metastatic potential. Many biological markers may also 
reflect its aggressiveness. Oncogenes c-myc, erb-b2 and tumor suppressor genes p53, 
Rb have been implicated in percentage varying from 10% to 35% of carcinoma. 
Genetic alterations on chromosomes 8p, lOp, lOq, 16q, 13q, 18q, 9p and 6q have 
been reported, suggesting the presence of tumor suppressor genes in these loci 
(64,65,66,163,164). Some of these loci are associated with cell adhesion molecules 
which have been implicated as tumor suppressors and in the development of 
carcinoma of prostate. 
Development and progression of cancers appear to be associated with 
changes of various biologic parameters. Determination of the expression of such 
biomarkers in putative pre-invasive neoplastic lesions is important not only in the 
understanding of carcinogenesis but also to develop models of early neoplasia. Such 
potential characterization of early neoplastic changes may help to identify the 
pathway to the more aggressive subtypes of dysplastic changes. The aim of this 
study was to compare and characterize the expression of some of these biologic 
markers in nodular prostatic hyperplasia, PESF lesions and various histological grades 
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of prostatic acinar carcinoma. Based on these expressions, possible correlation of 
these biological markers between PIN lesions and carcinoma of prostate are assessed. 
Finally, whether there is a progression or continuum existing between PES[ and 
carcinoma of prostate may be determined. However, correlation of the biologic 
markers with stage and survival has not been considered and included in this study. 
While the sequence of prostatic hyperplasia, PIN and carcinoma was 
examined, the selection of cases has some limitations and the source of lesions needs 
to be clarified here. At the time of this study, prostatectomy was rarely performed for 
carcinoma, and this was performed as Millin's operation for hyperplasia or in the 
setting of radical cystectomy for urothelial carcinoma of the bladder. Thus the source 
of hyperplastic lesions is from nodulectomy in Millin's operation or from TUR-P. 
Majority of PES[ lesions, in particular the high-grade lesions PIN 2 and PES[ 3, are 
from prostatectomy without carcinoma，and from the peripheral zone. Finally, all 
carcinomas with the exception of 3 prostatectomies are derived from TUR-P for 
obstructive carcinomas, most often in patients known to have prostatic carcinoma, 
which generally represent advance or high stage of disease. Although it would be 
interesting to compare PE^ lesions associated with carcinoma and PES[ lesions 
without carcinoma, the cases of PIN" associated with carcinoma were rare as 
prostatectomy for carcinoma was only just beginning to be practiced, therefore the 
PIN lesions in this study are restricted to those not associated with carcinoma, but 
overall they represent FIN lesions from the peripheral zone, which is the zone 
clinically significant for carcinoma. 
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I. p53 Protein 
Our study demonstrated the absence of p53 accumulation in the luminal or 
secretory cells of glandular epithelia in prostatic hyperplasia and all grades of PIN 
lesions. On the other hand, up to 31% of all PCa were positive for p53 
immunoreactivity. Only two cases of PES[ 3 lesions demonstrated occasional p53 
positive cells and several other cases with infrequent cells exhibiting weak nuclear 
staining. Such an infrequent p53 accumulation suggests that p53 mutation is not 
associated with the development ofPIN lesions. However, molecular analyses of p53 
mutation in FJN lesions are lacking with no information available in the literature. 
These are perhaps important to confirm the absence of p53 mutation in PIN lesions. 
Other immunohistochemical studies have demonstrated, in contrast, the presence of 
p53 accumulation or overexpression of p53 in PINf lesions, however these studies 
were made in prostatectomy associated with carcinoma and also suggested that the 
interpretation of the results did not discriminate secretory or luminal cells with basal 
cells (71,80,165,166,167). While these observations support a close relationship 
between high-grade PES[ and carcinoma in patients with prostatic carcinomas, both 
expressing high-levels of p53 protein accumulation, one can argue that PIN lesions 
associated with carcinoma which commonly express p53 may in fact reflect Pagetoid 
spread of cancer cells into acini or duct interpreted as PES[ lesions. In our cases, 
isolated FJN lesions without an underlying carcinoma demonstrate in fact that p53 
mutation does not occur in these lesions. However, whether primary prostate 
carcinomas derived from an adjacent FJN lesion or both lesions developed 
independently under the influence of certain factors in the neoplastic process remains 
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to be determined. This study of p53 immunoreactivity on various prostatic lesions 
indicates that p53 does not accumulate in benign lesions, and in high-grade FJN 
lesions, providing that those were not associated with a carcinoma. From this 
perspective, FJN may not represent a precursor lesion to carcinoma. Arguably, PIN 
lesions associated with carcinoma, and which express p53 in the same frequency as 
carcinoma may represent a subpopulation of cancerous cells, which have spread 
within ducts or acini. 
Furthermore, overexpression of p53 in immunohistochemistry does not 
always represent or reflect p53 mutations; binding of p53 protein by viral protein or 
to cellular proteins such as mdm 2 may lead to intracellular accumulation, and to 
artefactual immunoreactivity not confirmed by molecular analysis (5,168). 
We found that the overexpression of p53 is correlated with histological 
grade of prostatic carcinomas and the association of higher frequency of p53 
accumulation with higher combined Gleason score. Such observations were in 
keeping with the results previously reported in the literature (169,170,171,172). 
Although such a correlation appears weak, it may be related to the relatively small 
number of cases of low-grade carcinoma examined. A more clear cut correlation is 
demonstrated when carcinomas are subdivided into 2 groups by a Gleason score 
below or above 6. 
We do not have follow-up information in most of our cases, and thus we 
have not examined the correlation of p53 with stage and prognosis. However, an 
association of p53 mutation with disease progression has been reported in many 
studies, and that higher percentage of p53 abnormalities was associated with untreated 
metastatic specimens as compared to untreated primary prostatic cancer (173,174). 
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It was interesting to note that occasional p53-reactivity was observed in the 
basal cells of benign prostate glands. Similar observation has been reported by 
Kallakury et al (169). They hypothesized that focal overexpression of p53 in basal 
cells of hyperplastic prostate glands might represent a premalignant lesion that gives 
growth advantage to such cells and some of them might eventually acquire further 
somatic mutations that allow progression to malignancy. However, the p53 
overexpression may also be a normal response to DNA repair or due to presence of 
other stabilization factors. 
P53 mutations therefore represent a late event of tumor progression in a 
subset of PCa and appear to be unrelated to the development of FJN as suggested by 
this study. 
II. PCNA 
A number of monoclonal antibodies to PCNA are commercially available, 
including 19A2, 19F4 and PC10. Immunostaining with the antibody PC10 has been 
reported to correlate with Ki-67 immunostaining, S-phase fraction, flow cytometry 
and bromodeoxyuridine labeling indices (175,176,177,178). However, other studies 
have shown no correlation between PC10 immunoreactivity and other proliferation 
indices (179,180). The discrepancies have been attributed to long half-life of PCNA 
which is more than 20 hours, resulting in staining persisting in cells which have left 
the cell cycle. Moreover, since PCNA is also involved in DNA repair, low amounts 
of PCNA may be present in all cells including non-cycling cells. This was 
demonstrated by a study which showed that it is possible to increase the 
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immunoreactivity to almost 100% by reducing the dilution of the anti-PCNA 
antibody (96). 
Montironi et al observed different staining patterns of PCNA 
immunostaining in prostatic specimens. The positive nuclei showed homogenous or 
granular types, or a mixture of both patterns of staining. The homogenous pattem 
was usually more darkly stained than the granular pattem which had a wide spectrum 
of staining intensities (58,97). Similar observations were seen in this study. Yu et al 
reported that PCNA labeling index based only on darkly stained nuclei was strongly 
correlated with S-phase fraction of flow cytometry (162). WeaMy stained nuclei 
were therefore ignored in the measurement of the PCNA labeling index. 
This study showed a progressive increase of proliferative rates from benign 
lesions through PESF to PCa. Similar observations were reported by Montironi et al in 
their studies on expression and location of PCNA in FJN lesions (58,97). The mean 
values of PCNA labeling indices observed in this study are comparable to their 
reported values except that no PCNA positive nuclei in luminal cells of benign 
hyperplasia was observed by Montironi et al. Moreover, in our study, a significant 
correlation between increased PCNA expression and both combined Gleason scores 
or primary Gleason scores was observed, indicating progressive increase in 
proliferation rates associated with tumor progression. 
The altered PCNA expression in ?IN lesions and PCa indicated an 
alteration of the regulation of PCNA expression. PCNA expression is regulated at 
both the transcriptional and post-transcriptional level. However, the transcriptional 
regulation is still not well understood which may involve regulatory effects of 
binding of homeodomain-containing proteins to the PCNA promotor. The post-
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transcriptional regulation involves stabilization of PCNA mRNA in the presence of 
growth factors such that the PCNA mRNA can be translated into protein with greater 
efficacy (96). It would appear that PCNA mRNA is produced continuously at low 
levels in many cells but is degraded rapidly without translation. PCNA production is 
induced in response to growth factors by stabilizing PCNA mRNA. 
In benign glands and in VJN lesions, previous studies have reported a 
significantly higher PCNA immunoreactivity in the basal cell layer than the luminal 
cells layer, indicating a high proliferative activity of the basal cells (58,181). This 
supports the common concept of the role of basal cells as stem cells for the luminal 
cells. In a more recent study on PCNA expression in normal prostate, PIN and 
prostatic adenocarcinomas, Montironi et al reported decrease of proportion of PCNA 
expression in prostatic epithelial acini from periphery through intermediate layers to 
the luminal layer. They observed a progressive expansion of proliferation 
compartment to luminal cells from normal prostate to PES[ to prostatic 
adenocarcinoma (97). Such type of expansion of the proliferative compartment had 
been investigated in the squamous cell epithelium of the uterine cervix by Mariuzzi 
et al that the width of the proliferative compartment is related to the degree of 
dysplasia, occupying the entire epithelial thickness in carcinoma-m-^zYw, and the 
differentiating and differentiated compartments decrease in width or even completely 
lost(182). 
This study confirms previous observations that PCNA overexpression is 
positively correlated with altered proliferation from hyperplasia to FJN and 
carcinoma (58,97,181). The correlation with overexpression and increasing 
neoplastic grade supports the prognostic significance of PCNA index as determined 
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by PC10 on needle biopsy specimens of PCa (183). Although there appears to be a 
continuum from increasing grade of PIN lesions to increasing grade of carcinoma by 
PCNA expression, which may represent an indicator of prognosis, such marker does 
not reflect a specific mechanism of tumorigenesis or malignant transformation, but 
rather represents a simple process of cell proliferation in the presence of activated 
growth factors. 
III. Ki-67 
A frequent objection to the use of immunohistochemistry to predict clinical 
outcome concerns the reliability of the results, which depend on subjective 
assessment of the observer. Computerized image analysis systems have been 
developed to alleviated such problems to give objective and reproducible results (92). 
Measurement of Ki-67 proliferative index by computerized image analysis has been 
reported in other tumors including breast cancers and lung cancers (92,184). In this 
study, the Ki-67 labeling indices were measured by both manual microscopic 
counting of positive nuclei and quantitative image analysis and were highly 
correlated (Spearman's rho=0.916, p<0.001). A proportional bias of 0.736 detected 
in the study reflected the differences in the measured attribute of tissue components 
by the two methods. Percentage positive nuclear area was measured in the 
quantitative image analysis whereas percentage of number of positive nuclei was 
measured by microscopic counting method. 
Both measurement methods showed a correlation of proliferative rate as 
expressed as Ki-67 labeling indices with histological grade of prostate carcinomas. 
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But quantitative image analysis yielded a lower coefficient of correlation than 
microscopic counting (Quantitative image analysis: Spearman's rho=0.610; manual 
microscopic counting: Spearman's rho=0.766). Moreover, no significant difference 
was detected by Kruskal-Wallis's analysis of variance of Ki-67 labeling index of 
different groups of PCa by quantitative image analysis whereas significant 
association of Ki-67 labeling index was detected by manual microscopic counting 
method. The lack of statistical significance in results measured by quantitative image 
analysis is probably due to a higher error rate during measurement. This is because, 
by measuring a total nuclear area of about 10,000 um^, only about 200 nuclei were 
measured by quantitative image analysis and is comparatively lower than the 
microscopic counting method which measures at least 500 nuclei each time. The 
precision was also greatly affected by the nuclear and antibody threshold settings of 
the image analyzer. 
The number of fields measured by quantitative image analysis in other 
previous studies varied from 2 to greater than 15 fields with a total number of cells 
measured varied from 100 to greater than 2000 (92,184). It appeared that a larger 
number of cells should be measured for prostatic specimens which are very 
heterogeneous in nature. However, it would take much longer time in each 
measurement. During this study, it took an average of 15 to 20 minutes to measure 
the Ki-67 labeling index for each case. From this experience, while computer 
assisted image analysis and quantitation may be more accurate, the careful 
microscopic semi-quantitation using consistent criteria appears to be more cost 
effective in both manpower and equipment terms. 
Statistically significant differences in mean Ki-67 indices of prostatic 
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hyperplasia and prostate cancer have been uniformly reported (185,186,187). 
However, previous studies of Ki-67 antigen immunostaining in prostate cancer have 
shown a variable relationship with tumor stage and grade. A weak correlation of Ki-
67 labeling index and tumor grade in prostatic cancer have been reported by Stattin 
et al and McLoughlin et al (74,88). But no significant association of Ki-67 labeling 
with Gleason scores was detected by Bubendorf et al (188). Few studies have been 
conducted to evaluated the Ki-67 immunoreactivity in PIN lesions. 
Ki-67 and PCNA immunoreactivities in prostatic lesions were closely 
correlated although Ki-67 labeling index was correlated with a higher value of 
PCNA labeling index. PIN and PCa were correlated with a higher cellular 
proliferative rate as defined by the Ki-67 and PCNA labeling indices. Moreover, the 
proliferative rate in PCa with high Gleason scores was significantly higher than in 
those with low Gleason scores. Our results confirmed the findings of Tamboli et al 
who reported an intermediate proliferative rate of high-grade FW in the continuum 
of tumorigenesis from benign prostate to PCa (189). The actual mean Ki-67 labeling 
indices were close to the values reported by Tamboli et al but was more than twice of 
those reported by Oomens et al and more than 5 times of those quoted by Thompson 
et al (189,190,191). However, similar to PCNA, Ki-67 antigen expressions do not 
reflect a specific mechanism of tumorigenesis, but rather a simple process of cell 
proliferation in the presence of activated growth factors. Our results indicates that 
PIN lesions have an intermediate proliferation rate between prostatic hyperplasia and 
PCa, and may reflect the biologic position of PES[ lesions in the multistep process of 
malignant transformation. 
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IV. EGFr 
Various non-steroidal growth factors and their receptors have been found in 
the human prostate and are implicated in the control of prostatic epithelial cell 
proliferation including the epidermal growth factor (EGF), transforming growth 
factor-a(TGF-a), and their common receptor, EGFr (192). EGF is required for in 
vitro proliferation of human prostatic epithelial cells (193). In vivo, the secretory 
epithelial cells are exposed to high concentrations ofEGF in the prostatic fluid (194). 
It was suggested that some of this EGF originates from other sources and it is likely 
that prostatic cells themselves secrete EGF (195). 
Our results showed strong expression of EGFr in the basal cells of prostatic 
epithelium in prostatic hyperplasia and PESF lesions but much weaker 
immunoreactivity in the luminal cells. Such differential expression of EGFr between 
the basal cells compartment and the secretory cells compartment of the normal 
prostatic epithelium has been described in previous reports indicating a significant 
regulatory role of EGF in cellular growth and proliferation of the basal cell layer of 
the prostatic epithelium (61,196,197). Although there was no significant difference 
in EGFr expression between the luminal cells of benign hyperplasia and PESf lesions, 
it was interesting to find that FIN 3 was associated with a much lower EGFr 
expression. However, the immunoreactivity of EGFr in the luminal cells among all 
prostatic hyperplasia and PESF lesions was weak and similar in both conditions. The 
significance of such finding is unknown. However, similar to our findings, Ibrahim 
et al did not find significant difference in EGFr protein expression in prostatic 
hyperplasia and PESf (198). It may be argued from these findings that PIN lesions, 
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like nodular hyperplasia, still represent a regulated proliferative process. 
Our results demonstrated significantly higher EGFr expression in PCa than 
in prostatic hyperplasia, PIN 1 and FW 3 lesions although significant difference in 
EGFr expression between PCa and PIN 2 lesion was not detected. EGFr expression 
was also correlated with histological differentiation of PCa, in that increasing 
expression was correlated with higher grades. Results on EGFr expression in PCa in 
previous studies were also conflicting. Both Maygarden and Ibrahim reported weak 
EGFr expression in PCa (61,196). Robertson et al also observed a low 
immunoreactivity of EGFr protein in PCa (197). However, using the same antibody, 
Ab-1, as Maygarden, Cohen et al observed positive immunoreactivity of EGFr in all 
prostatic carcinomas in a more recent study (199). Fox et al used another EGFr 
antibody, E12, and reported positivity in stage Al PCa (200). These discrepancies in 
EGFr protein expression can partly be explained by differences in the antibody used 
and staining methods. Since frozen tissues were used in some of the studies 
including those of Maygarden and Ibarhim, while others including ours were 
examined in fixed tissue, and thus immunohistochemical results might be affected by 
tissue preservation. Ibrahim indicated presence of certain protease, such as prostatic 
specific antigen, that may destroy or alter the EGFr and interfere with recognition of 
the antibody (196). 
The increased EGFr in PCa indicated a strong requirement of its ligand for 
tumor growth. Cohen et al reported co-expression of transforming growth factor-
alpha (TGFa), a potent mitogen, and EGFr in a significantly higher frequency in 
prostatic carcinoma than in the prostatic epithelium of prostatic hyperplasia. This 
indicated a shift to an autocrine stimulatory pathway of growth in epithelial cells of 
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PCa which may confer growth advantage of tumor cells and promote a proliferative 
state (199). The contrast between PIN lesion and carcinoma, with respect to EGFr, 
suggests that the 2 lesions may develop according to different mechanisms, and the 
autocrine stimulation may be present in carcinoma, but not in PIN lesion. 
Although we found no significant difference between incidence of EGFr 
expression and different grades of carcinoma, such results may reflect the relatively 
small number of cases studied, and consequently there may be overlap of tumor of 
different grades. More importantly, however, our findings demonstrated that 
overexpression of EGFr is significantly correlated with high-grade PCa (above 
Gleason score 6), and these findings concurred with most observations in the 
literature (199,201). 
The observation of cytoplasmic staining of EGFr in most cases of PCa in 
the study was not well understood. In some cases the membranous staining was 
indistinct from the cytoplasmic staining. Previous studies using frozen tissues 
showed mainly cytoplasmic pattern of staining (61,196,199). But Fox et al showed 
predominant membranous staining using archival specimens (200). Since the 
antibody used in this study is specific for the extracellular domain of the EGFr 
protein, the presence of cytoplasmic staining of EGFr in PCa may be explained by 
overexpression of abnormal EGFr gene products containing the external domain. 
Another explanation is that such overexpression may be due to increased binding of 
ligand to the EGFr probably through autocrine pathway. Binding of ligand to EGFr 
protein normally triggers recruitment of EGFr to clathrin-coated pits, followed by 
internalization of the EGFr-ligand complex and its delivery to lysosomes for 
degradation (202). Increased binding of ligand to EGFr probably causes increased 
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endocytosis of EGFr-ligand complex which was detected in high amounts in the 
cytoplasm. 
V. E-Cadherin 
E-cadherin has been described as an invasion or metastasis suppressor 
because its expression is lost from epithelial cells as they progress to advanced or 
high-grade tumor. Reintroduction of E-cadherin DNA in tumor cell lines cause 
suppression of their invasive property or phenotype (203). Molecular studies have 
shown that human prostate cancer frequently show loss of heterozygosity in the long 
arm of chromosome 16 (16q) where the coding gene of E-cadherin resides (204). 
Strong continuous membranous expression of E-cadherin in both the basal 
and secretory cells of the glandular epithelium in prostatic hyperplasia indicated the 
significant role of E-cadherin in maintaining cell adhesion among the epithelial cells. 
The basolateral distribution of E-cadherin molecules is probably related to 
maintenance of cell polarity and cellular architecture of the prostatic epithelium. 
Previous reports have described the loss of E-cadherin expression in PCa, and also 
correlated such alterations with metastasis, cancer stage, recurrence rate and patient's 
survival (122,205,206). Our study showed significant association of loss of E-
cadherin with PCa in comparison with prostatic hyperplasia ^><0.001) but did not 
show significant correlation ofloss ofE-cadherin expression with histological grade. 
Our results showed a higher frequency of loss of E-cadherin expression in 
PCa than Umbas et al (117). Although they observed loss of E-cadherin expression 
in a high proportion ofhigh-grade PCa, they reported reduced E-cadherin expression 
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was present in 28% of intermediate-grade PCa but normal expression in low-grade 
PCa. In this study, loss of E-cadherin expression in low-grade and intermediate-
grade PCa were similar in proportions and were 54% and 50% respectively. The 
difference may be due to differences in techniques and study group. Umbas et al 
used frozen tissues in their study while formalin fixed archival tissues were 
evaluated in this study. E-cadherin may be lost during fixation resulting in a lower 
expression which is evident as 11% of prostatic hyperplasia were also negative for E-
cadherin expression. However, loss of E-cadherin expression has also been reported 
in well-differentiated pancreatic cancer (grade I) (207). Therefore alteration in E-
cadherin expression may occur in early stages of tumor progression. 
Although E-cadherin expression appeared to be suppressor of cell 
detachment, its expression does not necessarily indicative of progression. Normal 
function of E-cadherin may be affected by impaired function of catenin through 
which E-cadherin is anchored to the cytoskeleton. Shimoyama et al have suggested 
that loss of a-catenin expression can be causally related to dysfunction of cadherin-
mediated interaction in a lung cancer cell line (PC9) (208). Morton et al found that 
impaired function of E-cadherin could be explained by homozygous deletion of the 
a-catenin gene in a prostate cancer cell line (PC3) (122). Moreover, increased 
tyrosine phosphorylation of P-catenin has been related to impaired E-cadherin 
function (209). Mutational inactivation of E-cadherin function was also reported for 
a subset of endometrial carcinoma and gastric cancers (210,211). 
Another study has shown a significant correlation between reduced E-
cadherin expression and tumor stage and overall survival. A significant higher 
survival rate for patients with normal E-cadherin expression was demonstrated 
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compared to patients with reduced E-cadherin expression. Moreover, reduced E-
cadherin expression was also correlated with progression after radical prostatectomy 
(212). In our study, reduced or loss of E-cadherin expression was present in 18 (95%) 
out of 20 cases ofhigh-grade carcinoma in contrast to 44% and 62% of intermediate-
grade and low-grade PCa. 
VI. CD44 
The standard form of CD44, CD44s, was detected by immunohistochemical 
methods in the prostate specimens in this study. The antibody used is specific for 
CD44 standard form protein which is present in all hematopoietic cells and 
neutrophils and fibroblasts were therefore positive in all tissues examined when 
present. In the study, CD44s immunoreactivity was found strongly expressed in the 
cytoplasmic membranes of basal cells of prostatic epithelium of benign lesions. This 
strong expression indicated a significant role of CD44s as a cell adhesion molecule 
in the prostatic epithelium. The expression of CD44s in the luminal cells were 
usually much weaker and it was difficult to distinguish whether the CD44s 
immunoreactivity arose from the basal cells or luminal cells at the boundary between 
them. Since only the presence of CD44s expression at the lateral borders between 
adjacent luminal cells were considered in the study, it is possible that expression of 
CD44s in benign lesions may be underestimated as a result of differential 
distribution of CD44s in basal border and lateral borders of the luminal cells. The 
expression of CD44s in the basal cells of prostatic epithelium is in concordance with 
similar findings reported in bronchial epithelium, gastric and intestinal mucosal 
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epithelium (130). 
Conflicting results of various studies on CD44s expression in prostatic 
tissue and prostate carcinoma cell lines have been reported. Several studies on CD44 
expression in human prostate carcinoma cell lines reported decreased expression of 
CD44 in a low metastatic, androgen-sensitive cell line (LNCaP) and elevated CD44 
expression in highly aggressive, androgen-independent cell lines (213,214,215). On 
the contrary, Kallakury et al reported strong membranous staining of CD44s present 
in epithelial cells of benign prostatic acini of 95% of 109 cases of PCa but 
approximately 70% of PCa showed significant loss of CD44s expression, which was 
correlated with high tumor grade and aneuploid status (143). Our results of CD44 
expression in benign prostate lesions and prostate carcinoma were close to those 
reported by Kallakury et al (143). There was decreased expression of CD44s in PCa 
which correlated with tumor differentiation (Spearman's rho=-0.433, p=0.002). The 
conflicting results of CD44 expression from prostate carcinoma cell lines are poorly 
understood. The difference may be due to differences in biological behavior of the 
tumor cells from tumor tissues obtained from histological specimens. As pointed out 
by Liu in his report, the LNCaP cell line was obtained from a supraclavicular lymph 
node metastasis of a patient who had disseminated bone involvement with the tumor 
(215). Whether the two metastases differ from each other was not known. This might 
be related to the low CD44 expression of the tumor cell line. Kogerman et al 
suggested that platelet-derived growth factor (PDGF) regulates the level of CD44 in 
cultured cells (216). Hence, the finding of variations in CD44 levels in cultured cell 
may be related to other modulating factors. Moreover, different integrin subunits 
have been reported in LNCaP and other prostatic cell lines including PC-3, DU-145 
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and 413-P which may account for differences in metastatic potential between the cell 
lines other than CD44 levels (217). In more recent reports, Nagabhushan et al and 
De Marzo et al both found significant association of loss of CD44 expression with 
tumor histological differentiation (218,219). Nagabhushan et al also observed a 
significantly lower CD44 expression in metastatic prostate cancer than primary 
prostate cancer (218). 
Although a significant difference in CD44 expression was not found 
between PIN 2 and PIN 3, or VJN 1 and PIN 2, there was a significant loss of CD44 
expression between PIN 1 and PIN 3, or between low-grade and high-grade PES[ 
lesions. While the number ofPIN 2 lesions was small, and hampered the significance 
of the statistical analysis, our results support that low-grade PESf lesion or PES[ 1 
should be separated from high-grade lesion, because they have different biological 
behavior (220,221). The expression of CD44 protein in PHSF lesions supports such 
hypothesis, and the proposal to reserve the terminology of PESf for high-grade FJN 
lesions, and to eliminate FJN 1 lesion from the nosology (30). Moreover, the similar 
frequency of CD44 expression in PESF 3 lesion and low-grade PCa is compatible with 
the premalignant nature of PESF lesion. 
Our findings of a correlated decrease of CD44s expression with histological 
grade of prostate carcinoma supports the hypothesis that decreased CD44s 
expression may result in decreased cell-cell adhesion, causing easy detachment of 
the cells from the basement membrane and enabling migration to both local and 
distant sites. While cell-matrix interaction and increased CD44s expression may be 
an important invasion promoter for some cancers, it appears that the loss of CD44s 
mediated cell-cell adhesion may be important to tumor progression and 
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dissemination in prostate carcinoma. 
Moreover, a recent report by Gao et al suggested a metastatic suppressor 
function of CD44s in prostate carcinoma. They showed that transfection-induced 
enhanced expression of CD44s in highly metastatic AT3.1 rat prostatic cells greatly 
suppresses their metastatic ability to the lungs without suppression of their in vivo 
growth rate or tumorigenicity indicating a metastatic suppressor function of CD44s 
(222). 
VII. nm23 
The nm23 gene is a putative anti-metastatic gene and previous studies have 
shown that expression of one of its gene products nm23-Hl mRNA was inversely 
correlated with metastasis in several human malignant tumors, including primary 
breast carcinoma，gastric carcinoma and malignant melanoma (148,149,150). 
Although nm23 gene products nm23-Hl and nm23-H2 have been associated with 
metastatic tumor and high-grade malignancy with metastatic potentials, the proteins 
expression in normal epithelium as well as neoplastic tissues is also well recognized 
(223,224). In this study, only 39% of glands in prostatic hyperplasia expressed 
nm23-Hl, of moderate intensity. This observation is in keeping with the expression 
of such protein in benign epithelium as reported in colonic and breast epithelium 
(223,224). Furthermore, the significantly more extensive and intensible expressions 
of nm23 in PCa are in agreement with the notion that nm23 gene represents a 
metastatic suppressor gene, and overexpression in carcinoma is in keeping with NDP 
kinase activity, and associated with the propensity for metastasis (223,224,225). 
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There was a progressive increase in nm23-Hl expression from benign hyperplasia to 
PIN to PCa (Spearman's rho 0.589, p<0.001). Such a progressive expression in both 
extent and intensity of nm23 in prostatic lesions ranging from benign to malignant is 
of interest. PES[ lesions which are morphologically situated between hyperplasia and 
carcinoma, and which have been qualified as dysplasia, inferring to its malignant 
potential, interestingly show significant nm23 expression. 
In many cases, the expression of nm23 in PESF lesions was similar to that 
observed in carcinoma, in that they showed strong cytoplasmic stain, including 
nuclear and membranous stain, and also showed heterogeneity in the intensity of 
immunoreactive cells. In this respect, PIN lesions show additional features in nm23 
expression, which herald those seen in PCa. One can argue that many PESf lesions 
may represent the intraepithelial spread of an adjacent carcinoma, thus not 
unexpectedly the PIN lesions showed similar features as the adjacent carcinoma. The 
PIN lesions we examined were not associated with carcinoma, and excluded such a 
possibility. 
The strong nm23 immunoreactivity in all histological grades of PCa is 
discordant with the proposed metastasis suppressor role of nm23 gene which 
expression have been previously described to be inversely correlated with metastatic 
potential in several human malignant tumors, including primary breast carcinoma, 
gastric carcinoma and malignant melanoma (148,150,224,225,226). More 
specifically, the study of Igawa et al on nm23 immunoreactivity in PCa reported a 
positive correlation of intense nm23-Hl staining with high stage, high-grade 
prostatic disease (226). They concluded that nm23-Hl was related to the 
proliferative phase of the cell cycle as demonstrated in tissue culture studies with 
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flow cytometry and Northern blot analysis instead of functioning as a metastasis 
suppressor gene. In our study, an overexpression of nm23 in PCa is in keeping with 
the metastatic potential of carcinoma. Such an expression of nm23 in carcinoma is 
significantly different from that found in prostatic hyperplasia and low-grade PIN 
lesions (PIN 1), observation that is concordant with the concept and function of 
nm23. It is of interest to note that the high-grade FJN lesions (PIN 2 and PIN 3) 
show no significant difference in expression of nm23 with PCa, indicating that a 
subset of high-grade ?JN or simply ?JN lesions demonstrate a metastatic potential. 
Such observations support that PLN[ lesions may be a precursor of invasive 
carcinoma, at least some of the PES[ lesions. This is more significant when 
considering that none of the cases of PIN selected in this study is associated with 
carcinoma. The absence of difference in nm23 expression among different grades of 
PCa may reflect the relatively small number of cases in each category and also 
possible overlap between grades. Conversely, in the study of Konishi et al on nm23 
expressions in non-metastatic and metastatic PCa, they also reported a high 
frequency of positive nm23 staining in non-metastatic as well as primary tumors of 
metastatic prostatic carcinomas except that there was a reduced expression in the 
metastatic tissue (151). The discrepancies in the expression of nm23 gene or of its 
products, and of tumor grade or stage, can partly be explained by the presence of the 
2 subunits of nm23 gene, namely nm23-Hl and nm23-H2 subunits, which 
expression can be imbalance or opposite giving rise to apparently contradicting 
results (227). Recent studies have confirmed the lack of direct relationships between 
nm23 expression and grade or stage of PCa, and suggested that tumor heterogeneity 
may be a more important factor for the metastatic potential (227). In addition, the 
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study of Zabrenetzky et al showed that the suppressive effects of nm23-Hl 
transfection on metastatic potential in Murine K-1735 melanoma cell lines are 
associated with increased thrombospondin expression, an extracellular matrix 
molecule involved in tumor progression (228). Furthermore, the overexpression of 
nm23 may be due to overlap with an identical protein called purine binding factor 
(PuF), transcribed through the c-myc proto-oncogene activation, and it may be such 
a c-myc activation that causes progression of the tumor cells, but not the nm23 gene 
itself(227). 
VIII. Association between Biomarkers and Prostate lesions 
Expressions of cell growth markers p53 and EGFr were very similar, and 
demonstrated two important observations. One was the lack of significant difference 
between nodular hyperplasia and any type of PDs[ lesions, and the other was a 
significant overexpression of p53 and EGFr in PCa of any grade as compared to PENT 
lesions and nodular hyperplasia. These observations suggest that while PIN lesions 
represent atypical proliferation of the prostatic epithelium, the growth regulation and 
differentiation remain within certain control, unlike carcinoma where neoplastic 
process appeared to have escaped growth regulation with loss of the protective 
function of p53. Alteration of p53 expression and upregulation ofEGFr seemed to be 
implicated in tumorigenesis ofPCa, but not in the development ofPIN lesions. 
Furthermore, there seemed to be poor correlation of p53 and EGFr 
expression with the grade of PCa. Our observation suggests that expressions of p53 
and EGFr do not represent prognostic markers in PCa. Though the number of cases 
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studied in each category ofPCa was relatively small, the prognostic values of p53 or 
EGFr remain to be assessed, not only in immunohistochemical study of larger series, 
but also using molecular analysis. In particular, the expression of p53 has been 
correlated with metastatic PCa and carcinoma refractory to hormonal therapy 
(229,230). 
The results shows a strong correlation between PCNA and Ki-67 labeling 
indices (both manual counting and quantitative image analysis methods) in the 
prostate specimens examined compatible with similar role of them as markers of cell 
proliferation. However, there was significant difference in PCNA labeling indices 
among low-grade, intermediate-grade and high-grade prostate carcinomas whereas 
no significant difference in Ki-67 expression between low-grade and intermediate-
grade, or intermediate-grade and high-grade PCa was detected, indicating that PCNA 
is a better classifier of PCNA than Ki-67 labeling index among various groups of 
PCa. However, use of PCNA as proliferation marker is limited by its long half life 
which results in presence of low amounts even in non-proliferative cells. Only 
strongly stained PCNA-positive cells should be considered during measurement and 
may cause difficulties in judgment of positive cells with intermediate staining 
intensities. Use of image analysis techniques for evaluation of PCNA labeling 
indices may probably eliminate such problem. 
As the cell proliferation markers were closely related to DNA replication 
and cell mitosis, PCNA and Ki-67 both were closely correlated, and demonstrated a 
progressive overexpression from nodular hyperplasia, PFN lesions of increasing 
grades and PCa of increasing grades. These observations confirmed similar previous 
findings of increasing proliferative activities in the sequence of hyperplasia, 
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dysplasia (PES[ lesions), and neoplasia in the prostate (97,181,189). 
While these proliferative indices support a continuum between nodular 
hyperplasia, PIhJ lesions and carcinoma, such markers only reflect a quantitative 
proliferation, and may not represent a specific step in the malignant transformation 
(97,181,189). Thus ?JN lesions remain a putative precursor of prostatic cancer, but 
not as an established precursor. Although PCNA and Ki-67 may be regarded as non-
specific markers of active cellular proliferations, our observations of increasing 
expression of these markers with increasing grade of PTN lesions and PCa, support 
others findings that they have a prognostic value, as they have been correlated with 
survival data (97,181,189,231). 
The results also shows a strong correlation of PCNA and Ki-67 expression 
with p53 protein accumulation in prostate lesions suggesting that prostate lesions 
with mutated p53 may be more likely to actively dividing than those negatively 
stained lesions. A previous study has shown that p53 gene product and the protein 
product of retinoblastoma gene and PCNA colocalize in cells infected with herpes 
simplex virus type I, whereas Ki-67 does not (232). However, since wild-type p53 
functions normally in DNA repair mechanisms, the increased p53 expression may 
also be related to DNA damage in highly proliferative cells. 
In addition, both P C N A and Ki-67 labeling indices were also significantly 
correlated with EGFr expression and nm23 expressions. Since EGFr is the common 
receptor for growth factors and mediates proliferative efTects on cells upon activation 
by binding with its ligands, it is logical that increased EGFr expression is associated 
with increased proliferation of cells which in tum displays increased proliferation 
markers ' expressions. 
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The strong association of nm23 expression with the proliferation markers 
confirms the relation of nm23 expression with the cell cycle and cell proliferation. 
The inverse correlation of nm23 expression with E-cadherin may imply a relation of 
its anti-metastatic function with cell adhesion molecules. Both nm23 and E-cadherin 
expressions were significantly different in prostatic hyperplasia and PDsT lesions, but 
were not significantly different in high-grade PES[ and PCa. Their expressions in ?JN 
lesions therefore distinctly differentiate such lesions from nodular hyperplasia and 
reveals their similarity with PCa. 
The strong association of reduced E-cadherin expression with the 
proliferation markers can partly be explained by acquisition of genetic loss in 
tumorigenesis as a result of high proliferation rate. The coding sequence of E-
cadherin gene resides on chromosome 16q which have been found to be frequently 
deleted in prostate cancers. However, it appeared that reduced expression of 
adhesion molecules may be related to dedifferentiation of cells in highly proliferative 
cells. 
Loss of normal cellular adhesion in neoplastic precursors or in tumors is an 
important phenomenon in the biology of neoplasms. It also reflects alteration in the 
growth control which favors the development of invasive behavior. Alterations in 
cell-cell adhesion are correlated with the loss of tumorous or lesional cells cohesion 
at the microscopic level, which may herald the progression into invasiveness and 
metastasis. The altered expressions of both CD44 and E-cadherin in PIN lesions and 
carcinoma of the prostate appear to be correlated with the neoplastic process, and the 
similar observations in PESI lesions support the neoplastic process of such lesion, and 
perhaps as the precursor of invasive carcinoma. Moreover, the correlation of 
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expression of these adhesion molecules with increasing grades of tumor reflect the 
increasing aggressiveness of the neoplasm. The loss of adhesion molecules in high-
grade tumor indicates the progressive nature of such loss; and that perhaps in earlier 
stage, low-grade carcinoma and even in PES[, the partial loss or abnormality of these 
adhesion molecules can be remedied. It has been shown in transfected cell lines and 
from post-treatment tumor that partial or complete restoration of adhesion molecules 
are possible (233,234). 
The significant alteration of the adhesion molecules, CD44 and E-cadherin 
in high-grade PDN[ lesions as compared to nodular hyperplasia reflect the altered cell 
growth in PENf lesions, toward loss of cell adhesion, loss of cell cohesiveness, and 
toward the propensity for invasion. Furthermore, despite the significant difference in 
the expression of these adhesion markers between PESf and high-grade PCa, there 
appears to be a continuity between PIN lesions and PCa as indicated by their similar 
expressions in high-grade PESf and low-grade PCa. From these perspectives, PIN 
lesions demonstrate features of loss of cell contact and invasiveness that characterize 
carcinoma. Adhesion molecules thus support the precursor nature of PIN lesions 
toward invasive carcinoma. 
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The process of tumorigenesis in prostatic cancer, as well as in many other 
neoplasms remains largely undetermined, but an well-accepted view is that it entails 
a multistep development where multiple biological alterations are implicated. This 
study examined the immunohistochemical expression of several biological markers 
including p53 protein, PCNA, Ki-67, EGFr, E-cadherin, CD44 and nm23 in the 
luminal cells in prostatic hyperplasia and PIN lesions, and in tumor cells of PCa. 
One of the two main objectives was to assess the relationship of these markers 
between the prostatic lesions which may reflect a genetic event which may 
participate or may be implicated in tumor development. The other was to determine 
whether the sequence of hyperplasia, dysplasia or intraepithelial neoplasia, and 
carcinoma applies to prostatic cancer, or whether PIN lesions is a precursor of 
carcinoma. 
Both the tumor suppressor gene p53 and EGFr markers significantly 
showed overexpression in carcinomas, but not in prostatic hyperplasia and PES[ 
lesions. Their overall overexpression in PCa was respectively 29% and 52%, 
relatively low incidence but in line with reports from the literature. The increasing 
alterations of these markers were correlated with higher grade of PCa, and suggest 
that p53 and EGFr gene mutations represent a late event in prostatic carcinogenesis. 
Such genetic events did not seem to participate in the development of prostatic 
hyperplasia and VJN. The expression of both p53 and EGFr showed no apparent 
continuity between hyperplasia, FJN and PCa. While the p53 gene may be 
implicated in the carcinogenesis of a small subset of PCa, it is possible that other 
recessive oncogenes are operative in the tumorigenesis of PIN lesions and PCa, and 
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these remain to be discovered. 
p53 and EGFr overexpression was both correlated with increasing grade in 
PCa, and this suggests that these markers may be of prognostic value. However, this 
study is limited by the lack of data to correlate with the tumor stage and the patient's 
survival, and therefore does not permit to draw any conclusion as prognostic factors. 
This study demonstrated a down-regulation of both E-cadherin and CD44 in 
carcinoma whereas CD44 expression was also correlated with increasing grade of 
carcinoma. Such altered expression of adhesion molecules are in keeping with those 
observed in many malignancies, and reflect the loss of epithelial integrity and the 
acquisition of invasiveness and metastatic potential. Thus both E-cadherin and CD44 
appear to be implicated in prostatic carcinogenesis whereas CD44 also appear to be 
implicated in tumor progression. 
E-cadherin also showed a progressive loss of expression correlated with 
increasing grade in PESf, and in addition demonstrated a continuous down-regulation 
from PESf lesions to PCa. These results support the link between PES[ and PCa, and 
the notion that FJN is a precursor lesion to carcinoma. 
The inverse correlation between p53 and EGFr with the expression of 
adhesion molecules E-cadherin and CD44 reflects the acquisition of invasive growth 
and metastatic behavior, as PCa progresses into higher grade. This observation also 
suggests that p53 and EGFr alterations may contribute to the development of 
invasiveness or metastatic phenotypes. 
An overexpression of the anti-metastatic gene products nm23 was observed 
in all PIK lesions and PCa, in sharp contrast to benign glands in hyperplasia, 
suggesting that alteration of the nm23 gene may be an early event, and that both 
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lesions share a similar molecular mechamsm in their development. The similar nm23 
expression in high-grade PIN and PCa further support the close link between ?JN 
and carcinoma, and the precursor role of PIN to invasive carcinoma. The similarity 
in nm23 overexpression between high-grade PES[ and various grades of PCa 
indicates that nm23 may not be involved in tumor progression, nor a useful marker for 
prognosis, a conclusion that is in line with molecular studies of both nm23-Hl and 
nm23-H2. 
Both cellular proliferation markers PCNA and Ki-67 were closely 
correlated with each other and demonstrated a continuity of their overexpression in 
the sequence from hyperplasia, PIN lesions of increasing grade and PCa of 
increasing grade. Although significant overexpression of these markers is observed 
in neoplastic processes, and may implicate them in carcinogenesis, they reflect 
mostly active cell division or high proliferation rates also seen in nodular hyperplasia. 
The strong correlation of the overexpression with increasing grade of PIN and PCa 
supports of that both PCNA and Ki-67 is useful prognostic factors in carcinoma. 
Measurement of Ki-67 by both traditional microscopic semi-quantitative 
counting and computer-assisted quantitative image analysis yielded similar results. 
Although computer-assisted quantitation produced more consistent and accurate 
results, its application in quantitation of proliferative markers in prostate tissues is 
hampered by the complex tissue architecture of prostatic tissues. Much more effort 
and time were devoted and spent in careful segmentation of luminal cells to prevent 
measurement of basal cells and stromal tissues during computer-assisted quantitation 
by image analysis. Careful microscopic semi-quantitation using consistent criteria is 
more cost-effective for measurement of proliferation markers in heterogeneous 
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prostatic tissues. 
The differences in expressions of all biologic markers studied between 
prostatic hyperplasia and PCa supports the commonly accepted view that hyperplasia 
is not related to the development of carcinoma, but a benign lesion in the prostate. 
While both hyperplasia and PINF lesions share similar findings of negative expression 
or accumulation of p53 and EGFr, immunoreactivities between these two lesions for 
PCNA, Ki-67, E-Cadherin, CD44, and nm23 are significantly different, indicating a 
lack of relationship between prostatic hyperplasia and PEN lesions. 
Apart from limitation by the lack of clinical information regarding the 
tumor stage and the patient's survival, this study of a relatively small number of PIN 
lesions and carcinomas may be limited by an imbalance among certain subcategories, 
and thus affected the power of statistical analysis. During the interpretation of results, 
the lack of intemal positive control required exclusion of a few cases in this study, 
and this reflected problems inherent to immunohistochemical techniques due to 
variation in tissue fixation and antigen expression of archival materials. 
A number of biological alterations, reflecting genetic changes have been 
observed in this immunohistochemical study, and some of these markers appear to be 
implicated in the process of prostatic tumorigenesis. Several markers, including 
adhesion molecules E-cadherin, CD44, nm23 cell growth protein, proliferative 
markers PCNA and Ki-67 demonstrated similar alterations between ?IN and 
carcinoma, and support the concept that PEN is a preinvasive lesion, or a precursor of 
malignant transformation. Although immunoreactivity for p53 or EGFr is 
significantly different between VJN lesions and carcinoma, this does not underscore 
the close relationship between these lesions as supported by other biological markers. 
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Furthermore, while one may be tempted to argue that PIM lesions may be 
heterogeneous and a subset of PIN lesions may not be correlated with cancer, this is 
not necessarily so. These observations may benefit from translation into molecular 
studies, using similar microdissection approach, which can not only confirm the 
expression of these biological markers, but may also lead or allow to specify the type 
















I. Table of incidence and mortality rates of prostate cancer in 
the United States from 1973 to 1995 by race 
Year Incidence Rates Mortality Rates 
All races White . Black All races White Black 
~~"i^~~ 64.2 62.6 106.3 21.7 20.3 39.5 
1974 ^ ~ ~ 64.8 100.7 21.7 20.2 39.7 
~ ~ i ^ ~ 70.6 68.9 111.5 21.6 20.1 40.6 
~ " i ^ ^ ~ 72.6 110.1 22.1 20.6 40.8 
" " " ] ^ ^ ~ 74.5 122.2 22.1 20.6 41.2 
~ i ^ m ~ 73.4 116.6 22.6 21.0 42.5 
~ ~ i i ^ ^ ~ 77.0 . 123.1 22.7 21.1 43.0 
~ " i ^ ^ ~ ~ 78.7 126.6 22.8 21.1 44.6 
~ ~ i ^ ^ ~ 80.8 126.9 22.9 21.0 45.8 
~ 1 9 8 2 82.2~~ 81.2 130.6 23.0 21.3 44.7 
~ ~ 1 ^ ^ ^ 83.8 134.1 23.4 21.6 46.6 
^ i ^ ^ " " " 82.9 139.6 23.4 21.5 47.1 
^ r ^ ^ ~ ~ 86.9 133.1 23.4 21.5 48.1 
~~1986 91.2 90.8 131.6 24.1 22.2 48.3 
^ 1 ^ 102.9 102.8 147.3 24.1 22.2 49.1 
^ i ^ 106.0 105.8 147.8 24.7 22.8 49.5 
^ 1 9 8 9 112.7 112.3 149.1 25.4 23.5 51.1 
1990 132.4 133.0 173.3 26.5 24.3 54.8 
~ ~ 1 ^ 169.3 169.1 223.3 26.4 24.7 54.9 
~ ~ i ^ 190.9 188.3 256.9 26.7 24.5 55.6 
1993 171.1 163.4 270.6 26.6 24.3 56.2 
1994 147.8 140.0 “ 245.7 25.9 23.8 55.1 
1995 137.2 129.8 211.6 24.9 22.9 53.5 
1991- 162.7 157.6 241.2 ~ ~ ^ ~ ~ ~ ~ ^ ~ ~ ~ ~ m ^ 
1995 
























































































































































































































































































































































































































































































































































































































































































































































































































































































































III. Table of incidence and mortality rate caused by prostate 
cancer in Hong Kong 
Year Incidence rate Mortality rate 
per 100,000 men per 100,000 men 
1975 2.9 1.2 
1980 4.5 1.3 
1985 6.2 1.9 
1986 6.1 2.3 
1987 5.6 2.7 
1988 7.5 2.1 
1989 7.1 2.6 
1990 7 2.7 
1991 8.3 3.4 








1. 0.05 M TBS, pH7.6: containing 6.055 g Trizma base (Catalog no.T-1503, 
Sigma) and 8.766 g anhydrous Sodium Chloride (Catalog no. 71381, Fluka) in 
1 L of distilled water. pH was adjusted to 7.6 with Beckman pI-10 pH meter 
calibrated with buffer standard pH7.00 (Catalog no. 82596, Fluka) 
2. 0.01 M Tris-HCl-CaCl2 Buffer, pH 7.2: containing 1.20 g Trizma base (Catalog 
no.T-1503, Sigma) and 1 g Calcium Chloride (Catalog no. C-614, Fisher) in lL 
of distilled water. pH was adjusted to 7.2 with Beckman pI-10 pH meter 
calibrated with buffer standard pH7.00 (Catalog no. 82596, Fluka). 
3. 0.01 M Citrate buffer pH 6.0: contains 2.1 g Citric acid monohydrate (Catalog 
no. 244, Merck) in 1 L of distilled water. pH is adjusted to 6.0 with 2 M NaOH 
(Catalog no. 71690, Fluka). 
4. 0.1% Trypsin solution: contains 0.10 g of Trypsin powder (Catalog no. T-8253, 
Sigma) in 100 mL of0.005M Tris-HCl-CaCl2 buffer, pH 7.8.5 
5. 0.005 M Tris-HCl-CaC12 Buffer, pH 7.8: containing 0.60 g Trizma base 
(Catalog no.T-1503, Sigma) and 1 g Calcium Chloride (Catalog no. C-614, 
Fisher) in lL of distilled water. pH was adjusted to 7.8 with Beckman pI-10 pH 
meter calibrated with buffer standard pH7.00 (Catalog no. 82596, Fluka). 
6. 0.025% Trypsin solution: contains 25 mg of Trypsin powder (Catalog no. T-
8253, Sigma) in 100 mL of0.005M Tris-HCl-CaCl^ buffer, pH 7.8. 
7. 3% Bovine serum albumin: original 30% BSA solution (Catalog no. A-7284, 
Sigma) was diluted 10 times with TBS, pH7.6. 
8. Biotinylated sheep anti-mouse whole antibody (Catalog no. RPN1001, 
Amersham Life Science): original concentrated antibody was prepared at a 
dilution of 1 in 50 with TBS, pH7.6. 
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9. Biotinylated donkey anti-rabbit whole antibody (Catalog no. RPN1004, 
Amersham Life Science): original concentrated antibody was prepared at a 
dilution of 1 in 200 with TBS, pH7.6. 
10. Harris's Hematoxylin solution: Prepared by dissolving 2.5 g of Hematoxylin 
powder (Catalog no. 51260, Fluka) in 25 mL of absolute Ethanol (Merck) and 
mixed with 50 g Potassium alum (Catalog no. 60060, Fluka) dissolved in 500 
mL of warm distilled water. The mixture was rapidly brought to boil. Then 1.25 
g of Mercuric oxide (Catalog no. 83373, Fluka) was added and the mixture was 
rapidly cooled in water bath followed by addition of 20 mL of glacial acetic 
acid (Catalog no. 100063, Merck). 
11. Methyl green solution: 1 g of Methyl green (Catalog no. 34052, BDH) was 
dissolved in 200 mL of acetate buffer pH 4.1 followed by extraction with 
chloroform. 
12. Washing buffer: containing 0.075% Brij-35 (Catalog no. 430AG-6, Sigma) in 
0.05 M TBS, pH 7.6. 
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